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 This dissertation will describe the development and application of novel methods for 
heterocycle synthesis. The first chapter will outline the development of a titanocene catalyzed 
epoxide-opening rearrangement to prepare indolines from epoxyanilines. A discussion of the 
reaction development, along with the substrate scope and limitations will be reported. 
The second chapter will describe progress toward expanding the scope of a 
Staudinger/aza-Wittig reaction used to prepare substituted 1,2,4-triazines. This methodology has 
been applied towards the synthesis of a model system for the DEF rings of the natural product 
noelaquinone.  The challenges associated with the Staudinger/aza-Wittig reaction, and the late-
stage oxidation strategy to prepare the DEF rings of the noelaquinone model system will be 
discussed. 
The third chapter will describe the importance and general preparation of (E)-alkene 
peptide isosteres. Using compounds prepared in the UPCMLD and published on PubChem as a 
reference, we present our ongoing initiative to expand the library of α,β-cyclopropyl-γ-amino 
acid analogs. 
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1.0  TITANOCENE(III)-CATALYZED CONVERSION OF EPOXYANILINES TO 
INDOLINES 
1.1 INTRODUCTION 
1.1.1 Indolines: The Preparation and Applications of a Privileged Scaffold 
Natural products that contain the indole and dihydroindole (indoline) scaffolds (outlined 
in bold in Figure 1-1) are ubiquitous in nature. In addition, the indoline and its nitrogen-
containing isostere, the azaindoline,1 have long been studied for their tremendous therapeutic 
potential, and are considered to be a privileged scaffolds.2 One of the well-known biologically 
active indolines of the Vinca alkaloids include the potent anticancer agent vinblastine 1-1.3 In 
addition to being biologically active, there exist many structurally complex and thus 
synthetically challenging indoline-containing molecules that have been recent targets for total 
synthesis. Two of such molecules include the cytotoxic chlorinated marine metabolite 
diazonamide A 1-2,4,5 and the highly substituted core of kapakahine F 1-3.6 Many strategies have 
been developed to prepare indoline-containing heterocycles, however, due to the important 
biological activity often associated with these heterocyclic building blocks,7,8 there remains a 
strong initiative to develop novel methods for their preparation. 
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O Ph
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N Cl
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N
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Cl
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HO
O
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diazonamide A
(nanomolar in vitro cytotoxicity)
1-3
kapakahine F  
Figure 1-1. Natural products containing the 3,3-disubstituted indoline core (outlined in bold) 
 
The Wipf research group has had an extensive interest in developing methods to prepare 
indolines and their derivatives for broad applications that range from Stemona alkaloid synthesis 
to botulinum neurotoxin metalloprotease inhibitors.9 One particularly useful method for indoline 
preparation involves the oxidative cyclization10 of N-protected tyrosine 1-4 and subsequent 
methanolysis to yield the hydroindoline derivative 1-5. This reaction has been widely utilized in 
the Wipf group for the preparation of Stemona alkaloids that include stenine 1-611 and 
tuberostemonine 1-712 (Scheme 1-1) and progress toward the preparation of tuberostemonone13 
and parvistemoline.14 
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N
H
H
H
O
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O O
H
HO
NHR
CO2HH
R = Boc or Cbz
N
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H
O
R
H
CO2Me
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1-5
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(-)-tuberostemonine
N
H
HO
O
1-6
(-)-stenine
PhI(OAc)2, MeOH
NaHCO3
 
Scheme 1-1. Oxidative cyclization of protected tyrosine 1-4 to form hydroindoline 1-5 
 
The preparation of indoles and indolines has been a topic of recent reviews,2,15 where the 
synthetic strategies utilized in their preparation have also been evaluated.16,17 In general, most 
one-step protocols to prepare indolines 1-8 (not including methods that begin with the indole 
core) are accomplished through either carbon-carbon bond formation (Path A) from aniline 
derivative 1-9 or carbon-nitrogen bond formation (Path B) via amine 1-10 (Scheme 1-2).  
 
N
R
N
R
X
Y
1
2
3
9
C3-C9 4
H
N
R
Y
1-9 1-8 1-10
Y = Br, I; X = leaving group or electrophile
Path A
Path A
Path B
N1-C8
Path B
 
Scheme 1-2. General bond disconnections for indoline formation 
 
The carbon-carbon bond formation reaction between C9 and C3 often involves activation 
of the aryl ring to function as a nucleophile. This is commonly achieved through metal/halogen 
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exchange with an aryl halide18 followed by the trapping of the reactive intermediate with an 
appended electrophile. Sakamoto and co-workers19 have demonstrated that zinc-ate complexes 
can undergo metal/halogen exchange to promote a 5-exo or 6-endo cyclization20 with epoxide 1-
11 to prepare the indoline 1-12 or hydroquinoline 1-13  scaffolds, respectively (Scheme 1-3). 
Substituted indolines have also been prepared using intramolecular Michael additions and 
carbozincation reactions.19  
 
I
N
Ts
O
metalating reagent
THF, -78 oC N
OH
Ts
N
OH
Ts
1-11 1-12 1-13
92%, 97:3
86%, 4:96
metalating reagent
1. Me3Zn(SCN)Li2
2. Me3ZnLi  
Scheme 1-3. Indoline formation using metal/halogen exchange 
 
Natural products of the duocarmycin family represent a well-studied class of cytotoxic 
molecules that contain the indoline core (Scheme 1-4). The parent natural product from this 
family is CC-1065 1-14, which was isolated by Martin and co-workers21 in 1981. Duocarmycin 
SA 1-15 is one of the most potent cytotoxic agents of its class, with an IC50 value of 10 pM in a 
L1210 (mouse lymphocytic leukemia cell line) cell assay.22. These compounds derive their 
cytotoxicity from selective binding to the minor groove of the DNA backbone and subsequently 
alkylating the N-3 of the adenine residue through the opening of the electrophilic cyclopropane.23 
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1-16
CPI core
NO NO
HN
O O
1-17
CBI core
N
HO OMe
OMe
OMe
N
O
HN
MeO2C
1-15
(+)-duocarmycin SA
HN
O
MeO OH
N
NO
HN
O
N
H OMe
OH
N O
NH2
1-14
(+)-CC-1065
analog
design
 
Figure 1-2. Natural products containing the CPI core  
 
Boger and co-workers have made significant contributions toward optimizing the 
synthesis24 and studying the biological activity23 of these natural products that contain the CPI 
(1,2,8,8a-tetrahydrocyclopropa[c]pyrrolo[3,2-e]indol-4-one) core 1-16 (Figure 1-2). In the course 
of their studies, they designed an analog of the reactive cyclopropane core, the CBI (1,2,9,9a-
tetrahydrocyclopropa[c]benz[e]indol-4-one) series 1-17, which is four times more stable, four 
times more potent, and easier to synthesize than 1-16.25 The formation of the activated indoline-
cyclopropane group can be accomplished through a 3-exo-tet cyclization using substrate 1-18, or 
a ring contraction of the hydroquinoline 1-20 to yield 1-19 (Scheme 1-4). Although there have 
been numerous approaches to prepare the CPI and CBI cores, two common methods Boger has 
accomplished this transformation are shown in Scheme 1-4. In the past, enantiopure samples of 
1-18 and/or 1-20 have been prepared either via separation using chiral HPLC or through various 
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forms of asymmetric catalysis.25 A recent publication by Boger26 demonstrates that the precursor 
to the CBI core can be prepared in a convergent manner by alkylating 1-21 with the enantiopure 
nosylated (S)-glycidol derivative to yield 1-22 in 87% yield and 99% ee (Scheme 1-4b). 
 
N
Cl
R2
N
OH
Boc1-18
1-20
HO
BnON
O
1-19
R2
1. Pd/C, H2
    MeOH
2. ADDP, PBu3
    toluene
NaH, THF
or 
DBU, THF/CH3CN
I
OBn
N
Boc
O
EtMgBr
THF, 23 oC
87%, 99% ee
1-22
(b)
I
OBn
N
H
Boc
O
ONos
DMF, NaH
88%
1-21
(a)
 
Scheme 1-4. Methods for obtaining the CBI core  
 
In an alternative approach toward the indoline core, Padwa and co-workers utilized an 
intramolecular [4+2] cycloaddition reaction to access various alkaloids, including classical 
targets of the Strychnos family.27,28 Scheme 1-5a shows one of the many examples from the 
Padwa group where researchers have used high temperatures to promote a cycloaddition reaction 
between the amino furan 1-23 and the appended olefin to produce a variant of the indoline core 
1-24. This methodology has recently been used in a (racemic) formal synthesis of the natural 
product dendrobine 1-25.29,30 An extension of this cycloaddition methodology involves the 
rhodium-catalyzed in situ generation of a carbonyl ylide from 1-26 that undergoes a [3+2] 
cycloaddition reaction to yield indoline 1-27 in 97% yield.31 This intermediate was further 
elaborated to complete a racemic synthesis of aspidophytine 1-28 shown in Scheme 1-5b. 
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1-23 1-242:1 
diastereomer mixture
N
O
N
O O
N2
CO2Me
Me
Rh2(OAc)4 
(1.5 mol%)
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N
O
N
O
CO2tBu
O
H CO2Me
Me
1-27
(endo-adduct)
1-26
MeO OMe OMe
MeO
N
N
H
MeOMe
MeO
O
O
steps
1-28
(rac)-aspidophytine
O
Me
Me
N
CO2tBu
Me
toluene, 165 oC
74% N
O
H
CO2tBu
H
Me
H
N
Me
Me
Me
H
Me
HH
O
O
1-25
(rac)-dendrobine
formal
synthesis
(a)
(b)
 
Scheme 1-5. Padwa’s synthesis of natural products using a cycloaddition approach 
 
Wipf and co-workers32 have developed a methodology to prepare substituted indoles 
using a similar intramolecular [4+2] cycloaddition reaction. It was found that heating allylic 
alcohols of type 1-31 in o-DCB using microwave irradiation provides substituted indoles 1-32 in 
modest to good yields (Scheme 1-6). This methodology is currently being applied toward the 
synthesis of natural products. 
 
SnBu3I1-29
O N
Boc
H
NaH, DMF
O N
Boc
SnBu3
1-30
n-BuLi, -78 oC, 15 min
R
CHO
then O
N
Boc OH
R
20 min, 180 oC
o-DCB, µW
N
R
H- Boc
1-31
1-32
12 examples
yields range between 36-84%
N
Boc
OHR
O
N
Boc
OHR
HO
H
- 2 H2O
 
Scheme 1-6. Wipf’s method for indole synthesis 
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When exploring indoline formation through a radical manifold, activation of the aryl ring 
(path A, Scheme 1-2) can also be accomplished by treating aryl bromides or iodides with 
Bu3SnH/AIBN,33 Bu3SnH/BEt3/O2,34 or SmI2.35,36 These reactive intermediates are able to add 
onto an appended olefin acceptor, thereby forming the 5-membered ring. One recent example 
published by Curran and co-workers37 involves the transfer of axial chirality of 1-33 to 
indolinone 1-35 (Scheme 1-7).38,39 
 
N
CH3
O
H3C I
CH3
N
CH3
O
CH3
H3C
Bu3SnH
Et3B/O2
benzene
1-33
97% ee
1-35
84% ee
N
CH3
O
CH3
CH3
H
1-34  
Scheme 1-7. Curran’s method to prepare indolines using chirality transfer 
 
1.1.2 Intramolecular Radical Reactions onto Aromatic Rings 
Radical cyclizations onto aromatic and heteroaromatic rings are known processes,40,41 
and, in particular, the intramolecular alkyl42 and phenyl43 radical additions onto heteroarenes 
have found many applications.44 The intermolecular rate constants for radical addition onto 
phenyl rings with triethylsilyl, tributylstannyl, primary alkyl, and methyl groups have been 
measured and are summarized in Table 1-1. The intramolecular rates for alkyl radical additions 
onto arenes are estimated to be near 4 x 10-5 s-1.45 
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Table 1-1. Rate constants for radical additions onto phenyl rings 
radical species rate constant 
Et3Si46 4.6 x 105 M-1s-1 
Bu3Sn47 <2 x 104 M-1s-1 
1o Alkyl48 3.8 x 102 M-1s-1 
Methyl49 4.6 x 101 M-1s-1 
  
When compared to alkyl radicals, aryl and alkenyl radicals have a greater propensity to 
cyclize onto aromatic rings due to their higher reactivity.  This is supported by the data shown in 
Table 1-2, where the difference between the carbon-hydrogen bond dissociation energy (BDE) 
between sp2 and sp3 hybridized carbon atoms is ca. 15 kcal/mol.  Another factor limiting the 
ability of alkyl radicals to cyclize onto the aromatic nucleus has been attributed to the 
SOMO/LUMO energy gap between the alkyl radical and the aromatic ring.48 
 
Table 1-2. Comparison of relevant bond dissociation energies (BDE). 
bond (R-R) BDE (kcal/mol) bond (R-R) BDE (kcal/mol) 
(Ar)sp2C-H 112 Methyl Csp3-Csp3 90 
(Ar)sp2C-Csp3 102b Methyl Csp3-OH 93 
Methyl Csp3-H 105 2o Csp3-H 98.5 
1o Csp3-H 101 3o Csp3-H 96.5 
aData used from Vollhardt et al.50 except where noted.  bData used from Togo51 
 
There exist few general methods to promote the addition of alkyl radicals onto substituted 
benzene rings since the process is often difficult to control.52 One exception lies in the field of 
xanthate transfer reactions where Zard and Quiclet-Sire53 have published a method that utilizes 
the xanthate fragmentation of 1-36 to generate an alkyl radical which then cyclizes to afford 
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homophthalimide 1-37 (Scheme 1-8).  Additionally, this methodology has been used to construct 
spirolactams54 and tetrahydroisoquinolinones.55 Although proven to be efficient, this 
methodology requires the use of a stoichiometric amount of oxidant that must be added 
throughout the duration of the reaction making experimental protocol rather cumbersome. 
 
N
O
CH3
S
O
S
OEt
(t-BuO)2 (1 equiv)
N
CH3
O
O
1-36 1-37
o-DCB, reflux
56%
 
Scheme 1-8. Zard’s method of alkyl radical cyclization onto aromatic rings 
 
Köhler and Speckamp45 have demonstrated that upon treatment of iodide 1-38 with 
Bu3SnH/AIBN, the resulting alkyl radical cyclizes onto the aromatic ring to afford the tricyclic 
sultam 1-39 in 48% yield (Scheme 1-9). The drawbacks to this methodology include a limited 
reaction scope, in addition to the use of anisole as the solvent. 
 
S
O
O
N
I
Bu3SnH/AIBN
S
OO
N
1-38 1-39
anisole, 96 oC
48%
 
Scheme 1-9. Köhler’s method of alkyl radical cyclization onto aromatic rings 
 
Beckwith and Storey56 have shown that alkyl radical cyclization can be accomplished 
through treatment of aryl bromide 1-40 with Bu3SnH/AIBN, promoting a 1,5-H atom transfer to 
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quench the resulting aryl radical.  The cyclopropyl radical intermediate 1-41 then cyclizes onto 
the aromatic nucleus to afford 1-42 in 43% yield (Scheme 1-10). As of today, the mechanism of 
oxidative rearomatization under reductive conditions is still not well understood. 
 
N
CH3
O
Br Bu3SnH/AIBN N
CH3
O
1-40
1-42
N
CH3
O
1-41
benzene, 80 oC
43%
 
Scheme 1-10. Beckwith’s alkyl radical cyclization through aryl radical translocation 
 
1.1.3 Titanocene(III) Chloride and Radical Chemistry 
Titanocene(III) chloride is commonly prepared by mixing titanocene(IV) dichloride 1-43 
with a reductant such as zinc or manganese metal in oxygen-free THF. The reagent is proposed 
to exist in equilibrium with its monomer 1-44, bridged dimeric species 1-45 and 1-46, and 
trinuclear species 1-47 (Scheme 1-11).57,58  
Cp2TiCl2
Zn or Mn
Ti Ti
Cl
Cl
Cl
Ti
Cp Cp Cp
Cp Cp Cp
Ti
Cl
Ti
Cp Cp
Cp Cp
Cl M
Cl
Cl
Ti
Cp Cl
Cp
Ti
Cp
CpCl
1-44 1-45
1-46
1-47
1-43
THF
M = Mn2+ or Zn2+
O
O
Ti
Cl
Cl
 
Scheme 1-11. Preparation of titanocene(III) chloride  
 12 
 
The use of titanocene(III) chloride to reductively open epoxides was first described by 
RajanBabu and Nugent.59 Early applications of the reductive epoxide opening reaction include 
the free radical deoxygenation of the methyl furanoside 1-48 as described in Scheme 1-12a. Here 
the epoxide was subjected to two equivalents of titanocene(III) chloride to afford intermediate 1-
49, which eliminates to form the internal olefin 1-50 in 66% yield.60,61 The transformation of 1-
48 into alcohol 1-52 is illustrated in Scheme 1-12b, where the epoxide was treated with one 
equivalent of titanocene(III) chloride in the presence of 1,4-cyclohexadiene to afford the reduced 
intermediate 1-51.  Upon acidic workup, the intermediate becomes protodemetallated to produce 
1-52 in 55% yield.59,62  
 
O
O
TrO
TrO
OMe
2 Cp2Ti(III)Cl
Cp2Ti(III)Cl
O
OTi(Cp2)Cl
TrO
TrO
OMe
O
OTi(Cp2)Cl
TrOTrO
OMe
Cl(Cp2)Ti
H
H+
1-48
1-49
1-51
O
TrOTrO
OMe
O
OH
TrO
TrO
OMe
1-52
1-50
(a)
(b)
O=TiCp2
THF, C6H8
55%
THF
66%
Cp2TiCl2
O
O
TrO
TrO
OMe
1-48
 
Scheme 1-12. Applications of titanocene(III) chloride 
 
 In addition to the epoxide opening reaction, RajanBabu and Nugent reported a hexenyl 
radical cyclization of radical intermediate 1-54 (derived from epoxide 1-53) to form the 
substituted cyclopentanol 1-55 (Scheme 1-13).59  
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O 2 Cp2Ti(III)Cl
HO
1-53
5-exo-trig
Cp2Ti(III)Cl
94%1-54
1-55
dr 1:1
OTi(Cp2)Cl
THF, rt OTi(Cp2)Cl
 
Scheme 1-13. Synthesis of cyclopentanol 1-55 using titanocene(III) chloride 
 
 Building on the initial work by RajanBabu and Nugent, Gansäuer developed a catalytic 
variant of the titanocene(III) epoxide-opening reaction.63,64 This technology can also be used to 
promote a 5-exo-trig radical cyclization, transforming epoxide 1-56 into alcohol 1-57 in 66% 
yield (Scheme 1-14). The proposed catalytic cycle for this titanocene(III) chloride annulation 
begins with the reductive opening of 1-56 to form the β-titanoxyradical 1-58. This radical then 
undergoes a 5-exo-trig cyclization onto the olefin, and the resulting radical intermediate 1-59 is 
reduced by titanocene(III) chloride to form 1-60. Subsequent protodemetallation by collidine 
hydrochloride 1-61 liberates the product 1-57, allowing for the titanocene(IV) dichloride to re-
enter the catalytic cycle. 
When compared to other single electron transfer (SET) reagents known to open epoxides, 
titanocene(III) chloride was shown to be superior when performing epoxide-opening radical-
mediated cyclizations.65 Recent advances in titanocene(III)-mediated transformations include the 
work by Cuerva who has demonstrated that the titanocene(III)-mediated SET works well in 
oxygen-free, aqueous media to synthesize γ-lactols.66 
 
 14 
 
Cp2TiCl
1/2 Mn
alkyl radical 
cyclization
Coll•HCl
(2 equiv)
reductive epoxide 
opening
1/2 MnCl2
Cp2TiCl2
Cp2TiCl
HO
O
Ti(IV)O
Ti(IV)O
Ti(IV)O Ti(IV)
SET
N
H Cl-
H
O
Cp2TiCl2 (5 mol%), Mn
Collidine-HCl, THF
66%
HO
1-56 1-57
98:2 mixture of epimers
1-56
1-58
1-59
1-60
1-61
1-57
 
Scheme 1-14. Gansäuer’s proposed catalytic cycle for the titanocene(III) chloride catalyzed annulation  
 
 Since then, titanocene(III) chloride catalysis has become widely investigated and 
utilized,67-74 where many applications prior to 2006 are summarized in a review by Barrero.75 In 
addition to detailed mechanistic investigations of the reductive epoxide opening process,76 and 
the use of chiral titanocene(III) complexes in asymmetric catalysis,77 recent advancements in 
titanocene(III) chloride catalysis include the use of metal hydride complexes as hydrogen atom 
transfer reagents. The technology of hydrogen atom transfer has been improved through the use 
of catalytic amounts of Vaska’s complex78 (IrCl(CO)PPh3)2 1-64 in the presence of a hydrogen 
atmosphere as shown in Scheme 1-15. This example shows how the yields for the transformation 
of epoxide 1-62 into bicycle 1-63 are improved by the presence of an in situ metal hydride 
complex used to trap reactive alkyl radical intermediates.79  
 15 
 
O
N
Ts
Cp2TiCl2 (7.5 mol%)
Coll*HCl (1.5 equiv)
Mn (3 equiv)
additives
additive = Vaska's complex
1-64 (10 mol%), H2 (4 atm)
1-64 (0 mol%)
1-63, 94%
1-63, 43%
N
TsH
HO
1-62
1-63
dr 74:26
Ir
Ph3P
Cl PPh3
CO
1-64  
Scheme 1-15. Recent applications of the radical cyclization 
1.2 RESULTS AND DISCUSSION 
1.2.1 Initial Methodology Development Using N,N-Diphenyl Substrates 
A new methodology80,81 has been developed that uses a catalytic amount of in situ 
generated titanocene(III) chloride to promote a novel epoxide-opening rearrangement 
transforming epoxyanilines into indolines. We envisioned exploring an unconventional approach 
toward indoline preparation that uses a radical process to install a quaternary carbon 
simultaneously with pyrrolidine formation, starting with readily available epoxidized allylic 
amines.10 Scheme 1-16 outlines our initial approach toward indoline formation.  Treatment of 1-
67 with titanocene(III) chloride will promote a reductive epoxide opening and thereby generate a 
persistent82 radical intermediate 1-66. The intermediate will then cyclize onto the aromatic ring 
to form the key bond between C3 and C9 (see Scheme 1-2, path A), producing indoline 1-65.  
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radical
1-65
N
R
R
OTiCp2Cl
N
R
R cyclization
OH
N
R
R O
1-66
1-67
Cp2Ti(III)Cl
 
Scheme 1-16. Proposed retrosynthesis for indoline methodology 
 
We began exploring the feasibility of our proposed methodology by preparing the N-
phenyl epoxide 1-71 using a three-step reaction sequence beginning with the alkylation of 1-68 
with allyl bromide to afford 1-69. Subsequent dihydroxylation using OsO4/NMO to afford diol 1-
70 and epoxide formation using p-Ts2O/NaH readily provided the product (Scheme 1-17). 
 
N
Ph
H
K2CO3, CH3CN
Br
N
Ph
1-68
OsO4, NMO, rt N
Ph
OH
1-69 1-70
p-Ts2O, NaH, 0 oC N
Ph O
1-71
OH
quant. 86%
57%  
Scheme 1-17.  Synthesis of diphenyl epoxide 1-71 
 
When attempting the radical cyclization with substrate 1-71 using conventional magnetic 
stirring, multiple products were observed by TLC analysis including the desired indoline.  The 
low indoline selectivity was initially attributed to the insolubility of the collidine hydrochloride 
and metal reductant in the reaction mixture.  To remedy this, sonication was employed as a more 
aggressive method of mixing, but TLC analysis following sonication still showed a complex 
mixture of byproducts (Scheme 1-18). These complex mixtures were separated using column 
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chromatography and further purified by HPLC if necessary. After analysis, six of the seven 
major products from the reaction mixture were identified and characterized. In addition to 
starting material, the byproducts detected (shown in Table 1-3) included diphenylamine 1-68, N-
allyl diphenylamine 1-69, the reduced epoxide 1-73, hydroquinoline 1-74, and the desired 
indoline 1-72. The presence of these compounds was confirmed by using either 1H/13C NMR 
spectroscopy and/or comparison of GC retention times of authentic samples. In addition to these 
compounds, there remained one unknown product (single peak in GC) that could not be 
assigned.  
 
N
Ph
1-71
O
N
Ph
HO
1-72
byproducts
Cp2TiCl2 (10 mol%), Mn
rt, coll-HCl, THF, ))))
 
Scheme 1-18. Scheme for radical cyclization on model system 
 
Although 3-alkyl indolines are known to be air sensitive and potentially undergo aerobic 
oxidation,83 we postulate the formation of the undesired compounds to originate from 
competitive radical fragmentation pathways of the initial radical species. During our initial 
studies it was observed that using excess reductant in the cyclization reaction afforded olefin 1-
69 as the major product and the cyclized products 1-72 and 1-74 as minor products in an average 
~3:1 ratio, respectively. To explain the numerous byproducts detected, we concluded that the 
titanocene(III) chloride catalyzed annulation was occurring at a slower rate than other radical 
fragmentation pathways. Table 1-3 outlines the product ratios detected as a result of changing 
both the reaction concentration and the manganese stoichiometry. During our attempts to 
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optimize the transformation to favor the desired indoline, we observed that when using sub-
stoichiometric amounts of reductant, the reaction proceeded with higher selectivity and produced 
only a minor percentage of the olefin 1-69. While this modification minimized the formation of 
the undesired olefin, in some cases the reaction did not proceed to completion (entry 1, Table 1-
3).  
 
Table 1-3. GC analysis of products from titanocene(III) chloride catalyzed radical cyclization 
N
Ph
1-71
O Ph2NH
N
Ph
Ph
N
Ph
Ph
H
OH
N N
Ph Ph
OH
OH
1-68 1-69 1-73 1-741-72  
entrya conc. 
[M]b 
Mn 
(mol%) 
1-71 
(%) 
1-72 
(%) 
1-68 
(%) 
1-69 
(%) 
1-73 
(%) 
1-74 
(%) 
ratio of  
1-72:1-74 
1 0.03 10 73.1 17.0 1.7 0.8 0 5.2 3.2:1 
2 0.10 20 35.9 38.6 5.4 4.1 3.2 11.7 3.2:1 
3 0.03 80 0.6 51.7 10.2 15.0 5.3 16.6 3.1:1 
4 0.03 50 1.9 38.3 5.6 5.2 1.6 12.5 3.0:1 
5 0.02 65 16.2 15.8 1.7 1.0 0.6 5.8 2.7:1 
6 0.03 65 7.2 57.3 3.4 3.2 2.9 13.2 4.3:1 
aPercentages relative to constituents in crude reaction mixture; sonication at 40-60% maximum output of 130 W was 
used as the means of mixing for all entries. bReaction times ranged between 1-2 h. 
 
The reaction concentration and the stoichiometry of the manganese metal were altered 
until the starting material was nearly consumed and the olefin formation was minimized 
according to GC analysis of the crude reaction mixtures. However, a mixture of the desired 
indoline 1-72 and undesired hydroquinoline 1-74 (entry 6, Table 1-3) were still observed. 
Focusing on obtaining solely the indoline, conditions involving the use of sub-stoichiometric 
amounts of reductant were applied to the methyl substituted epoxide 1-77, which was prepared 
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using our standard procedure of alkylation of 1-68 with 3-bromo-2-methylpropene, 
dihydroxylation of 1-75 using OsO4/NMO to afford diol 1-76, and epoxide formation using p-
Ts2O/NaH to afford 1-77 (Scheme 1-19). 
 
N
Ph
H
K2CO3, CH3CN
Br
N
Ph
1-68
OsO4, NMO, rt N
Ph
OH
1-75 1-76
p-Ts2O, NaH, 0 oC N
Ph
O
1-77
OH
57% 84%
70%
 
Scheme 1-19. Synthesis of disubstituted epoxide 1-77 
 
We theorized that the reductive opening of 1-77 should form a more stabilized tertiary 
radical, therefore promoting a more selective cyclization to afford the desired 3,3-disubstituted 
indoline.  When subjecting 1-77 to our reaction conditions, we qualitatively observed a faster 
reaction rate, as well as exclusive selectivity for the indoline (Scheme 1-20).   
 
N
Ph
1-77
O N
Ph
HO
Cp2TiCl2 (10 mol%), Mn (65 mol%)
1-78
rt, coll-HCl (2 equiv), THF (0.03 M)
1. 82% (sonication, 50 min)
2. 84% (conventional stirring, 7 h)  
Scheme 1-20. Radical cyclization to form indoline 1-78 
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Indoline 1-78 was formed in less than 1 h when using the sonication protocol, and was 
isolated in 82% yield.  We also tested to see if this substrate would undergo the desired 
transformation when using conventional magnetic stirring.  This would allow for the use of 
standard laboratory equipment and protocol when performing these oxygen-sensitive 
transformations, and eliminate the need for a specialized setup to perform oxygen-sensitive 
reactions utilizing sonication.  Gratifyingly, under otherwise identical conditions, the desired 
product was obtained after 7 h, and isolated in 84% yield.  At this point, we were pleased with 
the reproducible yields obtained with the N-phenyl system and decided to further expand the 
scope of this methodology. 
1.2.2 Screening Protecting Groups and Reaction Optimization 
 The use of an N-protected epoxide would allow access to free (N-H) indoline substrates. 
Since the methyl-substituted epoxide substrate reacted to form the desired indoline cleanly, it 
was chosen as a benchmark for further investigations.  To begin the search for a compatible 
protecting group, the Boc-protected epoxide was prepared. This was accomplished in two steps, 
beginning with alkylation of Boc-protected aniline 1-79 to afford 1-80, followed by subsequent 
oxidation with m-CPBA (Scheme 1-21). 
 
N
Br
N
Boc
N
Boc
O
m-CPBA, CH2Cl2
1-79
1-80
1-81
K2CO3, CH3CN
-40 oC - rt
35%
Boc
87%
H
 
Scheme 1-21. Synthesis of Boc-protected epoxide 1-81 
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Subjecting this substrate to the optimized radical cyclization conditions, the major 
product of the reaction was an acid-catalyzed cyclization of the Boc group onto the epoxide 
(Scheme 1-22) to form intermediate 1-82.  This intermediate was treated with KOH/MeOH to 
afford 1-83, according to 1H NMR and MS analysis of the crude reaction mixture. Due to the 
undesired side reaction observed, the Boc protecting group was dismissed as a possible candidate 
for our methodology. 
1-81
N
Boc
O
N O
O
CH3HO
N
OH
CH3
OH
H
1-82
1-83
Cp2TiCl2 (10 mol%), Mn (80 mol%)
rt, coll-HCl (2 equiv.), THF (0.03 M)
)))), 1.25 h
56%
KOH
MeOH
70% (crude)N O
O
OHor
 
Scheme 1-22. Radical cyclization attempt using Boc-protected epoxide 1-81 
 
The benzyl-protected epoxide 1-86 was prepared over four steps, beginning with a 
reductive amination of benzaldehyde with aniline to give 1-85, followed by a three step sequence 
of alkylation, dihydroxylation and epoxide formation (Scheme 1-23).   
 
NH2 1. PhCHO N
Bn
H
1. K2CO3, CH3CN
Br
N
Bn
O
1-84 1-85 1-86
2. NaBH4, MeOH
70%
2. OsO4, NMO, rt
3. p-Ts2O, NaH, 0 oC
      38% (3 steps)  
Scheme 1-23. Preparation of benzyl-protected epoxide 1-86 
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After subjecting epoxide 1-86 to titanocene catalysis, a complex mixture of products was 
observed (Scheme 1-24). These products were separated by chromatography, and characterized 
by 1H NMR.  Based on the tentatively assigned side products 1-87-1-90, it was evident that a 
benzyl protecting group on nitrogen would not be tolerated under the reaction conditions.  
 
Cp2TiCl2 (10 mol%) 
Mn (65 mol%)
N
Bn
Ph
H
OHN
Bn
1-86
O
N
OH
Bn
N
N
OH OH
PhBn
1-87
16%
1-88
9%
1-89
12%
1-90
5%
rt, coll-HCl (2 equiv)
THF (0.03 M)
)))), 1.5 h
 
Scheme 1-24. Isolated products from radical cyclization of epoxide 1-86 
 
We briefly investigated the reactivity of the unprotected epoxide 1-92, prepared by 
alkylation of the benzyl-protected intermediate 1-85 to afford olefin 1-91.  In a 3-step sequence, 
the olefin was dihydroxylated, the benzyl group was removed by using Pd/C and H2, and 
transformed into the epoxide through the standard epoxidation conditions to give 1-92 in 66% 
yield over 3 steps (Scheme 1-25). 
 
N
Bn
H
K2CO3, CH3CN
Br
N
H
O
1-85
N
Bn
1. OsO4, NMO, rt
1-91
1-92
2. Pd/C, H2, MeOH
3. p-Ts2O, NaH, 0 oC
      66% (3 steps)97%  
Scheme 1-25. Preparation of unprotected epoxide 1-92 
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After subjecting 1-92 to titanocene(III) chloride catalysis, the only identifiable product 
recovered from the complex reaction mixture was the reduced alcohol 1-93 (Scheme 1-26).  It is 
possible that the Thorpe-Ingold effect84 may play a role to promote the cyclization reaction.  It 
was concluded that the incorporation of a bulky protecting group was necessary to promote the 
annulation reaction. 
 
N
H
H
OH
N
H
O
1-92 1-93
Cp2TiCl2 (10 mol%), Mn (65 mol%)
rt, coll-HCl (2 equiv), THF (0.03 M)
)))), 1.5 h
9%  
Scheme 1-26. Titanocene(III) chloride catalyzed reaction with unprotected epoxide 1-92 
  
The next protecting group of interest became the trifluoroacetamide, due to its ability to 
be hydrolyzed over the parent acetamide. The epoxide 1-94 was prepared by treating 1-92 to 
TFAA in pyridine (Scheme 1-27).  
 
N
Ph H
OH
N F3C
OO
CF3
1-95 1-96
N
H
Ph
1-92
O
TFAA, py
N
Ph
O
F3C O
1-94
~1:1 ratio
Cp2TiCl2 (10 mol%)
DMAP, 0 oC
      74%
Nano-Zn (100 mol%)
rt, coll-HCl (4 equiv)
THF (0.1 M), 1 h
OH
 
Scheme 1-27. Synthesis and radical cyclization using the trifluoroacetamide epoxide 1-94 
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During this trial, it was difficult to initiate the radical reaction through the use of our 
standard conditions.  Using Nano-Zinc1 in place of manganese,85 the epoxide was subjected to 
the cyclization conditions where the 1H NMR analysis of the crude reaction mixture showed a 
~1:1 ratio of cyclized 1-95 to reduced 1-96 compound. These results were promising since we 
were able to minimize the amount of side products produced. In addition, it appeared that only 
one competing radical pathway was in operation. Aiming to employ a bulkier protecting group 
that can be removed under mild conditions, the Cbz-protected epoxide 1-98 was prepared in 
three steps from Cbz-protection of aniline using our general protocol (Scheme 1-28). 
 
NH2 Cbz-Cl, NaHCO3
Br
N
Cbz
H
N
Cbz
O1. NaH, THF, 0 oC to rt
1-84 1-97 1-98
2. m-CPBA, CH2Cl2
         79% (2 steps)
THF
quant.  
Scheme 1-28. Synthesis of Cbz-protected epoxide 1-98 
 
When subjecting epoxide 1-98 to the cyclization conditions, a decrease in reactivity and 
selectivity was observed for the desired product 1-99, versus the reduced product 1-100. This 
was a significant problem because, in addition to not fully consuming the starting material, there 
were often different ratios of the desired indoline to reduced product, as outlined in Table 1-4.  
 
 
                                                 
1 Nano-Zinc is a high purity metal of small particle size (100 nm) and greater reactivity than 
most commercially available zinc metal, and was obtained as a gift from Umicore Zinc 
Chemicals.  
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Table 1-4. Reductant screening for radical cyclization of Cbz-protected epoxide 1-98 
Cp2TiCl2 (10 mol%), M (mol%)
N
Cbz H
OH
N
Cbz
1-98
O N
OH
Cbz
1-99 1-100
rt, coll-HCl (4 equiv), THF (0.1 M)
 
entry M (mol%) conversion (TLC)  1-99:1-100 (determined by 1H NMR of crude) 
1 Mn (150) complete ~2:1 
2 Nano-Zn (70) complete ~1:1 
3 Zn (70) complete ~1:1 
4 Li (150) messy inconclusive 
5 Mg (156) no rxn. - 
6 Fe (150) no rxn. - 
7 Sm (150) incomplete inconclusive 
 
In the cyclization of alkyl radicals onto aromatic systems, the ratios of the cyclized 
product to the reduced product can reflect the relative rates of cyclization versus the relative rates 
of reduction.42 Therefore, it was necessary to optimize the reaction conditions to promote the 
cyclization, while avoiding reduction of the β–titanoxy radical through either hydrogen atom 
abstraction or SET to the tertiary radical intermediate.74 As shown in Table 1-4, varying the 
choice of reductant did not significantly affect the ratio of cyclized to reduced products, and 
starting material remained in some cases (according to TLC analysis).  
In addition to qualitative analysis, consumption of starting material was determined by 1H 
NMR through the disappearance of the hydrogen resonance at δ = 2.50 (A of AB, 1 H, J = 4.8 
Hz) on the epoxide methylene group of 1-98; however, in most cases it was difficult to determine 
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due to the presence of the broad singlet of the collidine methyl peak (δ = 2.45).  Therefore, crude 
ratios were determined from integration of δ = 4.12 (A of AB, 1 H, J = 11.8 Hz) of the indoline 
1-99 compared to the methyl group (δ = 0.88 (d, 3 H, J = 6.9 Hz)) of 1-100. The diagnostic 
chemical shifts observed in 1H NMR spectra of the crude material are assigned to the appropriate 
structures as shown in Figure 1-3. 
 
conditions
N
Cbz H
OHN
Cbz
1-98
O
N
OH
CH3
CH3
Cbz
CH3
1-99 1-100
δ = 1.36 (s, 3 H)
δ = 3.95 (A of AB, 1 H), 3.71 (B of AB, 1 H)
δ = 1.34 (s, 3 H)δ = 2.50 (A of AB, 1 H)   
    2.47 (B of AB, 1 H)
Hc
HdHa
Hb
Ha
δ = 4.12 (A of AB, 1 H)
δ = 0.88 (d, 3 H)
 
Figure 1-3. Diagnostic chemical shifts used to determine product ratios of 1-99:1-100 
 
Since no significant change in indoline selectivity could be achieved through varying the 
reductant, our focus was shifted toward varying the loading of the precatalyst.  The standard 
precatalyst loading in all aforementioned titanocene(III) chloride catalyzed reactions was 10 
mol% of titanocene dichloride.  When using 5 mol% of precatalyst, the starting material was 
consumed and an increase in the indoline to reduced substrate selectivity from ~2:1 to ~3:1 was 
observed, determined by 1H NMR of the crude reaction mixture (Table 1-5).  When the loading 
was lowered further to 3 mol%, the selectivity determined by 1H NMR of the crude reaction 
mixture was a ~7:1 ratio of 1-99:1-100, but the reaction did not proceed to completion.  Finally, 
with a loading of 1 mol%, only 1-100 (35% conversion) was observed in the 1H NMR of the 
crude reaction mixture, in addition to unconsumed starting material (entry 3, Table 1-5).  Based 
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on these results, it was clear that the precatalyst loading played a crucial role in the selective 
formation of the desired indoline product.   
 
Table 1-5. Optimizing precatalyst loading for titanocene(III) catalyzed indoline formation 
Cp2TiCl2 (X mol%), Mn (150 mol%)
N
Cbz H
OH
N
Cbz
1-98
O N
OH
Cbz
1-99 1-100
rt, coll-HCl (4 equiv), THF (0.1 M)
 
entry Cp2TiCl2 
(mol%) 
product ratio  
(1-99:1-100) 
(crude 1H NMR) 
product ratio  
(1-99:1-100) 
(1H NMR, isolated) 
unconsumed 
starting material 
1-98 
reaction 
time 
(h) 
1 5 ~3:1 3.6:1 consumed 24 
2 3 ~7:1 10.3:1 18% (isolated) 18 
3 1 1-99 only - 65% 
(crude 1H NMR) 
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When using 3 mol% of the precatalyst, we observed complete consumption of the starting 
material, in addition to preserving the isolated ~10:1 ratio of 1-99:1-100.  The crude mixture was 
then subjected to Cbz-deprotection using Pd/C and H2, providing 63% (2 steps) of indoline 1-101 
after purification (Scheme 1-29).   
 
1. Cp2TiCl2 (3 mol%), Mn (150 mol%)
    reflux, coll-HCl (1.5 equiv), THF (0.1 M)
N
Cbz
1-98
O
N
OH
H
1-101
2. MeOH, Pd/C, H2 (1 atm)
63% (2 steps)  
Scheme 1-29. Radical cyclization to prepare indoline 1-101 
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In addition to using 1-98 as a model system, the ethyl carbamate 1-103 was prepared in 
three steps, beginning with carbamate formation using ethyl chloroformate followed by 
alkylation and oxidation to give the epoxide in 65% over 3 steps (Scheme 1-30).  Epoxide 1-103 
was subjected to the optimized conditions and displayed similar reactivity to the Cbz-protected 
substrate 1-98 providing the desired indoline product 1-104 in 65% yield. We were satisfied with 
these results when using the benzyloxycarbamate and ethoxycarbamate groups as protecting 
groups and set out to expand the scope of the methodology. 
 
Cp2TiCl2 (3 mol%), Mn (150 mol%)
N
OH
CO2Et
NH2
Br
N
CO2Et
H
N
CO2Et
O1-84
1-104
NaHCO3
EtO(CO)Cl 1. NaH, THF, 0 oC to rt
1-102 1-103
2. m-CPBA, CH2Cl2, 0 oC
        73% (2 steps)
reflux, coll-HCl (1.5 equiv), 
THF (0.1 M)
    65%
THF
89%
 
Scheme 1-30. Synthesis of indoline 1-104 
1.2.3 Preparation of Substituted Indolines  
After developing the optimized procedure to prepare the desired indolines, the next 
challenge was to test the synthetic utility of this transformation by using substituted 
epoxyanilines. The reaction scope was explored by varying both the sterics and electronics 
around the aromatic ring.  A series of Cbz-protected epoxides were prepared using a general 
three-step protocol that begins with carbamate formation from the requisite aniline, followed by 
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methallylation and epoxidation to prepare the desired epoxides (Table 1-6). The epoxyanilines 
were subjected to titanocene(III) chloride catalysis to afford the respective indolines (Table 1-7). 
The para- and ortho-methyl substituted epoxides 1-106 and 1-108 (entries 1 and 2, respectively) 
provided indolines in good to modest yields. A potential reason for the lower observed yield in 
entry 2 may be from the fact that the radical generated has only one reactive site available due to 
the o-substituted methyl group. 
 
Table 1-6. General preparation for substituted Cbz-protected epoxides 
NH2 1. Cbz-Cl, NaHCO3, THF
2. NaH, THF, 0 oC to rt
Br
N
Cbz
N
Cbz
Om-CPBA
R1
R1 R1
CH2Cl2, 0 oC
R2
R2 R2
 
entry carbamate R1 R2 epoxide yield (3 steps) 
1 1-105 CH3 H 1-106 68% 
2 1-107 H CH3 1-108 72% 
3 1-109 OCH3 H 1-110 73% 
4a 1-111 Cl H 1-112 66% 
5 1-113 CO2CH3 H 1-114 75% 
aDMF was used as solvent for alkylation. 
 
The 5-methoxyindoline 1-117 was isolated in low yield (21%, 2 steps). It is possible that 
the electron-rich molecule decomposed through air oxidation, since it was observed that the 
product was isolated as a purple oil after purification.  Electron-deficient substrates underwent 
the epoxide-opening rearrangement to afford indolines in good yields (entries 4 and 5).80,81 When 
epoxide 1-112 was subjected to radical cyclization conditions and subsequent Cbz deprotection, 
indoline 1-101 was isolated, which lacked the chlorine substituent. 
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Table 1-7. Indolines prepared using titanocene(III) catalysis 
N
Cbz
O
R1
R2
1. Cp2TiCl2 (3 mol%)
    Mn, THF, reflux
2. MeOH, Pd/C, H2 N
R3
R1
R2
OH
 
entry epoxidea R1 R2 R3 product yield 
1 1-106 CH3 H H 1-115 62%b 
2 1-108 H CH3 H 1-116 35%b 
3 1-110 OCH3 H H 1-117 21%b 
4 1-112 Cl H Cbz 1-118 41%c 
5 1-114 CO2CH3 H H 1-119 56%b 
aSee experimental section for epoxide preparation. bYield determined over 2 steps. cCbz group 
was not removed using Pd/C and H2. 
 
 
Further investigation of the cyclization with epoxide 1-112 showed that the chloride 
remained intact for the cyclization and that Cbz-protected indoline 1-118 could be isolated in 
41% (entry 4, Table 1-7).  It is likely that the aryl chloride is reduced upon subjecting the crude 
mixture to the Cbz deprotection conditions.86 Although not investigated, alternative methods that 
facilitate Cbz deprotection in the presence of aryl halides are known.87,88 To expand the scope of 
our reaction to heteroaromatic systems, the epoxide 1-122 was prepared in four steps from 1-120 
beginning with alkylation using KOH/DMF to afford 1-121, followed by a 3-step sequence of 
NBS bromination, dihydroxylation and epoxide formation (Scheme 1-31).  This substrate was 
tested in the cyclization where a messy reaction mixture was observed by TLC analysis. In this 
case, only the reduced alcohol 1-123 was isolated in 25% yield. 
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N
HO
Br
N
Br
O
NN
H
1-120
KOH, DMF 1. NBS, CH3CN
Br
1-121
1-122
Cp2TiCl2 (3 mol%), Mn
1-123
70 oC 2. OsO4, NMO
3. p-Ts2O, NaH
    82% (3 steps)
reflux, THF (0.1 M)
25%
71%
 
Scheme 1-31. Synthesis of epoxide 1-122 and attempted radical annulation 
 
We were successful in the preparation of the slightly more complex indoline scaffold 1-
126 shown in Scheme 1-32 beginning with 1-124. Through the use of a 3-step protocol involving 
alkylation, dihydroxylation and epoxide formation, 1-125 was isolated in 61% yield over 3 steps. 
When the epoxide was treated with 3 mol% of in situ generated titanocene(III) chloride, 
followed by acetic anhydride, 1-126 was obtained in 69% over 2 steps. In this case, the acylation 
of the alcohol was performed to aid in the purification the indoline product. 
 
N
N
OAc
1-124
1-126
N O
1-125
2. OsO4, NMO
3. p-Ts2O, NaH
1. Cp2TiCl2 (3 mol %)
    THF, Mn, reflux
2. Ac2O, THF
61% (3 steps)
69% (2 steps)
H
1. CH3CN, K2CO3
Br
 
Scheme 1-32. Synthesis of tetrahydroquinoline 1-126 
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 When applying our optimized conditions to epoxide 1-71, the reaction was complete 
within 45 min according to TLC analysis and subsequent 1H NMR of the crude reaction mixture 
showed a ~3.3:1 ratio between the desired indoline 1-72 and hydroquinoline 1-74 (Scheme 1-
33a). Purification by chromatography on neutral alumina afforded a 3.8:1 mixture of 1-72 to 1-
74 in 87% yield. Additionally, upon submitting epoxide 1-77 to the optimized conditions, the 
desired indoline 1-78 was isolated in an excellent 89% yield (Scheme 1-33b). 
 
Cp2TiCl2 (3 mol%), Mn
THF, reflux
87%
3.8:1
N
Ph
1-71
O N
Ph
HO
1-72
N
Ph
OH
1-74
N
Ph
1-77
O
N
Ph
1-78
Cp2TiCl2 (3 mol%), Mn
THF, reflux
89%
(a)
(b)
OH
 
Scheme 1-33. Applying optimized reaction conditions to model substrates 1-71 and 1-77 
1.2.4 Preparation of Azaindolines  
Azaindole (outlined in bold) and azaindoline natural products are less common in nature, 
however, these scaffolds are attractive isosteres of indoles and indolines in pharmaceutical 
research.89 Two examples of azaindole natural products are variolin B 1-127, and deoxyvariolin 
B 1-128, which have been isolated from the rare Antarctic sponge, Kirkpatricka varialosa 
(Figure 1-4). Compounds containing the azaindole core have found many therapeutic 
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applications that include HIV-1 attachment inhibitors90,91 (1-129 and 1-130) and treatment for 
neurological diseases92 (1-131) (Figure 1-4). 
 
N N
N
N
N
NH2
R
NH2
1-127: variolin B, (R = OH)
1-128: deoxyvariolin B, (R = H)
N
HN
O
N
O
N
Ph
O
Me
1-130
HIV inhibitor
N
N
O
N
NH
Me
Cl
O
1-131
N
N
H
O
N
O
N Ph
O
OMe
1-129
HIV inhibitor
 
Figure 1-4. Biologically active azaindoles (outlined in bold) 
 
The next step toward broadening the scope and application of our methodology was to 
prepare azaindolines. This could be accomplished by using aminopyridines in place of anilines. 
Azaindoline precursors (2- and 4-aminopyridine 1-132 and 1-133, respectively) are shown in 
Scheme 1-34. Although the Cbz protection and subsequent alkylation of the carbamates using 
methallyl bromide to produce 1-134 and 1-135 occurred without a problem, epoxide formation to 
produce 1-136 and 1-137 using either a 2-step dihydroxylation/ring closure protocol, or a direct 
epoxidation using m-CPBA or DMDO could not be accomplished. 
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Y
X NH2
1. Cbz-Cl
2.
Y
X N
Cbz
OsO4, NMO 
then NaH, p-Ts2O
DMDO
Br
Y
X N
Cbz
O
m-CPBA
1-132: X = N, Y = CH
1-133: X = CH, Y = N
O
O
or
Y
X N
Cbz
O1-134: X = N, Y = CH1-135: X = CH, Y = N
1-136: X = N, Y = CH
1-137: X = CH, Y = N  
Scheme 1-34. Initial attempts to prepare pyridine epoxides 
 
Although chemoselective epoxidation of alkenes in the presence of the pyridine ring is 
precedented, attempts to efficiently prepare 1-136 and/or 1-137 were unsuccessful. It was found 
that exposure of either 1-134 or 1-135 to dihydroxylation conditions using osmium tetroxide 
resulted in no reaction. In contrast, treating the olefins with m-CPBA or DMDO produced polar 
compounds that were difficult to isolate.80,81 These observations were attributed to the Lewis 
basic nature of the pyridine nitrogen, which is known to react with both m-CPBA or DMDO to 
form N-oxide products.93 
In contrast, an ortho-chlorine substitution94 proved to be sufficient to attenuate the 
reactivity of the pyridine nitrogen.  Curtius rearrangement of the known carboxylic acid 1-13895 
followed by subsequent trapping of the intermediate isocyanate with benzyl alcohol afforded the 
Cbz-protected aminopyridine 1-139 in 33% yield over 3 steps (Scheme 1-35). Subsequent 
methallylation and epoxidation using m-CPBA led to epoxide 1-140, which, when treated with 
catalytic titanocene(III) chloride, provided an intermediate 4,6-dichloro-5-azaindoline. This was 
then treated with Pd/C under an atmosphere of H2 to give azaindoline 1-141 in 52% yield over 2 
steps.80,81 
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N
Cl
Cl N
Cbz
O
N
N
H
OH
1-140
1-141
N ClCl
O OH
N ClCl
N
H Cbz
1-1391-138
1. Cp2TiCl2 (3 mol %)
    Mn, THF, reflux
1. (COCl)2, THF
2. NaN3, acetone 1. NaH, THF
3. BnOH, toluene
33% (3 steps)
2. m-CPBA  
    CH2Cl2
2. Pd/C, H2, MeOH
Br
64% (2 steps)
52% (2 steps)  
Scheme 1-35. Preparation of 5-azaindoline 1-141 
 
1.2.5 Regioselectivity Studies and Potential Applications 
 To further expand the scope of the methodology, the regioselectivity and 
diastereoselectivity of the annulation were investigated. Epoxide 1-144 (prepared in 4 steps from 
1-142) was subjected to titanocene(III) catalysis, which afforded a 1:1 mixture of regioisomers 1-
145 and 1-146 in 63% yield. Subsequent reduction of the ethyl carbamates using LiAlH4 
provided N-methyl indolines 1-147 and 1-148, respectively (Scheme 1-36).81 Reduction of the 
carbamates was necessary since the materials were not stable to high temperature 1H NMR 
analysis in DMSO-d6. 
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TBSO N
CO2Et
O
OH
NH2
1. TBSCl, imid., THF
2. EtOCOCl, py
    CH2Cl2
90% (2 steps)
OTBS
N
H CO2Et
Br
1. NaH, TBAI, THF
2. m-CPBA, CH2Cl2
40% (2 steps)
Cp2TiCl2 (3 mol %)
Mn, THF, reflux, 63% R2 N
R1
OH
N
R1
OH
R2
1-145, R1 = CO2Et, R2 = OTBS
                               
1-147, R1 = CH3, R2 = OTBS
1-146, R1 = CO2Et, R2 = OTBS
                               
1-148, R1 = CH3, R2 = OH
LiAlH4
85%
LiAlH4
77%
(1-145:1-146 = 1:1)
1-142 1-143
1-144
 
Scheme 1-36. Regioselectivity studies for radical annulation reaction 
 
With access to indolines 1-145 and 1-146, the preparation of cyclopropanes similar to 
those found in the duocarmycin family of natural products (Figure 1-2) was attempted. It was 
observed that after the treatment of 1-145 with MsCl, followed by treating the crude reaction 
mixture to TBAF in THF, the desired product 1-149 could be detected by 1H NMR as well as 
MS analysis (Scheme 1-37). Unfortunately, the cyclopropane proved to be an unstable 
compound to fully characterize, although similar C2BI analogs 1-150 are known to be stable and 
have been prepared by Boger.96 Furthermore, when exposing 1-146 to the same reaction 
conditions, the mixture appeared to have decomposed and 1-151 was not observed. 
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N
CO2Et
O
N
CO2Et
OTBSO N
CO2Et
OH
1-149
1. MsCl, NEt3, CH2Cl2
2. TBAF, THF
1. MsCl, NEt3, CH2Cl2
2. TBAF, THF
1-146
1-145
1-151
N
CO2Et
OH
OTBS
NO
Cl
Boc
1-150
N-Boc C2BI
 
Scheme 1-37. Attempts to prepare CPI analogs 
 
1.2.6 Diastereoselectivity Studies  
The cyclic epoxide 1-155 was prepared in an effort to probe the diastereoselectivity of the 
cyclization reaction. To begin, allylic alcohol 1-153 was prepared in 3 steps97 from 1-152 by 
oxidation to the unsaturated ketone followed by Luche reduction (Scheme 1-38).98 Activation of 
the alcohol using MsCl followed by displacement with Cbz-aniline afforded the olefin 1-154 in 
56% yield over 2 steps. Epoxidation of the olefin using m-CPBA yields 1-155 in 84%. 
Presumably the epoxidation reaction produces 1-155 as a mixture of diastereomers, however, due 
to the instability of the epoxide, the diastereoselectivity was not determined. Instead, the product 
was used immediately following purification in the key titanocene(III) chloride catalyzed 
cyclization reaction to provide 1-156 in a low 12% yield. Efforts to optimize this reaction were 
unsuccessful and the isolated yields were reproducibly low. When monitoring the cyclization 
reaction by TLC analysis there appeared to be multiple compounds formed in addition to the 
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desired hydrocarbazole 1-156. The resulting alcohol was oxidized using Dess-Martin 
periodinane to yield ketone 1-157 in 63% yield. The relative stereochemistry of the ketone was 
confirmed to be syn due to the strong nOe observed between the tertiary methyl group and the 
methine hydrogen using 2D-NOESY NMR.81 This low isolated yield represents a limitation for 
this methodology to construct hydrocarbazoles. 
 
N
Cbz m-CPBA 
Na2CO3
CH2Cl2/H2O
84%
N
Cbz
O
N
Cbz
H3C
HO
Cp2Ti(III)Cl
 (3 mol %) Dess-Martin
H
1-154
1-155 1-157
Ph
Ph
THF, reflux
12%
N
Cbz
H3C
O
HCH2Cl263%
1-156
OHO 1. SO2Cl2, CCl4
2. quinoline, 190 oC
3. NaBH4, CeCl3, MeOH
26%, 3 steps
1. MsCl, CH2Cl2, NEt3
2. NaH, DMF
1-152 1-153 56%, 2 steps
N
Cbz
Ph
H
 
Scheme 1-38. Preparation of hydrocarbazole scaffold 
 
1.2.7 Potential Reaction Mechanisms 
Various mechanisms for the titanocene-catalyzed annulation can be postulated. The first 
one involves the Lewis acid activation of the epoxide by the precatalyst or catalyst to promote an 
electrophilic aromatic substitution. The second involves the reductive opening of the epoxide via 
SET followed by radical cyclization onto the aromatic ring.  The former is demonstrated in 
Scheme 1-39 where epoxide 1-98 may be activated by titanocene dichloride to provide 
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intermediate 1-158, which is predisposed to undergo a Friedel-Crafts99-101 (FC) rearrangement to 
afford indoline 1-99.  Although present in the reaction mixture, the manganese salts are not 
believed to play a role in the FC manifold. 
 
N
Cbz
O
Friedel-Crafts
1-98
N
OH
Cbz
1-99
Cp2TiCl2 (3 mol%)
Mn (150 mol%)
coll-HCl (1.5 equiv.)
N
Cbz
O
L(Cp2)Ti
1-158
-H+
 
Scheme 1-39. Proposed scheme for indoline 1-99 formation through FC manifold 
 
In contrast, after the reductive epoxide opening of 1-98 to generate 1-159, the radical can 
cyclize onto the aromatic ring and undergo oxidative rearomatization to provide indoline 1-99 
(Scheme 1-40).  
N
OH
Cbz
radical cyclization
1-99
N
Cbz
O
N
Cbz
O
L(Cp2)Ti
1-159
1-98
-e-, -H+
Cp2TiCl2 (3 mol%)
Mn (150 mol%)
coll-HCl (1.5 equiv.)
 
Scheme 1-40. Proposed formation of indoline 1-99 through the radical cyclization manifold 
 
Preliminary results indicate that the path in Scheme 1-40 is the general pathway operating 
in our system since: 1) although the activated p-methoxy aromatic substrate 1-110 is suited for 
FC-type reactions, when performing the cyclization reaction only about a 20% yield of desired 
indoline 1-117 was observed; 2) it is known in the literature, as well as through our unreported 
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results, that using the FC alkylation reaction to form indanes and indolines through an acyclic 
aliphatic epoxide tether often results in low yields with multiple side products, including the 
aldehyde.102-104 Unfortunately, under our optimized conditions, neither of these compounds were 
detected in the 1H NMR analysis of our crude reaction mixtures. 
The sensitivity of the reaction to both ambient oxygen and water was investigated. When 
subjecting 1-98 to titanocene(III) catalysis in a reaction flask open to ambient air, 1-99 was 
isolated in 14% yield, in addition to 43% of recovered starting material (Table 1-8, entry 1). This 
observation suggested that the desired reaction is inhibited by ambient oxygen, thus requiring the 
rigorous deoxygenation of the reaction solvent. To test the sensitivity of the reaction to water, 
epoxide 1-103 was subjected to titanocene(III) catalysis using a degassed mixture of distilled 
THF:H2O in an equivolume ratio. The experiment resulted in the recovery of 89% of the starting 
material, and indicated that the reaction was sensitive to water (entry 2). Although some 
titanocene(III) chloride-mediated processes utilize water as a co-solvent,105 this catalytic process 
appears to be inhibited by its presence. Additional control experiments using either only 3 mol% 
of the precatalyst (entry 3) or only 1.5 equiv of manganese metal (entry 4) under otherwise 
identical reaction conditions failed to afford indolines.80,81 These observations suggest that the in 
situ generated titanocene(III) chloride reagent is responsible for promoting the annulation via a 
radical pathway.  
In order to further elucidate the mechanism of oxidative rearomatization under the 
reductive conditions, we tested whether the precatalyst would be able to oxidize the hypothesized 
cyclohexadienyl radical intermediate, thereby regenerating the titanocene(III) catalyst and 
facilitating the rearomatization. 
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Table 1-8. Condition used in control experiments to determine reaction sensitivity 
N
R O
N
R
conditions
collidine•HCl, THF
OH
 
entry epoxide R Cp2TiCl2 (mol%) Mn (equiv) product(s), yield 
1 1-98 Cbz 3 1.5 1-99, 14% (1-98, 43%)a,c 
2 1-103 CO2Et 3 1.5 1-104, 0% (1-103, 89%)b,c 
3 1-98 Cbz 3 0 1-99, 0% 
4 1-98 Cbz 0 3 1-99, 0% 
5 1-98 Cbz 3 0.15 1-99, 35% (1-98, 38%)c 
aReaction performed in a flask open to the atmosphere in distilled, non-degassed THF; bReaction performed in a 
degassed mixture of distilled THF:H2O (1:1); cStarting material was recovered from the reaction. 
 
When epoxide 1-98 was subjected to 15 mol% of manganese reductant, 1-99 was isolated 
in 35% yield, in addition to 38% of starting material (entry 5, Table 1-8). This result indicates 
that a stoichiometric amount of manganese reductant is required to achieve optimal yields during 
the cyclization reaction. 
In accordance with the general mechanism published on titanocene(III) chloride catalysis 
(shown in Scheme 1-14 above), it is envisioned that our transformation may proceed through the 
sequence shown in Scheme 1-41.  The reagents required for the reaction include the titanocene 
dichloride precatalyst, collidine hydrochloride and manganese metal.  We believe the sequence 
begins with the generation of the titanocene(III) chloride species, followed by the reductive 
epoxide opening of 1-160 to form radical 1-161. This intermediate likely undergoes a reversible 
cyclization onto the aromatic ring, which may proceed through a chair-like Beckwith-Houk 
transition state106,107 to afford intermediate 1-162.  This species then undergoes an oxidation to 
provide the rearomatized compound 1-163.108 The indoline is then liberated from the catalyst by 
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protodemetallation of the alkoxide by using 1-61. This provides the product 1-164, and the 
precatalyst, which is eligible to be reduced to Cp2Ti(III)Cl and re-enter the catalytic cycle. 
   
X
N
Cbz
O
X
N
Cbz
oxidation
1/2 Mn0
alkyl radical 
cyclization
X
N
Cbz
OTi(IV)
X
N
Cbz
H
OTi(IV)
X
N
Cbz
Coll•HCl
1-61
OH
reductive epoxide 
opening
1/2 MnCl2
OTi(IV)
alkyl radical 
reformation
H+
X = CH or N
Cp2TiCl2
Cp2TiCl
1-160
1-161
1-162
1-163
1-164
 
Scheme 1-41. Proposed catalytic cycle for titanocene(III) chloride radical cyclization  
 
Although the mechanism of oxidative rearomatization process under reductive conditions 
remains to be established,108 two main pathways have been postulated.  The first is applicable to 
our system and involves the single-electron oxidation of the cyclohexadienyl radical 1-162 and 
subsequent proton loss to afford the rearomatized compound 1-163.106,109-111 The second pathway 
may involve the loss of a hydrogen atom from intermediate 1-162, which may then undergo a 
radical recombination to provide the aromatic product 1-163.112,113 The postulated mechanistic 
pathways remain speculative in the absence of additional rigorous mechanistic investigations. 
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1.3 CONCLUSIONS 
In conclusion, a new method to prepare indolines and azaindolines utilizing an epoxide-
opening rearrangement catalyzed by in situ generated titanocene(III) chloride was developed. 
Although this reaction was not regioselective, many of the desired indolines could be prepared in 
good to moderate yields. Control experiments indicate that the reaction is sensitive to both water 
and ambient air, and requires the presence of both the precatalyst and the manganese metal to 
promote the annulation.  
The substrate scope of the reaction has been limited to the use of 1,1-disubstituted 
epoxyanilines to prepare 3,3-disubstututed indolines. One 5-azaindoline has been prepared using 
the analogous 4-aminopyridine group as the radical acceptor. In general, the azaindoline scaffold 
was more difficult to access due to the challenges associated with the preparation of the requisite 
epoxide starting materials. 
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2.0  1,2,4-TRIAZINE SYNTHESIS USING THE STAUDINGER/AZA-WITTIG 
REACTION  
2.1 INTRODUCTION 
2.1.1 Applications of the Staudinger/aza-Wittig (SAW) Reaction 
The azide is a versatile functional group in organic synthesis, and methods for its 
preparation114 and synthetic applications have been reviewed.115 Figure 2-1 shows general 
examples of the organic azide being used in synthesis that include the preparation of isocyanates 
2-1 from acid chlorides 2-2 (Curtius rearrangement),116 lactams 2-3 from ketones 2-4 (Schmidt 
reaction),116 and diazo compounds 2-11 from β-ketoesters 2-10.31 Additional applications include 
the 1,2,3-triazole 2-9 synthesis using a copper-catalyzed [3+2] cycloaddition with alkynes 2-8 
(“click chemistry”),117 and transforming chloroenamines 2-12 into 3-amino-2H-azirines 2-13, 
which serve as efficient precursors for α,α-disubstituted amino acids.118 For this chapter, the 
relevant transformation involving the organic azide is the Staudinger/aza-Wittig (SAW) 
reaction.116 This tandem reaction begins with the decomposition of organic azides to reactive 
iminophosphoranes 2-5 through treatment with trialkyl/triaryl phosphines and phosphites. These 
intermediates may be hydrolyzed to the corresponding amines 2-6, or in the absence of water and 
the presence of a reactive carbonyl group, may undergo the aza-Wittig reaction to yield 2-7. In 
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both the hydrolysis and aza-Wittig reactions, the phosphine oxide byproducts are often difficult 
to remove during purification. To aid in their removal, polymer support variants have been 
developed.119 
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Scheme 2-1. General applications of the organic azide functional group 
 
The reactivity profile of the iminophosphorane intermediate 2-5 lends itself to an 
intermolecular aza-Wittig reaction in the presence of an aldehyde, ketone, acid halide, or 
heterocumulene to afford the respective product represented as 2-7.120 Less reactive functional 
groups such the imide, ester, and amide may react with 2-5 in an intramolecular fashion. 
Applications of the SAW reaction in natural product synthesis include the work by Williams and 
co-workers121 to prepare members of the Stemona alkaloid family such as (-)-stemonine 2-17 and 
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(-)-stemospironine.122 Highlights of the preparation of stemonine include the treatment of the 
advanced intermediate 2-14 with EtPPh2 in benzene, followed by reduction of the imine using 
NaBH4 in THF and MeOH. The pyrrolidino-butyrolactone system 2-16 was installed using an 
iodine-induced cyclization event, where the product was further converted to the natural product 
2-17. 
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Scheme 2-2. Williams’ preparation of stemonine 2-17 
 
During the preparation of the potent anticancer agent apratoxin A, Forsyth and Chen123 
installed the sensitive thiazoline ring using the SAW reaction in the late stages of their synthesis. 
Treating the advanced intermediate 2-18 with PPh3 and THF promoted the Staudinger/aza-Wittig 
reaction with the thioester to provide the thiazoline 2-19 in 63% yield (Scheme 2-3). Subsequent 
protecting group removal and macrolactonization afforded apratoxin A 2-20. 
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Scheme 2-3. Thiazoline formation using the Staudinger/aza-Wittig reaction 
 
Eguchi and Takeuchi124 have demonstrated that azides such as 2-21 can be transformed 
into iminolactam derivatives 2-22 in a one-pot process in good yields as shown in Scheme 2-4. 
This transformation provides precedence for the aza-Wittig reaction with phthalimides, and the 
inspiration to expand the methodology for the synthesis of 1,2,4-triazines similar to 2-23. 
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Scheme 2-4. Staudinger/aza-Wittig reaction to form iminolactam derivatives 
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2.1.2 Wipf Group Methodology: 1,2,4-Triazine Synthesis 
The synthesis of 1,2,4-triazines in the Wipf group began with studies conducted by Dr. 
David Amantini, Dr. Stephan Elzner and Dhezi Fu, who have demonstrated that alkyl azides 
such as 2-24 shown in Scheme 2-5 can be treated with trialkyl/aryl phosphines to afford 1,2,4-
triazines such as 2-25. Under this reaction manifold, a series of substituted triazines of this class 
have been successfully prepared (unpublished results). 
 
PR3, toluene
2-24 2-25
Staudinger
aza-Wittig
N
O
N
N
H
N
O
O
N
H
N3
 
Scheme 2-5. Staudinger/aza-Wittig reaction to prepare 1,2,4-triazines 
 
In addition to the studies using cyclic imides, Amantini, Elzner and Fu demonstrated that 
aryl hydrazides 2-26 could undergo reductive amination to prepare hydrazide derivatives similar 
to 2-27. After alkylation and subsequent TBS deprotection to provide 2-28, alcohol activation 
and azide displacement yields 2-29. The azides were finally treated with trialkylphosphines to 
promote a SAW reaction, thereby forming triazines 2-30 in 54-86% yields for the R-groups 
shown in Scheme 2-6.  
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Scheme 2-6. Preparation of substituted 1,2,4-triazines 
  
During their studies, a second-generation approach toward hydrazides similar to 2-29 was 
developed. This method employs the azido aldehyde in the reductive amination reaction step 
(Scheme 2-7). After alkylation with benzyl bromide to afford 2-29, the azides have been 
transformed into triazines in the same manner as previously shown in Scheme 2-6. 
 
R
H
N
O
N
H
N3 R
H
N
O
N
N3
BnBr, K2CO3, DMF
R
H
N
O
NH2
O
N3
1. 4Å MS, CH2Cl2
2. NaCNBH3,
    CH3CN/AcOH
2-26 2-31 2-29
Bn
CF3
N
R =
  
Scheme 2-7. Alternative approach toward preparing hydrazide 2-31 
 
 
 50 
 
Both linear approaches are effective in the preparation of 2-30, although we envisioned 
developing a convergent approach toward the synthesis of similar hydrazides. This could be 
accomplished by the coupling of a functionalized 1,1-disubstituted hydrazine with an activated 
carboxylic acid to arrive at 2-29. 
2.1.3 Xestospongia Metabolites: Noelaquinone and Related Structures 
 In addition to developing a novel methodology, this SAW reaction could potentially be 
used toward natural product synthesis. Noelaquinone 1-32 was isolated in 1996 from an 
undescribed species of Xestospongia by Scheuer at Derawan Island, Indonesia (Scheme 2-8).125 
This marine metabolite has the potential to be biologically active since a similar natural product, 
halenaquinone 2-38 has been shown to possess antibiotic,126 cytotoxic and antifungal activity.127 
Halenaquinone and xestoquinone are also known inhibitors of Pfnek-1,128 a kinase responsible 
for the phosphorylation of Pfmap-2. This phosphorylation sequence has been identified as a 
critical step in the life cycle of the parasite and is being targeted as a method to treat malaria.129 
Although no total synthesis of noelaquinone has been published to date, halenaquinone has been 
a target for synthetic chemists.130,131 Additional natural products isolated by Scheuer from the 
undescribed species of Xestospongia include the previously reported halenaquinone132 2-38, 
Kitagawa’s quinol 2-33 and monosulfate133 2-34, xestoquinone134 2-35, and the discovery of 
methoxyhalenaquinone 2-36 and hydroxyhalenaquinone 2-37.  
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Scheme 2-8. Noelaquinone and other natural products isolated by Scheuer 
2.1.4 Wortmannin and Halenaquinone Analogs Prepared in the Wipf Group 
  A group of natural products that contains the tricyclic furan group similar to 
halenaquinone is the viridin family,135 which includes wortmannin 2-39 and viridin 2-40 (Figure 
2-1). Wortmannin and viridin are classified as potent kinase inhibitors, however, their inhibition 
is not selective, thus making them poor candidates for therapeutics.136 The Wipf research group 
maintains initiatives to design protein tyrosine kinase inhibitors137 and phosphatidylinositol 3-
kinase (PI-3 kinase) inhibitors,138 since the development of selective as well as potent inhibitors 
for the PI-3 kinase family is believed to have therapeutic potential.139 
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Figure 2-1. Natural products containing the reactive tricyclic furan group 
 
The proposed biological activity of the molecules shown in Figure 2-1 is believed to arise 
from the addition of a kinase residue 2-41 to the reactive Michael acceptor of wortmannin 
(highlighted) thereby forming a covalent adduct 2-42 that inhibits the protein function (Scheme 
2-9).140,141 Researchers in the Wipf group have prepared and analyzed a library of nucleophilic 
adducts of wortmannin and found that analog PX-866 2-43 is a potent phosphoinositide (PtdIns)-
3-kinase inhibition. The N,N-diallylamine adduct of wortmannin exhibited an IC50 value of 0.1 
nM against PtdIns-3-kinase.142  
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Scheme 2-9. Proposed mechanism of action for kinase inhibition and the design of inhibitor PX-866 2-43 
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 The Wipf research group has also studied halenaquinone and derivatives to function as 
kinase inhibitors in Plasmodium falciparum, the parasite responsible for malaria in humans.143 
Malaria is estimated to result in 300-500 million clinical cases every year, and over two million 
people infected will die as a result.144,145 The U.S. Army is also actively involved in research to 
further understand and prevent malaria since many of its personnel are at risk of contracting the 
disease while deployed.  Researchers at the Walter Reed Army Institute of Research (WRAIR) 
continue to study and develop new treatments for drug-resistant strains of malaria.146 In an effort 
to develop a new kinase inhibitor, Wipf147 and Wakefield148 published the synthesis of a 
thiophene-containing analog of halenaquinone, thiohalenaquinone 2-44. The rationale behind the 
analog design was to attenuate the reactivity of the Michael acceptor by replacing the furan ring 
with thiophene. Computational analysis showed that 2-44 is 2.6 kcal/mol lower in relative strain 
energy than 2-38, which, in part, was theorized to increase the selectivity profile of the molecule 
for the targeted kinase (Figure 2-2). 
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Figure 2-2. Proposed analog of halenaquinone, thiohalenaquinone 2-44 
 
The synthesis of thiohalenaquinone was accomplished by treating 2-46 (prepared in 12 
linear steps from 2,3-dibromothiophene 2-45) with the diene precursor 2-47 to promote a Diels-
Alder reaction followed by a palladium-catalyzed Heck cyclization to provide 2-49 in 10% yield 
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over 4 steps. After a global desilation, the resulting alcohol was oxidized using MnO2 to give 
aldehyde 2-50 (Scheme 2-10).  
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Scheme 2-10. Preparation of thiohalenaquinone 
  
 The allylation using allyltributyltin afforded alcohol 2-51 as an inconsequential mixture 
of diastereomers. The endgame of the synthesis includes a ruthenium2 catalyzed olefin 
isomerization/metathesis sequence to form the A ring of thiohalenaquinone, where after a series 
of oxidation state adjustments around the periphery of the core the preparation of 2-44 was 
completed (Scheme 2-11). In collaboration with the Dow group at the Walter Reed Army 
Institute of Research (WRAIR), a series of samples that were prepared by Wakefield were 
screened against Pfnek-1. The natural product analog 2-44 inhibited Pfnek-1 with an IC90 value 
of 4.6-6.7 µM,148 which is similar to the IC50 values of xestoquinone 2-35 and halenaquinone 2-
                                                 
2 The catalyst used in this transformation is the Hoveyda-Grubbs 2nd generation. 
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38, which are 1.1 µM and 3.0 µM, respectively.148 Additional molecules prepared in the 
endgame of the synthesis were also screened, and the results are presented in Table 2-1. 
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Scheme 2-11. Preparation of thiohalenaquinone 
 
Table 2-1. IC90 values of thiohalenaquinone analogs prepared by Wakefield 
S
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2-55 2-44  
entry thiohalenaquinone analog IC90 (µM) 
1 2-54 2.8-3.9 
2 2-53 >2500 
3 2-55 >2500 
4 2-44 4.6-6.7 
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2.2 RESULTS AND DISCUSSION 
2.2.1 Model System Studies for the DEF Rings of Noelaquinone 
 In the Wipf group, the SAW methodology was being applied toward the synthesis of the 
1,2,4-triazine-containing natural product noelaquinone. Amantini and Elzner began studies 
toward the preparation of a model system of noelaquinone. They reported subjecting 2-56 to the 
SAW conditions outlined in Scheme 2-12, however, no triazine products 2-57 or 2-58 were 
observed. 
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?
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Scheme 2-12. Screening the SAW reaction conditions on substituted lactams 
 
 This failed result inspired the design of a second-generation approach toward preparing 
model system 2-59, which is derived from homophthalimide 2-61 rather than the lactam 2-56. 
The homophthalimide could be prepared through hydrazide formation between acid 2-62 and 
hydrazine 2-63, followed by an annulation using diethylmalonate as the source for the remaining 
carbons (Scheme 2-13). The first step toward assembling 2-59 would be to prepare 2-63 as the 
requisite coupling partner. 
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Scheme 2-13. General retrosynthesis of the model system for noelaquinone 
 
 Two approaches were investigated for the preparation of 2-63. The first approach 
involved hydrazine formation through an electrophilic amination protocol. Using this protocol 
allowed us to prepare the target in a convergent manner. Although there are many reagents 
known to promote electrophilic amination reactions,149 the O-
diphenylphosphinylhydroxylamine150 2-66 was prepared and utilized for the task. Upon 
treatment of azide 2-65151 with 2-66 using either EtOH and potassium carbonate or DMF and 
cesium carbonate,152 no desired hydrazine product was detected (Scheme 2-14). 
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Scheme 2-14. First approach toward preparation of hydrazine 2-63 
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The second approach began with screening conditions for the preparation of a stable 
hydrazone from the commercially available 2-hydroxyethylhydrazine 2-67. It was necessary to 
protect the hydrazine to prevent undesired side reactions during the conversion of the distal 
hydroxy group into the azide. Using this approach with the hydrazine group already in place 
eliminated the need for electrophilic amination protocols. A series of aldehydes and ketones153 
were screened in search of a stable protecting group for 2-67 in its hydrazone form. It was 
observed that the resulting hydrazones 2-68 (derived from the aldehydes and ketones shown in 
Scheme 2-15) were unstable during purification by chromatography on SiO2, or during 
subsequent steps in the linear sequence. 
 
N
N
OH
H
2-68
unstable during purification 
and/or storage
Ph
O
H
O
H
O
H
MeO
BnO
Ph
O
Ph
condensation
R
R
THF, heat
H2N
N
OH
H
2-67  
Scheme 2-15. Initial protecting group study for 2-67 
 
 It was later realized that the condensation of 2-67 with ethyl pyruvate 2-69 provided a 
hydrazone that was stable to hydrolysis upon workup, as well as column chromatography 
(Scheme 2-16).154 Identifying a stable hydrazone was critical since the sequence involves the 
handling of intermediate 2-71, where if hydrolysis occurs during the purification step after azide 
displacement, the formation of 2-73 could be dangerous due to the explosive nature of low 
molecular weight organic azides.115 
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 Activation of alcohol 2-70 with MsCl followed by azide displacement provided an 
intermediate that, after purification to remove the residual sodium azide, was treated with BnBr 
and K2CO3 in DMF to afford the N-benzylhydrazone 2-72 in 50% yield over 3 steps. This 3-step 
sequence was performed without incident using 45 g of alcohol 2-70 to prepare azide 2-72. The 
hydrazone was stable to storage on the benchtop for months without noticeable decomposition 
by 1H NMR. 
 To cleave the hydrazone, 2-72 was treated with excess hydrazine dihydrochloride in 
aqueous THF to yield 2-63 in 63% yield.155 During the scale up of this reaction, it was found that 
excess hydrazine dihydrochloride, or conc. HCl and hydrazine hydrate needed to be added to 
drive the reaction to completion. Yields could be obtained as high as 91% for this deprotection. 
Changing the acid source to acetic acid ensured complete conversion to 2-63 from 2-72. This 
compound proved to be unstable to storage and was used immediately after purification by 
column chromatography. 
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Scheme 2-16. Synthesis of hydrazine synthon 2-63 
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2.2.2 Preparing the Precursor for the Staudinger/aza-Wittig Reaction 
After developing a sequence to obtain the hydrazine on preparative scale, our efforts 
became focused toward the preparation of 2-61. In accordance to Scheme 2-17, the preparation 
was accomplished in a convergent manner beginning with the coupling of acid chloride 2-74 
with hydrazine 2-63 to afford hydrazide 2-75 in 69% yield after recrystallization. Treatment of 2-
75 with 5 mol% of CuI, 10 mol% of picolinic acid, 2 equiv of diethylmalonate and 3 equiv of 
Cs2CO3 in dioxane afforded the α-aryl malonate (not shown).156,157 This intermediate was used 
crude after workup, and treatment with cat. p-TSA in aqueous toluene promoted a 
cyclization/decarboxylation to yield 2-61 in 70% over 2 steps.  
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Scheme 2-17. Preparation of homophthalimide 2-61 
 
The resulting homophthalimide served as a key intermediate in the approach to complete 
the model system of noelaquinone. The remaining two steps consisted of the Staudinger/aza-
Wittig reaction and the subsequent oxidation at the benzylic position to arrive at the DEF ring 
system 2-59.  
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2.2.3 Testing the Staudinger/aza-Wittig Reaction/Enamine Oxidation 
Our initial approach toward the model system involved performing the SAW reaction 
followed by oxidation at the benzylic position of the product to arrive at 2-59.  In general, either 
PBu3 or DPPB as the phosphine source promotes the SAW reaction. Microwave irradiation of 
the reaction in place of conventional heating greatly decreases reaction times, as established by 
Amantini and Elzner. In experiments using the homophthalimide 2-61 in the SAW reaction, the 
isolation of 2-76 was quite challenging due to rapid (aerobic) oxidative decomposition of the 
substrate. Additionally, the removal of the phosphine oxide impurities was problematic since 
they often co-eluted with the product during purification. The 1H NMR analysis of the purified 
material from the SAW reaction typically showed the diagnostic chemical shift of the vinyl 
methine singlet at 5.55 ppm (1 H), indicating that compound 2-76 was the preferred tautomer 
over 2-60 (Scheme 2-18).3 
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Scheme 2-18. Staudinger/aza-Wittig then oxidation approach 
 
                                                 
3 See Scheme 2-19 below for reference compounds. 
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Molecules with cores similar to 2-76 have been prepared by Fritz and co-workers158 
through the condensation of homophthalic acid 2-77 and various diamines in refluxing o-DCB. 
The products from the SAW reaction were characterized to have a vinyl methine of similar 
chemical shift to those observed in 2-78 (Scheme 2-19). 
 
CO2H
CO2H
H2N N
On
o-DCB, reflux
2-77 2-78
δ = 5.55 +/-0.35 ppmH
H
N
nNH2
n = 1-2  
Scheme 2-19. Fritz’s preparation of ketene aminals 2-78 
 
During the storage of enamine 2-76 at room temperature, the desired triazine 2-59 was 
obtained. These conditions presumably allow for the aerobic oxidation of the DEF ring system. 
Although isolated by purification using SiO2 and characterized as the enamine, a purity check by 
1H NMR of the sample after several days showed the disappearance of the singlet at 5.55 ppm 
and the presence of two new doublets at 8.39 ppm (1 H, J = 7.8 Hz) and 8.22 ppm (1 H, J = 8.4 
Hz). 
A potential mechanism for this auto-oxidation process is proposed in Scheme 2-20. In the 
presence of ambient oxygen the hydroperoxy intermediate 2-79 may be formed.159 After opening 
the cyclic peroxide and proton transfer to form 2-80, a dehydration event can afford the desired 
DEF ring system. Due to the rapid decomposition during purification as well as the phosphine 
oxide impurities that often accompanied the desired product, a quantitative assessment of the 
SAW reaction was not obtained. It was evident that the initial approach toward the DEF ring 
system needed to be revised. 
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Scheme 2-20. Proposed mechanism for auto-oxidation of enamine 2-76 
 
Our strategy changed from initially trying to isolate and characterize the unstable 
enamine toward directly oxidizing the intermediate to the ketone under controlled conditions. 
Ideally, it was envisioned performing a one-pot SAW reaction/oxidation sequence to afford 2-59 
directly. Table 2-2 summarizes some of the conditions screened to promote the SAW 
reaction/oxidation of the enamine intermediate to arrive at 2-59. The SAW step was 
accomplished using conditions outlined in Table 2-2 below.  
The subsequent oxidation step was problematic when using both organic oxidants such as 
Fremy’s salt or inorganic oxidants such as CAN in aqueous media. In both cases, we failed to 
isolate 2-59. In general, the reactions resulted in decomposition of the enamine intermediate into 
compounds that were difficult to isolate and characterize. These results indicated that promoting 
a controlled 4-electron oxidation on 2-76 was not reproducible. 
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Table 2-2. Staudinger/aza-Wittig reaction and oxidation sequence 
N
O
O
N
Bn
N3
N
N
N
O Bn
2-61
H
2-76
N
N
N
O Bn
O
D E F
2-59
oxidation
conditions
PBu3, PhCl
180 oC, µW
15-20 min
 
 
 
 
 
 
 
Based upon the proposed mechanisms of oxidative enamine coupling chemistry utilized 
in MacMillan’s research group,162-164 a possible mechanism for the desired oxidation pathway 
begins with the single electron oxidation of the enamine nitrogen to give the radical cation 2-81 
and its tautomer 2-82. This intermediate then may be oxidized again, forming a transient 
benzylic cation that is immediately quenched by the aqueous media. The α-hydroxy imide 2-84 
can then tautomerize to 2-85, which may then undergo the same 2-electron oxidation sequence to 
arrive at the desired product 2-59 (Scheme 2-21). 
 
entry oxidation conditions 
1 Fremy’s salt, EtOH(aq.)160 
2 CAN, THF (aq.)161 
3 CAN on alumina, THF (aq.) 
4 K3Fe(CN)6, Cs2CO3, THF (aq.) 
5 5% CAN, NaBrO3, THF (aq.) 
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Scheme 2-21. Proposed mechanism for 4-electron oxidation of enamine 2-76 
 
It is precedented that enamines undergo dimerization/oligomerization under oxidative 
conditions.165,166 Another explanation of possible decomposition pathways involves the oxidative 
dimerization of intermediate 2-82 to generate 2-87, which may become oxidized further under 
the reaction conditions (Scheme 2-22).  
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Scheme 2-22. Possible oxidation pathways of 2-76 
 
Efforts to promote the enamine oxidation by bubbling air through a solution of the 
isolated SAW product at 23 oC were also unsuccessful. At this point, our synthetic strategy was 
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redirected toward oxidizing the benzylic position to the ketone before performing the SAW 
reaction. 
2.2.4 Oxidation to Ketone Followed by the Staudinger/aza-Wittig Reaction 
A second-generation endgame sequence was developed, which involved the oxidation of 
2-61 to the trione 2-90, as outlined in Scheme 2-24. In this case, performing the SAW reaction 
on the trione would lead directly to the DEF ring system. Oxidation reactions of similar 
homophthalimides to triones have been accomplished, as shown in Scheme 2-23, where the 
yields for the SeO2 oxidation range in 12-62% (over 2 steps).167 In addition to this method, 
oxidations using dye-sensitized photochemical conditions also afford homophthalimides; 
however, the reaction is often not selective.168 
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2. SeO2, dioxane
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H2N N
H
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R1. RCOCl, dioxane
2-89
12-62% (2 steps)  
Scheme 2-23. Preparation of homophthalimides using benzylic oxidation 
 
An alternative approach toward the oxidation of 2-61 involved the use of CAN in 
aqueous THF to afford the trione. According to qualitative analysis (TLC), the oxidation of the 
benzylic position was a clean reaction; however, the isolated yields of the desired compounds 
were near 30% at best when using either CAN or a mixture of HNO3/AcOH (Scheme 2-24). 
When attempting to promote the SAW reaction using trione 2-90 under our established 
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conditions (Table 2-2), no desired triazine was detected by 1H NMR analysis (even though the 
azide starting material was usually consumed according to TLC analysis of the reaction 
mixtures).  
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Scheme 2-24. Preparation of 2-59 using a 2-step oxidation/SAW sequence 
 
The standard microwave irradiation conditions may have been too harsh for the 
potentially sensitive trione, although when screening lower temperatures for the SAW by using 
thermal heating in place of microwave irradiation no desired product was observed. These results 
indicated that using the homophthalimide at the necessary oxidation state in the SAW reaction 
allows for an efficient approach toward the construction of 2-59; however, an alternative 
functional group would need to be used in place of the ketone. 
2.2.5 Oxidation to Thioketal Followed by the Staudinger/aza-Wittig Reaction 
A third-generation approach was developed by installing a cyclic thioketal through 
treatment of 2-61 with 2-91.169 The thioketal approach would allow for incorporation of the 
necessary oxidation state at the benzylic position and presumably provide a more robust 
substrate to perform the SAW reaction. 
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Scheme 2-25.  Preparation of thioketal 2-92 
 
Thioketal incorporation occurred in high yields to provide 2-92 in 59% yield over 3 steps 
from 2-75. When subjected to the SAW conditions, the azide was transformed into triazine 2-93 
in low to moderate yields (Scheme 2-26). Inspection of the (600/150 MHz) 1H/13C NMR spectra 
of 2-93 indicated a mixture of compounds (inseparable by column chromatography) in a 1.7:1 
ratio (determined from the integration of the AB methylene of the benzyl group). Based on the 
13C NMR, it appeared that the isolated material was comprised of a mixture of two regioisomers, 
which were putatively assigned as 2-93. Through the use of high temperature 1H NMR analysis it 
was not possible to conclusively determine the composition of the apparent mixture. Further 
chromatographic analysis must be done in order to confirm the presence of either conformational 
isomers or regioisomeric products. 
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Scheme 2-26. Putative products from the Staudinger/aza-Wittig reaction when using azide 2-92 
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We felt that removing the thioketal might provide a less complex NMR spectrum, and 
therefore the products from the SAW reaction (when using azide 2-92) were used in the 
deprotection reaction as isolated. In general, the thioketal removal was problematic since the 
conditions screened either did not react with the substrate or caused complete decomposition.  
 
Table 2-3. Conditions to remove thioketal from SAW product 2-93 
N
O
N
N
Bn
SS
N
N
O
N
Bn
SS
2-93
N
O
N
N
Bn
O
conditions
2-59  
 
entry conditions 
1 PIFA, CH3CN/H2O170 
2 NBS, acetone/H2O171 
3 CuCl2, CuO, acetone/H2O172 
4 I2, DMSO173 
5 PIFA, MeOH/H2O 
6 CAN, CH3CN/H2O174 
7 PIFA, THF H2O, AcOH 
8 30% H2O2, MeOH 
9 Hg(OAc)2, CH3CN/H2O175 
10 AgNO3, NCS, CH3CN/H2O 
11 Chloramine T, EtOH/H2O176 
12 NaNO2, TFA/ H2O177 
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Conditions screened for the desulfurization of 2-93 involved mercury salts, copper salts, 
hypervalent iodine, and silver nitrate/halosuccinimide mixtures, most of which were used in 
stoichiometric excess. The conditions outlined in Table 2-3 were applied to 2-93, but resulted in 
the decomposition of starting material. It is important to note that many of the 1H NMR spectra 
of the crude material isolated from the oxidative desulfurization contained a singlet (δ = 9.93) 
and doublet (δ = 7.80, J = 8.4 Hz) that are characteristic of benzaldehyde. This hypothesis was 
confirmed by addition of benzaldehyde to the 1H NMR sample containing the crude reaction 
mixture for entry 12 (Table 2-3), resulting in an increased signal intensity for the singlet (δ = 
9.93) and doublet (δ = 7.80, J = 8.4 Hz) in the 1H NMR (600 MHz) of the crude reaction mixture 
and supporting the oxidative cleavage of the N-benzyl group. 
It is well precedented that the p-methoxybenzyl group can be removed from amines 
under oxidative conditions.178 Although not as common, there are examples where tertiary N-
benzyl groups are removed using CAN in aqueous THF179 and aqueous acetonitrile solutions.180 
It may be possible that the N-benzyl group is being cleaved under the conditions intended to 
oxidize the thioketal through a pathway proposed in Scheme 2-27, where the N-benzyl amine 2-
93 gets oxidized to give intermediate 2-94. This compound can then undergo a second single 
electron oxidation to afford 2-95, which, when hydrolyzed may explain the source of 
benzaldehyde in the crude reaction mixture. In all cases, it was not clear whether or not the sulfur 
atoms on 2-93 were being oxidized but not hydrolyzed, or not oxidized at all. It appeared that the 
conditions to remove the thioketal group on 2-93 must be orthogonal to the basic nitrogen atoms 
present. A window of reactivity could not be found to allow for the selective desulfurization of 
2-93 without oxidative decomposition, and therefore this approach was discontinued. 
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Scheme 2-27. Potential oxidative pathway for benzaldehyde formation 
2.2.6 Oxidation to Dimethoxyketal Followed by the Staudinger/aza-Wittig Reaction 
 In an effort to identify a protecting group that could be removed under conditions tolerant 
to the basic nitrogen atoms, the desulfurization event was performed prior to the SAW reaction. 
Gratifyingly, the transformation of 2-92 into the dimethoxyketal using PIFA in dry MeOH170 was 
complete in less than 1 h, providing 2-97 in an unoptimized 60% yield (Scheme 2-28). This 
result was significant since it indicated that the methanolysis of the thioketal seemed to be 
substrate dependent. It also indicated that the aza-Wittig product 2-93 may have been oxidized 
but was not readily hydrolyzed due to sterics or electronic effects before oxidative 
decomposition. The dimethoxyketal was subjected to the SAW conditions, and the desired 
triazine 2-98 was isolated in 61% yield after recrystallization. This was the first time we were 
able to cleanly remove the thioketal protecting group as well as to characterize the product from 
the SAW reaction. The last step was to hydrolize the dimethoxyketal to the ketone, which turned 
out to be challenging.  
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Scheme 2-28. Desulfurization/SAW sequence to arrive at 2-59 
 
 Qualitative reactions monitored by 1H NMR showed that the conversion of 2-98 to 2-59 
could be accomplished using HCl/H2SO4 to promote the hydrolysis, although this result has not 
been reproducible. It is important to note that the spectrum obtained from the hydrolysis of 2-98 
was superimposable to that of the product isolated from the auto-oxidation product 2-59 obtained 
through the pathway described in Scheme 2-21. At this time, conditions to promote the 
hydrolysis of 2-98 to give a sample of pure 2-59 have not been identified. If the deprotection 
reaction is successful, this would demonstrate our first-generation sequence toward preparing a 
model DEF system of the natural product noelaquinone. 
2.3 CONCLUSIONS 
In summary, a method to prepare an advanced hydrazine intermediate has been 
developed. This intermediate can be readily transformed into the homophthalimide 2-61 (Scheme 
2-17). The azide undergoes the SAW reaction to produce the enamine product 2-76 (Scheme 2-
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29). It was observed that aerobic oxidation of the enamine produces the desired triazine product 
2-59, unfortunately, attempts to promote a controlled oxidation of 2-76 into 2-59 failed.  
Subjecting the benzylic thioketal 2-92 to the SAW reaction produced a putative mixture 
of 2-93, which, when treated to oxidative desulfurization conditions, led to a complete 
decomposition of the substrate. Removal of the thioketal prior to the SAW reaction to produce 2-
97 occurred with ease, and the subsequent SAW reaction could be accomplished to prepare 2-98 
in moderate yields.  Although a qualitative result shows that the dimethoxyketal 2-98 can be 
hydrolyzed using harsh acidic conditions, a procedure needs to be developed to reproducibly 
facilitate this process. If this problem can be solved, we could demonstrate access to the core of 
the natural product noelaquinone. 
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Scheme 2-29. Summary of progress toward the preparation of 2-59 
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3.0  PREPARATION OF α,β-CYCLOPROPYL-γ-AMINO ACIDS 
3.1 INTRODUCTION 
3.1.1 Peptide Mimetics: A Frontier in Therapeutic Agents 
 The amide bond is one of the most common covalent linkages found in proteins, many of 
which are responsible for critical biological functions. The dipeptide linkage is represented as 3-
1 in Figure 3-1, where the two torsion angles in the peptide bonds are φ (Cα-N bond angle) and ψ 
(Cα-C bond) with respect to the amide bond plane, and the amide bond angle, ω, with is typically 
180o.181,182 In the lab, amide bonds may be formed under mild conditions;183,184 however, these  
bonds can only be hydrolyzed using strongly acidic or basic conditions.178 Nature, on the other 
hand, employs a wide variety of enzymes (proteases) that are responsible for amide bond 
hydrolysis under physiological conditions. Due to this relative ease of degradation by nature, 
molecules containing amide bond linkages are not often practical pharmaceutical candidates.182 
Since nature’s machinery is adept in the scission of the amide bond, chemists have studied its 
properties and developed bioisosteres to replace this ubiquitous functional group.  
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Figure 3-1. Dipeptide bond angles and peptide isosteres 
 
Figure 3-1 shows an example of a parent dipeptide (Phe-Leu) 3-2 and a peptide mimic 
(Pheψ[CH2O]-Leu) 3-3, where the amide bond has been replaced by a methyleneoxy group.182 
Figure 3-2 shows a generic amide (outlined) and a variety peptide isosteres that mimic the amide 
functionality.182 The analogs are often isoelectronic to the amide bond, but less susceptible to 
enzymatic hydrolysis. Peptide mimics continue to be developed to treat diseases that range from 
malaria144,185 and AIDS186 to renin inhibitors to treat hypertension187 and kinase inhibitors to treat 
cancer.188  
One common amide bond isomers is the aminomethylene group (ψ[CH2N]). Methods for 
installing this group involve the reductive amination of an amine with an aldehyde. This 
approach has been used by Fairlie and co-workers189 to prepare peptide mimics that inhibit the 
cysteine protease caspase-1. Cysteine proteases are responsible for a multitude of cellular 
functions. The ability to inhibit caspase-1 could treat diseases such as chronic inflammation190 
and malaria as well as triggering apoptosis.191 
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Figure 3-2. Peptide bioisosteres 
 
The reductive amination methodology has been applied toward analogs of the lead 
peptide mimic (ψ[CH2N]) 3-7 (Scheme 3-1).189 Oxidation of the advanced intermediate 3-4 with 
the Dess-Martin reagent provides aldehyde 3-5. This product was converted into analog 3-6 
through a reductive amination protocol using NaBH(OAc)3. The incorporation of the 2-
hydroxybenzylamine onto the lead benzylamine analog increased the inhibition of caspase-1 by a 
factor of 12. 
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Scheme 3-1. Preparation of analogs for non-covalent caspase-1 inhibitors 
 
An alternative method for preparing (ψ[CH2N]) amide bond isosteres involves the 
reaction of 1,2-aminoiodides 3-9 with protected amino acids to form dipeptides 3-10 (Scheme 3-
2). In this case, Campiglia and Grieco192 prepared 11 examples by using this methodology. The 
coupled products showed no racemization by analytical HPLC analysis. 
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Scheme 3-2. Preparation of aminomethylene peptide isosteres 
 
Peptide isosteres have also been incorporated into the synthesis of natural product 
analogs.193 The β-lactam 3-12 was prepared in high enantiopurity using a [2+2] reaction between 
an imine and an α-siloxy ester bearing a chiral auxiliary.194,195 Scheme 3-3 shows the preparation 
of an analog to the antitumor agent taxol 3-15. After the acylation of the secondary alcohol 3-11 
 78 
 
with the β-lactam 3-12 and global silyl deprotection of 3-13, analog 3-14 was shown to be up to 
100 times more potent than the parent natural product.196 
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Scheme 3-3. Preparation of taxol analogs using an enantiopure β-lactam 
3.1.2 Peptide Mimetics in the Wipf Research Group 
The Wipf group has made significant contributions to the field of peptidomimetics. Initial 
research involving the development of methods to prepare (E)-alkene dipeptide isosteres 
(ψ[RC=CH]) began with the SN2’cuprate additions to vinyl aziridines 3-16.197 This methodology 
provided access to allylic amines of the type 3-17, as shown in Scheme 3-4. 
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Scheme 3-4. Peptide isostere preparation using aziridines 
 
Wipf’s approach toward the preparation of (E)-alkene dipeptide isosteres has elegantly 
evolved through the use of a divergent multi-component reaction (DMCR).198,199 To prepare the 
allylic amine 3-19, alkyne 3-18 is hydrozirconated and the resulting vinyl zirconocene is then 
transmetalated to zinc. This vinyl zinc species undergoes an addition to the in situ generated 
imine to afford 3-19 in 64% over 3 steps. The intermediate is transformed into 3-20 over 4 steps. 
This fragment has been incorporated into analogs of the natural product gramicidin S (3-21). 
Gramicidin S is a cyclic decapeptide that exhibits a wide variety of biological activities, 
including antibiotic and antimicrobial properties.200 The ψ-[(E)-C(CH3)=CH] replacement for the 
D-Phe-Pro represented as 3-22 was found to uphold the secondary structure (β-sheet) of the 
parent gramicidin S. This was confirmed through the use of circular dichroism analysis. Earlier 
work by Wipf and Xiao201 involved the preparation and characterization of gramicidin S analogs 
3-23 and 3-24, i.e cyclo(-Val-Orn-Leu-ψ[(E)-C(R)=CH]-DPhe-Pro-)2 where R = CH3 and CF3, 
respectively (Figure 3-3). 
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Scheme 3-5. Preparation of isosteres of gramicidin S 
 
These gramicidin S analogs were prepared by using the methodology outlined in Scheme 
3-5. The secondary structural features of the bis-CF3 analog 3-24 closely resembled the natural 
product according to solution and solid-state analysis.  
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Figure 3-3. Gramicidin S analogs 3-23 and 3-24 
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The ability for gramicidin S and its peptide isosteres to selectively target the 
mitochondria in the cell led to the development of truncated analogs of 3-21. Two examples of 
gramicidin S analogs prepared in the Wipf research group are XJB-5-131 3-28 and a lower 
molecular weight analog, JP4-039 3-29. These peptide mimics have the ability to protect cells 
from reactive oxygen species (ROS) that cause oxidative stress,202 and are effective at treating 
hemorrhagic shock and radiation exposure; two properties that offer a wide array of therapeutic 
applications.203 The analogs were prepared by coupling the peptide isostere 3-25 with peptide 3-
26. After saponification of the methyl ester, the 4-amino-TEMPO group (4-AT), which is 
believed to be critical for the biological activity, was coupled to prepare XJB-5-131 3-28 in 72% 
yield. A similar approach has been used to prepare the XJB-5-131 analog JP4-039 3-29.13 
Additional examples of applications of peptide bond isosteres developed in the Wipf research 
group have been a topic of a recent review.204 
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Scheme 3-6. Gramicidin S peptide mimics with therapeutic properties 
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3.1.3 First Generation Preparation of α,β-Cyclopropyl-γ-amino Acids 
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Figure 3-4. Evolution of dipeptide isosteres in the Wipf research group 
 
As an extension of the DMCR methodology, the concept of cyclopropane dipeptide 
isosteres (ψ[RCp], 3-31, shown in Figure 3-4) was developed. Cyclopropane analogs are 
proposed to be less susceptible to oxidation than the (E)-alkene isosteres 3-30.205 In 2005, 
Wipf206 and Stephenson207 demonstrated the synthesis of α,β-cyclopropyl-γ-amino acids derived 
from allylic amines.  
A water-accelerated carboalumination reaction208 with alkyne 3-32 was followed by 
transmetalation to form the vinyl zirconocene and subsequent addition to imine 3-33 to afford 3-
34 in 85% yield (Scheme 3-7). The allylic amine was treated under the Charette-modified 
Simmons-Smith cyclopropanation209,210 conditions (which uses DME to stabilize the zinc 
carbenoid species) to afford 3-35 in 95% yield. The removal of the TBDPS ether in 91% 
liberated the free alcohol 3-36, which was then eliminated to the olefin through a 3-step sequence 
that proceeded in 81% yield to form 3-37 via a modified Grieco protocol.211 After ozonolysis of 
the olefin to the methyl ester 3-38 and a 2-step protecting group switch to the N-Cbz group, the 
racemic cyclopropane core of 3-39 was isolated. This methodology has been applied in the Wipf 
research group toward the preparation of a library of compounds containing cyclopropyl peptide 
mimics.212 
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Scheme 3-7. First generation preparation of the racemic cyclopropane core 3-39  
 
To obtain enantiopure material, a tartrate resolution was performed (using L-tartaric acid) 
with amine 3-40 to afford 3-41 in 38% yield (Scheme 3-7). The resolved material was then 
protected as benzyl carbamate 3-42. After saponification and peptide coupling with L-Phe-OMe-
HCl, the dipeptide 3-43 was isolated in 59% yield (Scheme 3-8). The crystal structure of 3-43 
indicates that the peptide mimic adopts a β-sheet conformation. This secondary structural feature 
is often associated with promoting protein-protein interactions, and thus the potential for 
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biological activity. These results inspired us to synthesize a library of molecules that contain the 
chiral scaffold of 3-42. 
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Scheme 3-8. Preparation of chiral dipeptide 3-43 
 
Molecules containing the phenylglycine derived α,β-cyclopropyl-γ-amino acid core 3-44 
(shown in Figure 3-5) are known pregnane X receptor (PXR) agonists.213 Some of these 
derivatives are active as inhibitors of cytochrome P450 (3-45 and 3-46), and inhibitors of the 
influenza NS1 protein function (H1N1 strain) (3-47).  
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Figure 3-5. Phenylglycine derived α,β-cyclopropyl-γ-amino acids 
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Additional examples of molecules that contain the general scaffold of 3-48 (Figure 3-6) 
with biological activities are published in the NIH database, PubChem.214 The goal for this 
research project was to diversify the pool of α,β-cyclopropyl-γ-amino acid derivatives available 
to biological screening. The R groups shown in 3-49 represent points of diversity for this 
scaffold. In our second-generation approach, the R1 and R3 groups represent the most versatile 
points of diversification.  The R2 group shown in 3-49 is inherent to the scaffold of the peptide 
mimic. 
 
R1 = acyl group; incorporated through acylation of amine
R2 - alkyl group; inherent to the cyclopropane core
R3 - amine; incorporated through amide bond formationPh
NH
R1
H
R2
R3
O
3-49
points for diversity
Ph
N
H
NH2
O
H
3-48
PubChem query  
Figure 3-6. Phenylglycine α,β-cyclopropyl-γ-amino acid derivatives listed in the NIH database, PubChem 
 
3.2 RESULTS AND DISCUSSION 
3.2.1 Second Generation Preparation of α,β-Cyclopropyl-γ-amino Acids 
 A second-generation approach to the α,β-cyclopropyl-γ-amino acid core 3-57 (originally 
proposed by Wipf and Stephenson) was executed. This route to access the cyclopropyl amino 
acid core utilizes a Wittig olefination to access the chiral allylic amine in place of the 
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hydrozirconation/transmetalation and subsequent imine addition methodology (as shown in 
Scheme 3-9). The second-generation approach to the core of the chiral α,β-cyclopropyl-γ-amino 
acid derivatives began with the Cbz protection of (R)-phenylglycine methyl ester hydrochloride 
3-50 followed by a 2-step Wittig-type olefination215 involving the use of phosphonium salt 3-52 
to afford the unsaturated ester 3-53 in 86% yield over 2 steps. Subsequent DIBAl-H reduction of 
the ester was accomplished in 89% yield, and the resulting alcohol 3-54 was protected as its 
TBDPS ether in 81% to afford 3-55 (Scheme 3-9). 
 
Ph
NH3Cl
OMe
O
CbzCl, NaHCO3
EtOAc/H2O Ph
NH
OMe
O
Cbz
72%
DIBAl-H, PhMe
then KOBut, THF
    -78 oC to 50 oC
CH3
CO2EtBr(Ph)3P
Ph
NH
Cbz
CH3
O
OEt
DIBAl-H, CH2Cl2
-78 oC to rt Ph
NH
Cbz
CH3
OH
TBDPSCl, imid.
DMAP, CH2Cl2 Ph
NH
Cbz
CH3
OTBDPS
81%
86%3-50 3-51
3-53
3-52
3-5489% 3-55
Et2Zn/DME, CH2I2
-30 oC to rt
73%
TBAF/AcOH
Ph
NH
Cbz
CH3
OTBDPS THF, reflux Ph
NH
Cbz
CH3
OH
87%3-56 3-57
αD = -18.7
(c = 1.38, CH2Cl2)
er  99:1  
Scheme 3-9. Preparation of chiral cyclopropane core 
 
 The key diastereoselective cyclopropanation step was executed using olefin 3-55 and 
employing the Charette-modified Simmons-Smith cyclopropanation209,210 conditions provided 3-
56 in 73% yield. The proposed origin of selectivity is shown in Figure 3-10. The transition state 
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of 3-58 is preferred due to the minimization of A1,3 strain, as opposed to transition state of 3-59, 
which involves a severe phenyl/methyl interaction. After treatment of the silyl ether with 
TBAF/AcOH in THF at reflux, alcohol 3-57 was isolated in 87% yield. This alcohol was used as 
the chiral building block for our library. 
 
N
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CH3H
C H
H
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CH3Ph
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H
H
X
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X
O
BnO
vs
3-58
favored
3-59
disfavoredX = DME or iodide  
Scheme 3-10. Directed cyclopropanation of allylic amine to prepare cyclopropane 3-56 
 
 A racemic sample of cyclopropane 3-57 was prepared according to the synthetic 
sequence outlined in Scheme 3-9.4 The enantiopurity of 3-57 was determined by analytical 
HPLC analysis by using a Chiracel-OD column. The chromatogram showed one single, resolved 
peak indicating that the er was greater than 99:1.5  
3.2.2 Preparation of Library Compounds 
 With access to gram quantities of alcohol 3-57, reaction conditions to promote amide 
bond formation (to install the R3 group) were investigated (Table 3-1). Oxidation of the alcohol 
                                                 
4 The 1H and 13C NMR data obtained for the racemic intermediates matched the data 
obtained from the respective chiral intermediates.   
5 For analytical HPLC conditions, see experimental section. 
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to the α,α-disubstituted carboxylic acid was accomplished using the Jones oxidation. When 
allowed to react at room temperature, the reaction took over 24 h to reach completion. To 
accelerate the reaction, the mixture was warmed from the initial temperature of 0 oC to reflux. 
The Jones oxidation reaction was carefully monitored by TLC analysis, and the reaction was 
quenched once 3-57 was consumed.  In all cases the carboxylic acid 3-60 was used without 
purification in the following amine coupling.  
 To promote the amide bond formation, we initially screened modified coupling 
conditions employing the carbodiimide EDCI;198 however, the yields for the coupling of 
tryptamine (to prepare 3-63) were ~20% when performing the reaction on ~500 mg scale. When 
using PyBroP216 to activate the carboxylic acid to couple the tryptamine, the yield was 57% (2 
steps, entry 3). The coupling between 2-aminomethyl pyridine and carboxylic acid 3-60 to yield 
3-61 was accomplished in slightly lower yields (45%, 2 steps, entry 1) than that of tryptamine 
when using PyBroP. When using T3P217 to activate the carboxylic acid, the coupling reaction 
between 3-60 and 5-methylfurfurylamine to produce 3-62 was accomplished in 55% (2 steps, 
entry 2). Overall, the use of either PyBroP or T3P produced the desired amides in good yields. 
The advantage of using T3P was demonstrated in the ease of purification over removing the 
byproducts accompanied with the use of PyBroP (Table 3-1).  
 With the R3 groups installed, the next step was to remove the Cbz group and acylate the 
resulting free amine. We initially envisioned performing this task in a one-pot process by using a 
palladium-catalyzed hydrogenolysis in the presence of an anhydride. However, there were two 
critical factors that caused this one-pot process to fail. The first major pitfall was the limited 
commercial availability of the requisite heterocyclic anhydrides, in addition to the low reactivity 
profile for their formation.218 The second major problem we experienced was in the 
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hydrogenolysis reaction since the use of an anhydride-compatible solvent such as EtOAc in place 
of MeOH led to limited reactivity and decomposition of the reaction mixture, rather than an 
efficient Cbz removal. Additional conditions screened to remove the Cbz group included the use 
of either HBr in AcOH88 or BBr3 in dichloromethane.219 Unfortunately, both of these methods 
worked with only modest results.  
 
Table 3-1. Preparation of Cbz-protected cyclopropane cores 
3-61
45% (2 steps)
3-62
55% (2 steps)
3-63
57% (2 steps)
Ph
NH CH3 H
N
O
N
Ph
NH CH3 H
N
O N
H
Ph
NH CH3 H
N
O
O
CbzCbz Cbz
Ph
NH
Cbz
CH3
OH
Jones ox., DMAP, CH2Cl2
Ph
NH
Cbz
CH3
OH
O
acetone
0 oC to reflux
amine provides
R3 group3-57
3-60
Ph
NH
R1
CH3
R3
O
 
entry coupling conditionsa product yieldb 
1 DIPEA, PyBroP, 2-aminomethyl pyridine 3-61 45% 
2 NEt3, T3P, 5-methylfurfurylamine 3-62 55% 
3 DIPEA, PyBroP, tryptamine 3-63 57% 
a See experimental section for reagent stoichiometry; bYields determined over 2 steps. 
 
We concluded that methanol was the optimal solvent for the Pd/C catalyzed 
hydrogenolysis of the Cbz group. Once complete, the reaction mixture was quenched with Celite, 
filtered and the free amine was dried on high vacuum to remove any residual methanol. The 
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acylation of the amine was accomplished by using a method published by Wipf and co-
workers.198 
The three cyclopropane scaffolds (3-61, 3-62, and 3-63) were transformed into a series of 
α,β-cyclopropyl-γ-amino acid derivatives shown in Table 3-2. In general, the products from the 
Cbz hydrogenolysis and subsequent acylation reactions were isolated in good yields (75-93%) 
over the 2 steps. When substituting BBr3 in dichloromethane to deprotect the Cbz group in place 
of a hydrogenolysis, the desired compound can be isolated in a slightly lower yield (47%, 2 
steps), underlining the superiority of the hydrogenolysis protocol. 
 
Table 3-2. Synthesis of phenylglycine derived α,β-cyclopropyl-γ-amino acid derivatives 
Ph
NH
Cbz
H
CH3
R3
O
2. CH2Cl2, NEt3
1. Pd/C, H2, MeOH
amine trapping
reagent
Ph
NH
H
CH3
R3
O
R1
3-64 = 3-65 = 3-66 = 3-67 =
O
O
NH
Ph
O
N
O
NO
H3C
 
entry starting material R1 group product, yield (2 steps) 
1 3-63 3-64 3-68, 90% 
2 3-63 3-65 3-69, 89% 
3 3-63 3-66 3-70, 75% 
4 3-63 3-67 3-71, 77% 
5 3-61 3-65 3-72, 85% 
6 3-61 3-66 3-73, 47%a 
7 3-61 3-67 3-74, 81% 
aConditions used: 1. BBr3, CH2Cl2; 2. CH2Cl2, DIPEA, DMAP, 3-66 
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3.3 CONCLUSIONS 
We have prepared a series of D-phenylglycine derived α,β-cyclopropyl-γ-amino acid 
derivatives in high diastereoselectivity and enantiopurity. A 6-step sequence provided the 
cyclopropane scaffold 3-57 from commercially available material. We demonstrated that the 
chiral alcohol core can be oxidized to the requisite carboxylic acid, activated, and coupled with a 
primary amine. Subsequent Cbz removal in these advanced intermediates via hydrogenolysis, 
followed by acylation of the amine using acid chlorides, anhydrides and isocyanates, afforded a 
small library of α,β-cyclopropyl-γ-amino acid derivatives in good yields.  
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4.0  EXPERIMENTAL 
4.1 GENERAL 
 All moisture-sensitive reactions were performed under an atmosphere of dry N2 unless 
otherwise noted.  All glassware was dried in an oven at >140 oC or flame-dried under an 
atmosphere of dry N2 unless otherwise noted.  Diethyl ether (Et2O) and tetrahydrofuran (THF) 
were dried by distillation over sodium/benzophenone under an argon atmosphere.  Dry CH2Cl2 
and toluene were purified by filtration through an activated alumina column.  Unless otherwise 
stated, solvents and reagents were used as purchased without further purification.  Benzyl 
alcohol was distilled prior to use.  Collidine hydrochloride (coll-HCl) was recrystallized from 
absolute ethanol. Manganese and zinc metals were activated through washing with 1 M HCl, 
followed by rinsing with acetone and drying under vacuum.  Titanocene dichloride was 
recrystallized from chloroform before use. 
 Analytical thin-layer chromatography (TLC) was preformed on pre-coated silica gel 60 
F254 plates (250 µm layer thickness). Visualization was accomplished by using either a 254 nm 
UV lamp or by staining with a PMA solution (5 g of phosphomolybdic acid in 100 mL of 95% 
EtOH), p-anisaldehyde solution (2.5 mL of p-anisaldehyde, 2 mL of AcOH, and 3.5 mL of conc. 
H2SO4 in 100 mL of 95% EtOH), Vaughn’s reagent (4.8 g of (NH4)6Mo7O24•4 H2O and 0.2 g of 
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Ce(SO4)2 in 100 mL of a 3.5 N H2SO4) or a potassium permanganate solution (1.5 g of KMnO4 
and 1.5 g of K2CO3 in 100 mL of a 0.1% NaOH solution). 
NMR spectra were recorded at room temperature in CDCl3 at 300 MHz/75 MHz (1H/13C 
NMR) using a BRUKER AVANCE 300 MHz spectrometer unless stated otherwise.  Chemical 
shifts (δ) are reported in parts per million and referenced from the residual solvent peak or 
tetramethylsilane (TMS).  Data are reported as follows: chemical shift, multiplicity, integration 
and coupling constant(s).  IR spectra were recorded on either a Nicolet AVATAR 360 FT-IR 
E.S.P. spectrometer (KBr or neat) or a Smiths Detection IdentifyIR FT-IR spectrometer (ATR).  
Melting points were uncorrected and determined using a Laboratory Devices Mel-Temp II.  
High-resolution mass spectrometry (HRMS) data (ESI/APCI technique) were recorded 
using a Waters Q-Tof ultima API-US instrument. HRMS data (EI technique) were recorded 
using a Micromass Autospec instrument. Mass spectrometry data were also recorded using an 
Applied Biosystems MDS SCIEX API 2000 LC/MS/MS system. Optical rotations were recorded 
on a Perkin-Elmer polarimeter (model 241).   
Titanocene-catalyzed radical cyclization reactions were performed under rigorous 
exclusion of oxygen under a positive pressure of dry Ar.  Tetrahydrofuran, in addition to being 
distilled, was deoxygenated (freeze-pump-thaw) three times and then stored under a positive 
pressure of dry argon.  Sonication was accomplished with the Sonics Vibracell device (model 
VCX 130) equipped with a 2 mm microtip.   
All organic azides and azide waste products should be considered highly toxic as well as 
potentially explosive and must be handled and stored with care.  Avoid using halogenated 
solvents when performing reactions involving sodium azide, in addition to using halogenated 
solvents in reaction workup. Avoid quenching/manipulating/treating sodium azide reactions with 
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acid, as generation of trace amounts of hydrazoic acid (HN3) may result in an explosion. In 
general, a safety shield must be used when conducting reactions involving either sodium azide or 
organic azide derivatives. 
4.2 CHAPTER 1 EXPERIMENTAL 
N
Ph
1-69  
N-Allyl-N-phenylaniline (1-69).220,221 General Protocol A.  According to a modified 
literature procedure, a solution of 5.07 g (29.9 mmol) of diphenylamine in 45 mL of acetonitrile 
was treated with 8.28 g (59.9 mmol) of K2CO3, 5.2 mL (60 mmol) of allyl bromide, and 533 mg 
(1.49 mmol) of TBAI. This reaction mixture was heated at reflux until the starting material was 
consumed according to TLC (hexanes). The solution was cooled to rt, diluted with 100 mL of 
H2O and extracted with 3 x 15 mL of EtOAc. The combined organic layers were dried (MgSO4) 
and concentrated in vacuo. The residue was purified by chromatography on SiO2 (hexanes) to 
afford 6.24 g (29.8 mmol, quant.) of 1-69 as a golden oil: 1H NMR δ 7.30-7.22 (m, 4 H), 7.06-
6.91 (m, 6 H), 5.93 (ddt, 1 H, J = 14.7, J = 9.9 Hz, J = 4.5 Hz), 5.26 (d, 1 H, J = 17.4 Hz) 5.15 
(d, 1 H, J = 10.2 Hz), 4.40-4.34 (m, 2 H); 13C NMR δ 148.0, 134.4, 129.4, 121.4, 120.9, 116.6, 
54.9. 
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1-70
Ph
N
OH
OH
 
3-(Diphenylamino)propane-1,2-diol (1-70).  General Protocol B.  To a solution of 4.86 
g (23.2 mmol) of N-allyl-N-phenylaniline (1-69) in 75 mL of a THF/acetone/pH 7.0 phosphate 
buffer solution (1:1:1) was added 3.53 g (30.1 mmol) of NMO and 700 µL of OsO4 (1 mol%, 
0.33 M in toluene). The reaction mixture was stirred overnight, quenched with a sodium bisulfite 
solution and extracted with 3 x 20 mL of EtOAc. The combined organic layers were dried 
(MgSO4) and concentrated in vacuo to afford a white solid, which was recrystallized from 
hexane/EtOAc to afford 4.85 g (19.9 mmol, 86%) of 1-70 as a white solid: mp 96-98 oC; IR 
(KBr) 3297, 2927, 1589, 1497, 1323, 1070 cm-1; 1H NMR δ 7.28-7.22 (m, 4 H), 7.04-6.94 (m, 6 
H), 4.05-3.95 (m, 1 H), 3.85-3.79 (m, 2 H), 3.73 (dd, 1 H, J = 10.6 Hz, J = 2.1 Hz), 3.55 (dd, 1 
H, J = 11.1 Hz, J = 5.4 Hz), 2.62 (bs, 1 H), 2.21 (bs, 1 H); 13C NMR δ 148.5, 129.6, 122.2, 
121.6, 69.7, 64.4, 55.1;  MS (EI) m/z 243 (M+•, 18), 182 (100), 167 (13), 91 (87); HRMS (EI) m/z 
calcd for C15H17NO2 243.1259, found 243.1260. 
 
Ph
N
O
1-71  
N-(Oxiran-2-ylmethyl)-N-phenylaniline (1-71).222 According to a modified literature 
procedure, a solution of 2.39 g (9.82 mmol) of 1-70 in 32 mL of THF was cooled to 0 oC and 
treated with 3.84 g (11.7 mmol) of p-Ts2O followed by 545 mg (21.6 mmol) of NaH (95%). The 
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reaction mixture was stirred at 0 oC for 3 h, and an additional 1.17 g (29.4 mmol) of NaH (60% 
dispersion in mineral oil) was added. The solution was allowed to stir overnight at rt, cooled to 0 
oC, and quenched with H2O. The mixture was extracted with 3 x 20 mL of EtOAc. The combined 
organic layers were dried (MgSO4), concentrated in vacuo and purified by chromatography on 
SiO2 (hexane:EtOAc; 6:1) to afford 1.26 g (5.59 mmol, 57%) of 1-71 as a colorless oil: IR (neat) 
3057, 2995, 2919, 1588, 1493, 1362, 1255, 748 cm-1; 1H NMR δ 7.25-7.19 (m, 4 H), 7.05-7.00 
(m, 4 H), 6.93 (tt, 2 H, J = 7.2 Hz, J = 0.1 Hz), 3.91 (dd, 1 H, J = 15.9 Hz, J = 3.6 Hz), 3.79 (dd, 
1 H, J = 15.6 Hz, J = 4.8 Hz), 3.19-3.14 (m, 1 H), 2.70 (app t, 1 H, J = 4.8 Hz), 2.50 (dd, 1 H, J = 
5.1 Hz, J = 2.7 Hz); 13C NMR δ 148.0, 129.4, 121.7, 121.1, 53.9, 50.4, 45.9;  MS (EI) m/z 225 
(M+•, 36), 182 (100), 167 (15), 104 (23); HRMS (EI) m/z calcd for C15H15NO 225.1153, found 
225.1145. 
 
N
Ph
OH
N
Ph
OH
1-72 1-74  
 (1-Phenylindolin-3-yl)methanol (1-72) and 1-phenyl-1,2,3,4-tetrahydroquinolin-3-ol 
(1-74). General Protocol C.  To a 3-neck flask was added 273 mg (1.21 mmol) of 1-71, 9.0 mg 
(0.036 mmol) of Cp2TiCl2, 286 mg (1.81 mmol) of collidine hydrochloride, and 99 mg (1.8 
mmol) of Mn. The vessel was fitted with a reflux condenser, and purged 3 times with Ar. After 
addition of 12.1 mL of THF (0.1 M), the reaction mixture was heated at reflux for 45 min. The 
color gradually changed from light orange to deep violet/blue. The mixture was cooled to rt, 
quenched with satd. NH4Cl and extracted with 3 x 10 mL of Et2O. The combined organic layers 
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were dried (MgSO4), and concentrated in vacuo. The residue was purified by chromatography on 
neutral alumina (hexane:EtOAc; 3:1 to 1:3) to afford 237 mg (1.05 mmol, 87%) of 1-72 and 1-74 
as a 3.8:1 mixture based on the integration of 1H NMR peaks at 4.10 ppm for 1-72 vs. 3.15 ppm 
for 1-74. 
1-72: 1H NMR δ 7.35-6.93 (m, 9 H), 6.75 (t, 1 H, J = 7.2 Hz), 4.10 (app t, 1 H, J = 7.8 
Hz), 3.87-3.80 (m, 2 H), 3.57-3.48 (m, 1 H), 1.52 (t, 1 H, J = 4.2 Hz); 13C NMR δ 147.5, 144.1, 
131.2, 129.4, 128.3, 125.0, 121.4, 119.1, 117.9, 108.8, 65.3, 55.4, 43.0. 
1-74: 1H NMR δ 7.35-6.67 (m, 9 H), 4.38-4.28 (m, 1 H), 3.72 (bd, 1 H, J = 11.1 Hz), 3.55 
(ddd, 1 H, J = 11.7 Hz, J = 4.5 Hz, J = 1.5 Hz), 3.15 (dd, 1 H, J = 16.5 Hz, J = 4.2 Hz), 2.88 (dd, 
1 H, J = 16.5 Hz, J = 4.8 Hz), 2.13 (d, 1 H, J = 7.8 Hz); 13C NMR δ 147.4, 143.9, 130.5, 129.6, 
126.8, 125.2, 124.5, 120.8, 119.0, 115.0, 64.3, 56.4, 36.2. 
 
Ph
N
1-75  
N-(2-Methylallyl)-N-phenylaniline (1-75).  According to General Protocol A, 4.20 g 
(24.8 mmol) of diphenylamine, 6.86 g (49.6 mmol) of K2CO3, 4.0 mL (40 mmol) of 3-bromo-2-
methylpropene, and 1.83 g (4.96 mmol) of TBAI (reaction time 24 h) afforded 3.17 g (14.1 
mmol, 57%) of 1-75 as a colorless oil: IR (neat) 3061, 3035, 2912, 2849, 2358, 1938, 1589, 
1495, 1363, 1228, 894, 747 cm-1; 1H NMR δ 7.18 (t, 4 H, J = 7.5 Hz), 7.00 (bd, 4 H, J = 8.1 Hz), 
6.87 (bt, 2 H, J = 6.9 Hz), 4.99 (bs, 1 H), 4.86-4.85 (m, 1 H), 4.19 (s, 2 H), 1.70 (s, 3 H); 13C 
NMR δ 148.2, 141.4, 129.3, 121.3, 120.6, 111.3, 58.4, 20.3; MS (EI) m/z 223 (M+•, 75), 208 
(19), 182 (100), 168 (57); HRMS (EI) m/z calcd for C16H17N 223.1361, found 223.1351. 
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OH
OH
1-76  
3-(Diphenylamino)-2-methylpropane-1,2-diol (1-76). According to General Protocol B, 
1.61 g (7.20 mmol) of 1-75, 1.26 g (10.8 mmol) of NMO and 218 µL of OsO4 (1 mol%, 0.33 M 
in toluene) produced a brown solid that was recrystallized from chloroform/hexane to afford 1.55 
g (6.05 mmol, 84%) of 1-76 as a white solid: mp 67-68 oC; IR (KBr) 3445, 3057, 2927, 2873, 
1588, 1494, 1363, 1240, 1035, 749 cm-1; 1H NMR (CD2Cl2) δ 7.35-7.20 (m, 4 H), 7.14-6.92 (m, 
6 H), 3.97, 3.84 (AB, 2 H, J = 15.4 Hz), 3.50-3.32 (m, 2 H), 2.27 (bs, 1 H), 1.86 (dd, 1 H, J = 6.0 
Hz, J = 1.2 Hz), 1.13 (s, 3 H); 13C NMR (CD2Cl2) δ 150.1, 129.7, 122.2, 122.0, 74.6, 68.6, 59.8, 
23.4; MS (EI) m/z  257 (M+•, 10), 182 (100), 169 (15), 104 (16); HRMS (EI) m/z calcd for 
C16H19NO2 257.1415, found 257.1419.  
 
1-77
Ph
N O
 
N-((2-Methyloxiran-2-yl)methyl)-N-phenylaniline (1-77).  To a solution of 430 mg 
(1.67 mmol) of 1-76 in 16 mL of THF at 0 oC was added 267 mg (6.68 mmol) of NaH (60% 
dispersion in mineral oil). The mixture was stirred for 10 min and 597 mg (1.83 mmol) of p-
Ts2O dissolved in 3 mL of THF was added dropwise. The disappearance of starting material was 
monitored by TLC (hexane:EtOAc; 2:1). The reaction mixture was quenched with H2O and 
extracted with 3 x 10 mL of Et2O. The combined organic layers were dried (MgSO4), 
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concentrated in vacuo and purified by chromatography on SiO2 (hexane:EtOAc; 10:1) to afford 
279 mg (1.16 mmol, 70%) of 1-77 as a colorless oil: IR (neat) 3037, 2982, 2924, 1588, 1495, 
1362, 1242, 749 cm-1; 1H NMR (CD2Cl2) δ 7.31-7.23 (m, 4 H), 7.05-6.93 (m, 6 H), 3.96, 3.90 
(AB, 2 H, J = 16.0 Hz), 2.68 (d, 1 H, J = 4.8 Hz), 2.57 (d, 1 H, J = 4.8 Hz), 1.38 (s, 3 H); 13C 
NMR (CD2Cl2) δ 148.9, 129.6, 121.8, 121.3, 57.1, 56.8, 52.4, 19.8; MS (EI) m/z 239 (M+•, 30), 
182 (100), 167 (15), 104 (23); HRMS (EI) m/z calcd for C16H17NO 239.1310, found 239.1311. 
 
N
Ph
OH
1-78  
(3-Methyl-1-phenylindolin-3-yl)methanol (1-78).  According to General Protocol C, 71 
mg (0.29 mmol) of 1-77, 2.2 mg (0.089 mmol) of Cp2TiCl2, 69 mg (0.44 mmol) of collidine 
hydrochloride and 24 mg (0.44 mmol) of Mn provided a mixture (reaction time 25 min) that was 
purified by chromatography on neutral alumina (hexane:EtOAc; 6:1 to EtOAc:EtOH; 5:1) to 
afford 63 mg (0.26 mmol, 89%) of 1-78 as a colorless oil: IR (neat) 3360, 3057, 2959, 2925, 
2866, 1591, 1501, 1462, 1385, 1024, 744 cm-1; 1H NMR δ 7.32 (t, 2 H, J = 7.5 Hz), 7.22 (d, 2 H, 
J = 7.6 Hz), 7.15 (dt, 2 H, J = 6.9 Hz, J = 1.2 Hz), 7.10 (bt, 1 H, J = 6.9 Hz), 6.95 (t, 1 H, J = 7.2 
Hz), 6.77 (t, 1 H, J = 6.9 Hz), 3.91, 3.66 (AB, 2 H, J = 9.6 Hz), 3.63 (A of ABX, 1 H, J = 10.5 
Hz, J = 6.0), 3.56 (B of ABX, 1 H, J = 10.5 Hz, J = 6.3), 1.70-1.65 (m, 1 H), 1.37 (s, 3 H); 13C 
NMR δ 146.9, 144.0, 135.6, 129.4, 128.2, 123.4, 121.2, 119.1, 117.8, 108.7, 69.1, 61.8, 45.6, 
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22.5; MS (EI) m/z  239 (M+•, 23), 208 (100), 193 (25), 130 (10); HRMS (EI) m/z calcd for 
C16H17NO 239.1310, found 239.1318. 
 
N
Boc
1-80  
t-Butyl 2-methylallyl(phenyl)carbamate (1-80).  To a solution of 125 mg (0.646 mmol) of 
Boc-aniline in 7 mL of acetonitrile was added 51 mg (1.3 mmol) of NaH (60% dispersion in 
mineral oil) followed by 104 µL (1.03 mmol) of 3-bromo-2-methylpropene. The disappearance 
of starting material was monitored by TLC (hexane:EtOAc; 4:1).  The reaction mixture was 
quenched with H2O, extracted with 3 x 10 mL of Et2O, concentrated in vacuo, and purified by 
chromatography on SiO2 (hexane:EtOAc; 10:1) to afford 132 mg (0.534 mmol, 87%) of 1-80 as 
an oil: 1H NMR δ 7.36-7.11 (m, 5 H), 4.84 (s, 1 H), 4.81 (s, 1 H), 4.16 (s, 2 H), 1.74 (s, 3 H), 
1.44 (s, 9 H). 
 
1-81
N
Boc
O
 
t-Butyl (2-methyloxiran-2-yl)methyl(phenyl)carbamate (1-81).25 According to a modified 
literature procedure, to a solution of 124 mg (0.501 mmol) of 1-80 in 5 mL of CH2Cl2 at -40 oC 
was added 185 mg (0.751 mmol) of m-CPBA (70%).  The reaction mixture was warmed to rt 
over 4 h, quenched with Na2S2O3 solution, extracted with 3 x 5 mL of CH2Cl2, dried (MgSO4), 
concentrated in vacuo, and purified by chromatography on SiO2 (hexane:EtOAc; 9:1 to 4:1) to 
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afford 46 mg (0.17 mmol, 35%) of 1-81: 1H NMR δ 7.35-7.17 (m, 5 H), 3.93, 3.64 (AB, 2 H, J = 
15.0 Hz), 2.54, 2.52 (AB, 2 H, J = 4.5 Hz), 1.43 (s, 9 H), 1.39 (s, 3 H). 
 
N
OH
OH
H
1-83  
2-Methyl-3-(phenylamino)propane-1,2-diol (1-83). To a 10 mL flask was added 54 mg (0.34 
mmol) of collidine hydrochloride, 4.3 mg (0.017 mmol) of Cp2TiCl2, followed by 46 mg (0.17 
mmol) of 1-81 (in 1 mL of THF).  The mixture was diluted with an additional 5 mL of THF 
(0.03 M) and 6.2 mg (0.11 mmol) of Mn was added before sonication was initiated (50% 
maximum power of 130 W).  The reaction mixture was quenched after 75 min by addition of 
10% HCl solution, extracted with 3 x 5 mL of Et2O, washed with 2 x 5 mL of satd. NaHCO3 
solution, dried (MgSO4), concentrated in vacuo, and purified by chromatography on SiO2 
(hexane:EtOAc; 6:1) to afford 20 mg (0.09 mmol) of 1-82 as a white solid.  This solid was 
dissolved in 3 mL of MeOH, treated with 50 mg (1.3 mmol) of NaOH, heated at reflux for 3 h, 
quenched with brine solution, neutralized with a HCl solution to pH 7, extracted with 3 x 20 mL 
of EtOAc, dried (Na2SO4), and concentrated in vacuo to afford 12 mg (0.067 mmol, 70%) of 
crude 1-83 that was analyzed without further purification: 1H NMR δ 7.20 (t, 2 H, J = 7.8 Hz), 
6.81-6.73 (m, 3 H), 3.65, 3.57 (AB, 2 H, J = 10.2 Hz), 3.35-3.10 (m, 5 H), 1.24 (s, 3 H);  MS 
(ESI) m/z 182.10 (M+H). 
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1-85
N
Ph
H
 
N-Benzylaniline (1-85).223,224 According to a modified literature procedure, to a solution of 2.75 
g (29.5 mmol) of aniline in 30 mL of Et2O was added 3.76 g (35.4 mmol) of freshly distilled 
benzaldehyde.  The reaction mixture was stirred at rt for 1.5 h, diluted with 60 mL of MeOH and 
10 mL of glacial acetic acid, and cooled to 0 oC when 1.11 g (29.5 mmol) of NaBH4 was added 
slowly.  Subsequently, the reaction mixture was warmed to rt, quenched with satd. NaHCO3, 
extracted with 3 x 20 mL of Et2O, dried (MgSO4) and concentrated in vacuo. The residue was 
recrystallized from hexane to afford 3.73 g (20.3 mmol, 70%) of 1-85 as a tan solid: mp 36-38 oC 
(lit 35-38 oC); 1H NMR δ 7.40-7.24 (m, 5 H), 7.17 (t, 2 H, J = 7.8 Hz), 6.71 (t, 1 H, J = 7.2 Hz), 
6.63 (d, 2 H, J = 8.1 Hz), 4.32 (s, 2 H), 4.01 (bs, 1 H); 13C NMR δ 148.4, 139.7, 129.5, 128.8, 
127.7, 127.4, 117.8, 113.1, 48.5. 
 
1-86
N
O
 
N-Benzyl-N-((2-methyloxiran-2-yl)methyl)aniline (1-86). To a solution of 298 mg (1.62 
mmol) of 1-85 in 5.5 mL of acetonitrile was added 450 mg (3.25 mmol) of K2CO3 and 295 µL 
(2.92 mmol) of 3-bromo-2-methylpropene.  The reaction mixture was stirred at rt, and the 
disappearance of starting material was monitored by TLC (hexane:EtOAc; 4:1).  The solution 
was quenched with H2O, extracted with 3 x 10 mL of Et2O, dried (MgSO4), and concentrated in 
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vacuo to afford an oil.  According to General Protocol B, the crude residue, 342 mg (2.91 mmol) 
of NMO and 98 µL of OsO4 (2 mol%, 0.33 M in toluene) afforded an oil that was dissolved in 16 
mL of THF and cooled to 0 oC.  After addition of 260 mg (6.50 mmol) of NaH (60% dispersion 
in mineral oil) the reaction was stirred for 15 min and 954 mg (2.92 mmol) of p-Ts2O was added 
portionwise.  The mixture was warmed to rt, quenched with H2O, extracted with 3 x 10 mL of 
Et2O, dried (MgSO4), concentrated in vacuo, and purified by chromatography on SiO2 
(hexane:EtOAc; 12:1) to afford 156 mg (0.616 mmol, 38%, 3 steps) of 1-86 as an oil: IR (neat) 
3058, 3028, 2923, 1598, 1504, 1452, 1388, 1232, 1197 cm-1;  1H NMR δ 7.31-7.13 (m, 7 H), 
6.71-6.66 (m, 3 H), 4.62 (s, 2 H), 3.65, 3.56 (AB, 2 H, J = 15.9 Hz), 2.68, 2.60 (AB, 2 H, J = 4.8 
Hz), 1.38 (s, 3 H);  13C NMR δ 149.1, 138.5, 129.4, 128.8, 126.9, 126.7, 117.0, 112.5, 56.9, 54.8, 
54.7, 52.2, 19.8;  MS (EI) m/z 253 (M+•, 11), 196 (35), 106 (14), 91 (100);  HRMS (EI) m/z calcd 
for C17H19NO 253.1466, found 253.1469. 
 
N
Bn
Ph H
OH
N
OH
Bn
N
N
OH OH
PhBn
1-87 1-88 1-89 1-90  
(1-Benzyl-3-methylindolin-3-yl)methanol (1-87). To a 10 mL flask was added 75 mg (0.48 
mmol) of collidine hydrochloride, 5.9 mg (0.024 mmol) of Cp2TiCl2, followed by a solution of 
61 mg (0.24 mmol) of 1-86 in 1 mL of THF.  The mixture was diluted with 7 mL of THF (0.03 
M), treated with 8.5 mg (0.15 mmol) of Mn, and sonicated at 50% of maximum power of 130 W.  
The reaction was quenched after 1.5 h by addition of 10% HCl solution, extracted with 3 x 5 mL 
of Et2O, washed with 2 x 5 mL of satd. NaHCO3, dried (MgSO4), concentrated in vacuo, and 
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purified by chromatography on SiO2 (hexane:EtOAc; 6:1) to afford 10.1 mg (0.0399 mmol, 
16%) of 1-87, 5.7 mg (0.022 mmol) of 1-88, 7.5 mg (0.032 mmol) of 1-89, and 3.2 mg (0.013 
mmol) of 1-90 as impure oils: 
1-87: 1H NMR δ 7.31-7.13 (m, 6 H), 6.85 (d, 2 H, J = 8.1 Hz), 6.73 (t, 1 H, J = 7.2 Hz), 4.73 (s, 
2 H), 3.67, 3.60 (AB, 2 H, J = 15.2 Hz), 3.55 (s, 2 H), 1.36 (s, 3 H). 
1-Benzyl-3-methyl-1,2,3,4-tetrahydroquinolin-3-ol (1-88): 1H NMR δ 7.41-7.09 (m, 6 H), 6.85 
(d, 2 H, J = 8.1 Hz), 6.73 (t, 1 H, J = 7.5 Hz), 4.76 (s, 2 H), 3.92, 3.83 (AB, 2 H, J = 15.6 Hz), 
3.83-3.64 (m, 2 H), 1.63 (s, 3 H). 
(4-Methyl-2-phenyl-1,2,3,4-tetrahydroisoquinolin-4-yl)methanol (1-89): 1H NMR δ 7.36-7.25 
(m, 5 H), 7.14-7.05 (m, 2 H), 6.72 (t, 1 H, J = 7.5 Hz), 6.53 (d, 1 H, J = 7.8 Hz), 4.35, 4.19 (AB, 
2 H, J = 15.0 Hz), 3.64, 3.58 (AB, 2 H, J = 10.6 Hz), 3.42, 3.06 (AB, 2 H, J = 9.0 Hz), 1.29 (s, 3 
H). 
3-(Benzyl(phenyl)amino)-2-methylpropan-1-ol (1-90): 1H NMR δ 7.35-7.17 (m, 8 H), 6.78-
6.68 (m, 2 H), 4.61, 4.58 (AB, 2 H, J = 16.9 Hz), 3.61 (app d, 2 H, J = 5.1 Hz), 3.46 (dd, 1 H, J = 
14.4 Hz, J = 8.1 Hz), 3.27 (dd, 1 H, J = 14.7 Hz, J = 6.3 Hz), 2.27-2.16 (m, 1 H), 0.98 (d, 3 H, J 
= 6.6 Hz). 
 
N
Bn
1-91  
N-benzyl-N-(2-methylallyl)aniline (1-91). To a solution of 1.16 g (6.33 mmol) of 1-85 in 12 
mL of acetonitrile was added 2.26 g (18.9 mmol) of K2CO3, and 1.0 mL (9.9 mmol) of 3-bromo-
2-methylpropene.  The mixture was stirred for 24 h at rt, quenched with H2O, extracted with 3 x 
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10 mL of Et2O, dried (MgSO4), concentrated in vacuo, and purified by chromatography on SiO2 
(hexane:EtOAc; 20:1) to afford 1.46 g, (6.14 mmol, 97%) of 1-91 as an oil: IR (neat) 3061, 
3027, 2910, 1655, 1598, 1504, 1357, 1230, 894 cm-1;  1H NMR δ 7.29-7.11 (m, 6 H), 6.65 (d, 4 
H, J = 7.2 Hz), 4.86 (s, 1 H), 4.83 (s, 1 H), 4.54 (s, 2 H), 3.86 (s, 2 H), 1.71 (s, 3 H); 13C NMR δ 
149.2, 140.7, 139.0, 129.2, 128.8, 126.9, 126.7, 116.6, 112.4, 110.8, 56.7, 54.2, 20.3;  MS (EI) 
m/z 237 (M+•, 13), 221 (10), 196 (11), 118 (26), 91 (94), 84 (100);  HRMS (EI) m/z calcd for 
C17H19N 237.1517, found 237.1515. 
 
N O
H
1-92  
N-((2-Methyloxiran-2-yl)methyl)aniline (1-92). According to General Protocol B, 979 mg 
(4.12 mmol) of 1-91, 579 mg (4.94 mmol) of NMO, and 62 µL of OsO4 (0.5 mol%, 0.33 M in 
toluene) afforded an oil that was dissolved in 4 mL of MeOH.  The solution was treated with 110 
mg (11% w/w, 0.05 mmol) of Pd/C and stirred under 1 atm of H2 at rt.  The disappearance of 
starting material was monitored by TLC (hexane:EtOAc; 1:1).  After 3 h, the mixture was 
filtered through Celite and concentrated in vacuo.  The crude residue was dissolved in 35 mL 
of THF, cooled to 0 oC, and treated with 314 mg (7.85 mmol) of NaH (60% dispersion in mineral 
oil).  The reaction mixture was stirred for 15 min, treated portionwise with 1.35 g (4.13 mmol) of 
p-Ts2O, and quenched after 1 h by addition of H2O.  The mixture was extracted with 3 x 15 mL 
of Et2O, dried (MgSO4), concentrated in vacuo, and purified by chromatography on SiO2 
(hexane:EtOAc; 6:1) to afford 441 mg (2.70 mmol, 66%, 3 steps) of 1-92 as an oil: IR (neat) 
3357, 3048, 2976, 2864, 1923, 1603, 1512, 1321, 1074 cm-1;  1H NMR δ 7.15 (t, 2 H, J = 7.2 
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Hz), 6.69 (t, 1 H, J = 7.2 Hz), 6.59 (d, 2 H, J = 8.4 Hz), 3.82 (bs, 1 H), 3.31, 3.28 (AB, 2 H, J = 
13.6 Hz), 2.81, 2.61 (AB, 2 H, J = 4.8 Hz), 1.39 (s, 3 H);  13C NMR δ 148.2, 129.4, 117.8, 113.0, 
56.4, 52.0, 47.8, 19.9;  MS (EI) m/z 163 (M+•, 37), 148 (6), 106 (40), 84 (100);  HRMS (EI) m/z 
calcd for C10H13NO 163.0997, found 163.0994. 
 
N
H H
OH
1-93  
2-Methyl-3-(phenylamino)propan-1-ol (1-93). A mixture of 90 mg (0.57 mmol) of collidine 
hydrochloride, 7.1 mg (0.029 mmol) of Cp2TiCl2, and a solution of 47 mg (0.28 mmol) of 1-92 
in 1 mL of THF was treated with 8.5 mL of THF, and 10.2 mg (0.187 mmol) of Mn.  Sonication 
was initiated at 50% of the maximum power of 130 W.  The reaction was quenched after 1.5 h 
with satd. NH4Cl, extracted with 3 x 10 mL of Et2O, concentrated in vacuo, and purified by 
chromatography on SiO2 (hexane:EtOAc; 6:1) to yield 4.3 mg (0.026 mmol, 9%) of 1-93 as an 
oil:225 1H NMR δ 7.18 (t, 2 H, J = 7.5 Hz), 6.72 (t, 1 H, J = 7.2 Hz), 6.65 (d, 2 H, J = 7.5 Hz), 
3.69 (dd, 1 H, J = 10.5 Hz, J = 4.8 Hz), 3.61 (dd, 1 H, J = 10.8 Hz, J = 6.9 Hz), 3.17 (dd, 1 H, J 
= 12.6 Hz, J = 7.5 Hz), 3.10 (dd, 1 H, J = 12.3 Hz, J = 5.4 Hz), 2.12-1.95 (m, 1 H), 0.99 (d, 3 H, 
J = 6.9 Hz). 
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1-94
NO
OF3C
 
2,2,2-Trifluoro-N-((2-methyloxiran-2-yl)methyl)-N-phenylacetamide (1-94).226 According to 
a modified literature procedure, to a solution of 147 mg (0.900 mmol) of 1-92 in 9 mL of 
pyridine at 0 oC was added 11 mg (0.090 mmol) of DMAP followed by 165 µL (1.17 mmol) of 
TFAA.  After 2.5 h the mixture was quenched with H2O, extracted with 3 x 10 mL of Et2O, dried 
(MgSO4), concentrated in vacuo, and purified by chromatography on SiO2 (hexane:EtOAc; 4:1) 
to afford 172 mg (0.667 mmol, 74%) of 1-94 as a white solid: 1H NMR δ 7.46-7.41 (m, 3 H), 
7.28-7.26 (m, 2 H), 3.99, 3.85 (AB, 2 H, J = 14.1 Hz), 2.56, 2.45 (AB, 2 H, J = 4.3 Hz), 1.42 (s, 
3 H); MS (EI) m/z 259 (M+•, 26), 172 (41), 104 (93), 77 (100); 13C NMR δ 157.3 (q, JC-P = 35 
Hz), 139.6, 129.4, 129.3, 128.3, 116.4 (q, JC-P = 287 Hz), 56.8, 54.9, 52.2, 19.4. 
 
N
Ph H
OH
N
OH
F3C
OO
CF3
1-95 1-96  
2,2,2-Trifluoro-1-(3-(hydroxymethyl)-3-methylindolin-1-yl)ethanone (1-95). According to 
General Protocol C, 61 mg (0.23 mmol) of 1-94, 5.8 mg (0.024 mmol) of Cp2TiCl2, 147 mg 
(0.940 mmol) of collidine hydrochloride and 15 mg (0.23 mmol) of Nano-Zn (reaction time 1 h) 
provided a mixture that was purified by chromatography on SiO2 (hexane:EtOAc; 4:1) to afford 
10 mg (0.040 mmol, 17%) of 1-95 and 10 mg (0.040 mmol) of 1-96 as oils. 
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1-95: 1H NMR δ 8.21 (d, 1 H, J = 7.8 Hz), 7.37-7.20 (m, 3 H), 4.38, 3.89 (AB, 2 H, J = 11.1 Hz), 
3.68, 3.60 (AB, 2 H, J = 10.8 Hz), 1.61 (bs, 1 H), 1.40 (s, 3 H); MS (EI) m/z 259 (M+•, 14), 228 
(100), 130 (42), 105 (25). 
2,2,2-Trifluoro-N-(3-hydroxy-2-methylpropyl)-N-phenylacetamide (1-96): 1H NMR δ 7.50-
7.40 (m, 3 H), 7.25-7.15 (m, 2 H), 4.14 (dd, 1 H, J = 13.5 Hz, J = 9.9 Hz), 3.70-3.60 (m, 1 H), 
3.51 (bd, 1 H, J = 9.0 Hz), 3.32 (dd, 1 H, J = 13.8 Hz, J = 5.4 Hz), 2.60 (bs, 1 H), 1.95-1.79 (m, 
1 H), 0.96 (d, 3 H, J = 6.9 Hz); MS (EI) m/z 261 (M+•, 15), 202 (100), 105 (64). 
 
N
H
Cbz
1-97  
Benzyl phenylcarbamate (1-97).227,228 General Protocol D.  According to a modified 
literature procedure, a solution of 2.04 g (21.9 mmol) of aniline in 50 mL of THF at 0 °C was 
treated with 2.02 g (24.0 mmol) of NaHCO3 followed by 3.4 mL (24 mmol) of benzyl 
chloroformate.  After 15, min the reaction mixture was warmed to rt, quenched with H2O and 
extracted with 3 x 20 mL of EtOAc. The combined organic layers were dried (MgSO4) and 
concentrated in vacuo to afford 4.97 g (21.9 mmol, quant.) of 1-97 as a white solid that was used 
without further purification: mp 76-77 oC (lit 80 oC); 1H NMR δ 7.40-7.20 (m, 8 H), 7.01 (t, 2 H, 
J = 7.2 Hz), 6.94 (bs, 1 H), 5.13 (s, 2 H); 13C NMR δ 153.6, 138.0, 136.2, 129.1, 128.7, 128.4, 
123.6, 118.9, 67.1. 
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1-98
N
O
Cbz
 
Benzyl (2-methyloxiran-2-yl)methyl(phenyl)carbamate (1-98). General Protocol E. 
To a solution of 2.91 g (12.8 mmol) of 1-97 in 60 mL of THF at 0 °C was added 1.02 g (25.6 
mmol) of NaH (60% dispersion in mineral oil). The reaction mixture was warmed to rt over 15 
min and 2.6 mL (26 mmol) of 3-bromo-2-methylpropene were added. The solution was stirred 
overnight, quenched with H2O and extracted with 3 x 20 mL of Et2O. The combined organic 
layers were dried (MgSO4) and concentrated in vacuo. The residue was dissolved in 80 mL of 
CH2Cl2, cooled to 0 oC and 5.67 g (23.0 mmol) of m-CPBA (70%) was added portionwise. The 
reaction mixture was quenched with aq. Na2S2O3 solution and extracted with 3 x 10 mL of Et2O. 
The combined organic layers were dried (MgSO4), concentrated in vacuo and purified by 
chromatography on SiO2 (hexane:EtOAc; 4:1 with 1% NEt3) to afford 3.01 g (10.1 mmol, 79%, 
2 steps) of 1-98 as an orange oil: IR (neat) 3520, 3036, 2934, 2360, 1706, 1597, 1494, 1405, 
1273, 1147, 1020 cm-1; 1H NMR δ 7.38-7.20 (m, 10 H), 5.14 (s, 2 H), 3.95, 3.72 (AB, 2 H, J = 
14.7 Hz), 2.50, 2.47 (AB, 2 H, J = 4.8 Hz), 1.36 (s, 3H); 13C NMR δ 155.6, 142.2, 136.5, 129.0, 
128.4, 128.0, 127.6, 127.2, 126.9, 67.5, 55.7, 55.5, 52.5, 19.4; MS (EI) m/z 297 (M+•, 23), 196 
(71), 132 (47), 91 (100); HRMS (EI) m/z calcd for C18H19NO3 297.1364, found 297.1351. 
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N
Cbz H
OH
N
OH
Cbz
1-99 1-100  
Benzyl 3-(hydroxymethyl)-3-methylindoline-1-carboxylate (1-99). A solution of 85 
mg (0.28 mmol) of 1-98, 7.0 mg (0.029 mmol) of Cp2TiCl2, 179 mg (1.14 mmol) of collidine 
hydrochloride, and 23.5 mg (0.427 mmol) of Mn in 2.8 mL of THF was stirred for 5 h at rt, 
quenched with satd. NH4Cl and extracted with 3 x 5 mL of Et2O. The combined organic layers 
were dried (MgSO4) and concentrated in vacuo to provide a residue containing 1-99 and 1-100 
(~2:1 ratio based on integration of the crude 1H NMR peaks at 4.15 ppm (1-99) vs. 0.88 ppm (1-
100)). The mixture was partially purified by chromatography on SiO2 (hexane:EtOAc; 4:1) to 
afford 36 mg (0.12 mmol, 42%) of 1-99 in addition to 37 mg of an inseparable mixture of 1-99 
and 1-100.   
1-99: 1H NMR δ 7.89 (bs, 1 H), 7.49-6.97 (m, 8 H), 5.24 (bs, 2 H), 4.12 (d, 1 H, J = 11.8 
Hz), 3.68 (d, 1 H, J = 11.7 Hz), 3.61, 3.53 (AB, 2 H, J = 10.8 Hz), 1.70 (bs, 1 H), 1.34 (s, 3 H); 
MS (EI) m/z 297 (M+•, 28), 222 (55), 130 (40), 91 (100). 
1-100: 1H NMR δ 7.44-7.41 (m, 10 H), 5.15, 5.11 (AB, 2 H, J = 12.6 Hz), 3.96 (dd, 1 H, 
J = 14.4 Hz, J = 9.6 Hz), 3.71-3.30 (m, 3 H), 1.86-1.70 (m, 1 H), 0.89 (d, 3 H, J = 6.9 Hz); MS 
(EI) m/z 299 (M+•, 10), 191 (20), 91 (100). 
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N
OH
H
1-101  
(3-Methylindolin-3-yl)methanol (1-101). General Protocol F. To a 2-neck flask was 
added 129 mg (0.433 mmol) of 1-98, 3.2 mg (0.013 mmol) of Cp2TiCl2, 102 mg (0.649 mmol) of 
collidine hydrochloride, and 35.6 mg (0.649 mmol) of Mn. The vessel was fitted with a reflux 
condenser and purged 3 x with Ar. After addition of 4.3 mL of THF (0.1 M), the reaction 
mixture was placed in a preheated oil bath and heated at reflux for 3 h. During this time, the 
solution gradually changed from light pink to a dark violet color. The mixture was cooled to rt, 
quenched with satd. NH4Cl and extracted with 3 x 10 mL of Et2O. The combined organic layers 
were washed with brine, dried (MgSO4) and concentrated in vacuo. The residue was dissolved in 
5 mL of MeOH and treated with 30 mg (25% w/w, 0.01 mmol) of Pd/C. The mixture was stirred 
at rt under 1 atm of H2 and the disappearance of starting material was monitored by TLC 
(hexane:EtOAc; 1:1). The solution was then quenched with Celite, filtered and purified by 
chromatography on SiO2 (hexane:EtOAc; 1:2) to afford 44 mg (0.26 mmol, 63%, 2 steps) of 1-
101 as a yellow oil: IR (neat) 3332, 2959, 2926, 2867, 1606, 1487, 1461, 1239, 1030, 747 cm-1; 
1H NMR δ 7.08-7.02 (m, 2 H), 6.73 (t, 1 H, J = 6.6 Hz), 6.62 (d, 1 H, J = 7.5 Hz), 3.59, 3.53 
(AB, 2 H, J = 10.5 Hz), 3.55, 3.26 (AB, 2 H, J = 9.0 Hz), 1.31 (s, 3 H); 13C NMR δ 151.6, 133.7, 
128.3, 123.2, 118.9, 110.0, 69.3, 56.9, 47.7, 22.4; MS (EI) m/z 163 (M+•, 32), 132 (100), 117 
(59); HRMS (EI) m/z calcd for C10H13NO 163.0997, found 163.0993. 
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1-102
N
EtO2C
H
 
Ethyl phenylcarbamate (1-102).229 According to a modified literature procedure, to a 
solution of 5.10 g (54.7 mmol) of aniline in 130 mL of THF at 0 oC was added 3.06 g (76.5 
mmol) of NaH (60% dispersion in mineral oil) followed by 6.3 mL (66 mmol) of ethyl 
chloroformate. The reaction mixture was warmed to rt, quenched with H2O after 3 h and 
extracted with 3 x 40 mL of Et2O. The combined organic layers were dried (MgSO4), 
concentrated in vacuo and purified by chromatography on SiO2 (hexane:EtOAc; 5:1 to 3:1) to 
afford 8.07 g (48.8 mmol, 89%) of 1-102 as a brown oil: 1H NMR δ 7.39-7.25 (m, 4 H), 7.05 (t, 
1 H, J = 6.9 Hz), 6.59 (bs, 1 H), 4.22 (q, 2 H, J = 7.2 Hz), 1.31 (t, 3 H, J = 7.2 Hz); MS (EI) m/z 
165 (M+•, 78), 119 (34), 93 (100), 65 (50). 
 
1-103
N
O
EtO2C
 
Ethyl (2-methyloxiran-2-yl)methyl(phenyl)carbamate (1-103). According to General 
Procedure E, 2.54 g (15.4 mmol) of 1-102, 1.23 g (30.8 mmol) of NaH (60% dispersion in 
mineral oil), 2.8 mL (28 mmol) of 3-bromo-2-methylpropene, and 5.70 g (23.1 mmol) of m-
CPBA (70%) provided an oil that was purified by chromatography on SiO2 (hexane:EtOAc; 4:1) 
to afford 2.66 g (11.3 mmol, 73%, 2 steps) of 1-103 as a golden oil: IR (neat) 3043, 2981, 2933, 
1702, 1597, 1536, 1408, 1299, 1023 cm-1; 1H NMR δ 7.35-7.18 (m, 5 H), 4.14 (q, 2 H, J = 6.9 
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Hz), 3.93 (A of ABX, 1 H, J = 14.7 Hz, J = 0.6 Hz), 3.71 (B of ABX, 1 H, J = 14.7 Hz, J = 0.9 
Hz), 2.51 (m, 2 H), 1.37 (s, 3 H), 1.19 (t, 3 H, J = 6.9 Hz); 13C NMR δ 155.8, 142.4, 128.9, 
127.1, 126.6, 61.9, 55.7, 55.3, 52.5, 19.4, 14.5; MS (EI) m/z 235 (M+•, 45), 178 (38), 134 (28), 
106 (100); HRMS (EI) m/z calcd for C13H17NO3 235.1208, found 235.1219. 
 
N
OH
CO2Et
1-104  
Ethyl 3-(hydroxymethyl)-3-methylindoline-1-carboxylate (1-104). According to 
General Protocol C, 125 mg (0.531 mmol) of 1-103, 3.9 mg (0.016 mmol) of Cp2TiCl2, 125 mg 
(0.796 mmol) of collidine hydrochloride, and 43 mg (0.79 mmol) of Mn provided a mixture 
(reaction time 2 h) that was purified by chromatography on SiO2 (hexane:EtOAc; 3:1) to afford 
81 mg (0.34 mmol, 65%) of 1-104 as an oil: IR (neat) 3433, 2976, 2931, 1693, 1600, 1487, 1413, 
1051cm-1; 1H NMR δ 7.85 (bs, 1 H), 7.24 (t, 1 H, J = 6.9 Hz), 7.11 (d, 1 H, J = 6.9 Hz), 6.98 (t, 1 
H, J = 7.2 Hz), 4.26 (bs, 2 H), 4.07 (d, 1 H, J = 11.4 Hz), 3.64 (d, 1 H, J = 11.4 Hz), 3.61 (dd, 1 
H, J = 11.4 Hz, J = 4.5 Hz), 3.52 (dd, 1 H, J = 10.5 Hz, J = 6.6 Hz), 1.97 (bs, 1 H), 1.34 (bs, 6 
H); 13C NMR δ 153.6, 142.9, 135.8, 128.6, 123.0, 122.8, 115.1, 69.7, 61.7, 57.7, 45.4, 23.2, 14.8; 
MS (EI) m/z 235 (M+•, 31), 204 (100), 160 (27), 130 (71), 117 (55); HRMS (EI) m/z calcd for 
C13H17NO3 235.1208, found 235.1202. 
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Cbz
H3C
1-105  
Benzyl p-tolylcarbamate (1-105). According to General Protocol D, 4.15 g (38.7 mmol) 
of p-toluidine, 3.57 g (42.6 mmol) of NaHCO3, and 6.0 mL (42.6 mmol) of benzyl chloroformate 
(reaction time 30 min) afforded a solid that was recrystallized from chloroform/hexane to afford 
8.12 g (33.6 mmol, 87%) of 1-105 as white needles: mp 82-84 oC; IR (KBr) 3319, 3195, 3032, 
2943, 1730, 1707, 1602, 1543, 1406, 1232, 1067, 739 cm-1; 1H NMR δ 7.39-7.20 (m, 7 H), 7.06 
(d, 2 H, J = 8.4 Hz), 6.72 (bs, 1 H), 5.15 (s, 2 H), 2.27 (s, 3 H); 13C NMR δ 153.7, 136.3, 135.4, 
133.2, 129.7, 128.7, 128.4, 119.1, 67.1, 20.9;  MS (EI) m/z  241 (M+•, 49), 197 (45), 133 (34), 91 
(100), 84 (91); HRMS (EI) m/z calcd for C15H15NO2 241.1102, found 241.1106. 
 
1-106
N
O
Cbz
CH3
 
Benzyl (2-methyloxiran-2-yl)methyl(p-tolyl)carbamate (1-106). According to General 
Protocol E, 4.42 g (18.3 mmol) of 1-105, 1.46 g (36.6 mmol) of NaH (60% dispersion in mineral 
oil), 2.8 mL (28 mmol) of 3-bromo-2-methylpropene, and 6.76 g (27.4 mmol) of m-CPBA (70%) 
provided an oil that was purified by chromatography on SiO2 (hexane:EtOAc; 4:1) to afford 4.43 
g (14.2 mmol, 78%, 2 steps) of 1-106 as a red oil: IR (neat) 3583, 3033, 2929, 1702, 1514, 1404, 
1271, 1146 cm-1; 1H NMR δ 7.33-7.24 (m, 5 H), 7.16-7.09 (m, 4 H), 5.14 (bs, 2 H), 3.91, 3.69 
(AB, 2 H, J = 14.7 Hz), 2.50, 2.47 (AB, 2 H, J = 4.6 Hz), 2.33 (s, 3 H), 1.35 (s, 3 H);  13C NMR 
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δ 155.9, 139.7, 136.9, 136.7, 129.8, 128.6, 128.1, 127.8, 127.1, 67.6, 55.9, 55.8, 52.7, 21.2, 19.5; 
MS (EI) m/z 311 (M+•, 35), 210 (46), 146 (48), 91 (95), 84 (100); HRMS (EI) m/z calcd for 
C19H21NO3 311.1521, found 311.1525. 
 
N
HCbz
CH3
1-107  
Benzyl o-tolylcarbamate (1-107). According to General Protocol D, 3.81 g (35.5 mmol) 
of o-toluidine, 3.28 g (39.1 mmol) of NaHCO3, and 5.5 mL (39 mmol) of benzyl chloroformate 
(reaction time 1 h) provided a solid that was recrystallized from Et2O to afford 7.41 g (30.7 
mmol, 86%) of 1-107 as a white solid: mp 83-84 oC; IR (KBr) 3297, 3036, 2959, 1695, 1588, 
1533, 1454, 1294, 1240, 1064 cm-1; 1H NMR (DMSO-d6, 350 K) δ 8.64 (bs, 1 H), 7.47-7.30 (m, 
6 H), 7.20-7.09 (m, 3 H), 5.16 (s, 2 H), 2.33 (s, 3 H); 13C NMR (DMSO-d6, 350 K) δ 153.9, 
136.6, 136.0, 131.3, 129.8, 127.9, 127.3, 127.2, 125.5, 124.4, 124.2, 65.3, 17.1;  MS (EI) m/z 241 
(M+•, 13), 197 (13), 133 (18), 104 (16), 91 (100); HRMS (EI) m/z calcd for C15H15NO2 241.1102, 
found 241.1107. 
 
1-108
N
O
Cbz
H3C
 
Benzyl (2-methyloxiran-2-yl)methyl(o-tolyl)carbamate (1-108). According to General 
Protocol E, 3.60 g (14.9 mmol) of 1-107, 1.19 g (29.8 mmol) of NaH (60% dispersion in mineral 
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oil), 2.2 mL (22 mmol) of 3-bromo-2-methylpropene, and 5.51 g (22.3 mmol) of m-CPBA (70%) 
provided an oil that was purified by chromatography on SiO2 (hexane:EtOAc; 4:1) to afford 3.88 
g (12.4 mmol, 84%, 2 steps) of 1-108 as an oil: IR (neat) 3033, 2931, 1708, 1583, 1493, 1406, 
1299, 1147, 1028 cm-1; 1H NMR (DMSO-d6, 350 K) δ 7.34-7.20 (m, 9 H), 5.09 (s, 2 H), 4.10-
3.20 (m, 2 H), 2.50, 2.41 (AB, 2 H, J = 4.7 Hz), 2.13 (s, 3 H), 1.32 (s, 3 H); 13C NMR (DMSO-
d6, 350 K) δ 154.6, 140.7, 136.3, 134.9, 130.2, 127.9, 127.8, 127.3, 126.9, 126.8, 126.0, 66.3, 
54.7, 51.2, 18.9, 16.6;  MS (EI) m/z 311 (M+•, 15), 210 (8), 118 (25), 91 (100); HRMS (EI) m/z 
calcd for C19H21NO3 311.1521, found 311.1527. 
 
N
H
Cbz
OMe
1-109  
Benzyl 4-methoxyphenylcarbamate (1-109).230 According to General Protocol D, 4.08 
g (33.1 mmol) of p-anisidine, 3.06 g (36.4 mmol) of NaHCO3, and 5.2 mL (36 mmol) of benzyl 
chloroformate (reaction time 30 min) provided a solid that was recrystallized 
(chloroform:hexane; 1:10) to afford 7.65 g (29.7 mmol, 90%) of 1-109 as a pink solid: mp 98 oC;  
IR (KBr) 3299, 3042, 2842, 1701, 1532, 1415, 1238, 1065, 1029, 825, 743 cm-1; 1H NMR δ 
7.42-7.24 (m, 7 H), 6.86-6.81 (m, 2 H), 6.59 (bs, 1 H), 5.17 (s, 2 H), 3.77 (s, 3 H); 13C NMR δ 
156.3, 153.9, 136.4, 131.0, 128.8, 128.5, 121.0, 114.5, 67.1, 55.7; MS (EI) m/z  257 (M+•, 11), 
213 (7), 122 (32), 91 (100), 65 (50); HRMS (EI) m/z calcd for C15H15NO3 257.1051, found 
257.1047. 
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1-110  
Benzyl 4-methoxyphenyl((2-methyloxiran-2-yl)methyl)carbamate (1-110). According 
to General Protocol E, 4.21 g (16.3 mmol) of 1-109, 1.30 g (32.7 mmol) of NaH (60% dispersion 
in mineral oil), 2.5 mL (25 mmol) of 3-bromo-2-methylpropene, and 6.04 g (24.5 mmol) of m-
CPBA (70%) provided an oil that was purified by chromatography on SiO2 (hexane:EtOAc; 4:1) 
to afford 4.34 g (13.2 mmol, 81%, 2 steps) of 1-110 as an oil: IR (neat) 3520, 3037, 2935, 2837, 
1701, 1609, 1585, 1512, 1444, 1428, 1294 cm-1; 1H NMR δ 7.32-7.12 (m, 7 H), 6.83 (d, 2 H, J = 
12.3 Hz), 5.12 (bs, 2 H), 3.89, 3.65 (AB, 2 H, J = 14.7 Hz), 3.74 (s, 3 H), 2.47, 2.45 (AB, 2 H, J 
= 4.5 Hz), 1.34 (s, 3 H); 13C NMR δ 158.2, 155.9, 136.6, 135.0, 128.4, 127.9, 127.5, 114.2, 67.4, 
55.8, 55.6, 55.4, 52.4, 19.3; MS (EI) m/z  327 (M+•, 23), 192 (15), 146 (23), 91 (81), 84 (100); 
HRMS (EI) m/z calcd for C19H21NO4 327.1470, found 327.1471. 
 
N
H
Cbz
Cl
1-111  
Benzyl 4-chlorophenylcarbamate (1-111). According to General Protocol D, 3.81 g 
(29.8 mmol) of p-chloroaniline, 2.57 g (32.8 mmol) of NaHCO3, and 4.6 mL (33 mmol) of 
benzyl chloroformate provided a solid that was recrystallized (chloroform/hexane; 1:10) to 
afford 6.57 g (25.1 mmol, 84%) of 1-111 as pink needles: mp 109-111 oC; IR (KBr) 3320, 3112, 
3037, 2954, 1707, 1594, 1528, 1403, 1237, 1065, 822, 737 cm-1; 1H NMR δ 7.41-7.23 (m, 9 H), 
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6.70 (bs, 1 H), 5.18 (s, 2 H); 13C NMR δ 153.4, 136.6, 136.0, 129.3, 128.9, 128.8, 128.7, 128.5, 
120.1, 67.4; MS (EI) m/z 261 (M+•, 20), 217 (15), 153 (79), 91 (100); HRMS (EI) m/z calcd for 
C14H12ClNO2 261.0556, found 261.0561. 
 
1-112
N
O
Cbz
Cl
 
Benzyl 4-chlorophenyl((2-methyloxiran-2-yl)methyl)carbamate (1-112). According to 
General Protocol E, 3.96 g (15.1 mmol) of 1-111, 1.21 g (30.2 mmol) of NaH (60% dispersion in 
mineral oil), 2.3 mL (23 mmol) of 3-bromo-2-methylpropene, and 5.58 g (22.6 mmol) of m-
CPBA (70%) provided an oil that was purified by chromatography on SiO2 (hexane:EtOAc; 4:1) 
to afford 3.96 g (11.9 mmol, 79%, 2 steps) of 1-112 as an orange solid: mp 58-60 oC; IR (KBr) 
3319, 3400, 3036, 2968, 2279, 1702, 1412, 1263, 1148, 1090, 1011, 837, 734 cm-1; 1H NMR δ 
7.32-7.16 (m, 9 H), 5.14 (s, 2 H), 3.86, 3.75 (AB, 2 H, J = 15.0 Hz), 2.51, 2.50 (AB, 2 H, J = 4.8 
Hz), 1.34 (s, 3 H); 13C NMR δ 155.5, 140.9, 136.3, 132.5, 129.2, 128.6, 128.5, 128.3, 127.9, 
67.8, 55.8, 55.4, 52.3, 19.4; MS (EI) m/z 331 (M+•, 33), 230 (46), 111 (42), 91 (100), 84 (94); 
HRMS (EI) m/z calcd for C18H18ClNO3 331.0975, found 331.0975. 
 
 
 
 119 
 
N
H
Cbz O
OMe
1-113  
Methyl 4-(benzyloxycarbonylamino)benzoate (1-113). According to General Protocol 
D, 3.80 g (25.1 mmol) of methyl 4-aminobenzoate, 2.32 g (27.6 mmol) of NaHCO3, and 3.9 mL 
(28 mmol) of benzyl chloroformate (reaction time 1 h) provided a solid that was recrystallized 
(chloroform/hexane; 1:10) to afford 6.47 g (22.6 mmol, 90%) of 1-113 as a white solid: mp 137-
139 oC; IR (KBr) 3311, 3117, 2956, 1729, 1694, 1602, 1537, 1451, 1323, 1221, 1042 cm-1; 1H 
NMR δ 7.98 (d, 2 H, J = 8.7 Hz), 7.45 (d, 2 H, J = 8.7 Hz), 7.42-7.31 (m, 5 H), 6.99 (bs, 1 H), 
5.20 (s, 2 H), 3.88 (s, 3 H);  13C NMR δ 166.9, 153.1, 142.3, 135.9, 131.1, 128.9, 128.7, 128.6, 
125.1, 117.8, 67.5, 52.2; MS (EI) m/z 285 (M+•, 38), 241 (43), 177 (77), 146 (88), 91 (100); 
HRMS (EI) m/z calcd for C16H15NO4 285.1001, found 285.0999. 
 
N
Cbz
O
OMe
O
1-114  
Methyl 4-((benzyloxycarbonyl)((2-methyloxiran-2-yl)methyl)amino)benzoate (1-
114). To a solution of 1.96 g (6.87 mmol) of 1-113 in 20 mL of DMF at rt was added 190 mg 
(7.55 mmol) of NaH (95% dispersion in mineral oil). The reaction mixture was stirred until H2 
evolution ceased, then 900 µL (8.93 mmol) of 3-bromo-2-methylpropene was added. The 
mixture was stirred overnight at rt, quenched with H2O, poured onto ice and extracted with 3 x 
20 mL of CH2Cl2. The combined organic layers were washed with 50 mL of H2O, dried 
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(MgSO4) and concentrated in vacuo. The crude residue was dissolved in 60 mL of CH2Cl2, 
cooled to 0 oC and treated portionwise with 2.03 g (8.24 mmol) of m-CPBA (70%). The 
disappearance of starting material was monitored by TLC (hexane:EtOAc; 2:1). The reaction 
mixture was quenched with aq. Na2S2O3 solution and extracted with 3 x 15 mL of CH2Cl2. The 
combined organic layers were dried (MgSO4), concentrated in vacuo and purified by 
chromatography on SiO2 (hexane:EtOAc; 5:1 to 3:1) to afford 2.06 g (5.79 mmol, 84%, 2 steps) 
of 1-114 as an oil: IR (neat) 3522, 3033, 2952, 1709, 1605, 1436, 1279, 1109, 1015, 773 cm-1; 1H 
NMR δ 8.01 (d, 2 H, J = 8.7 Hz), 7.37-7.25 (m, 7 H), 5.17 (s, 2 H), 3.92, 3.85 (AB, 2 H, J = 14.8 
Hz), 3.89 (s, 3 H), 2.51 (app s, 2 H), 1.34 (s, 3 H); 13C NMR δ 166.5, 155.2, 146.5, 136.1, 130.5, 
128.6, 128.3, 128.2, 128.0, 126.6, 68.0, 55.9, 55.0, 52.3, 52.2, 19.4; MS (EI) m/z 355 (M+•, 62), 
324 (30), 254 (55), 132 (49), 91 (100); HRMS (EI) m/z calcd for C20H21NO5 355.1419, found 
355.1415. 
 
N
OH
H
H3C
1-115  
(3,5-Dimethylindolin-3-yl)methanol  (1-115). According to General Protocol F, 163 mg 
(0.523 mmol) of 1-106, 3.9 mg (0.016 mmol) of Cp2TiCl2, 123 mg (0.784 mmol) of collidine 
hydrochloride, and 43 mg (0.78 mmol) of Mn provided an oil (reaction time 3 h) that was 
purified first by chromatography on neutral alumina (hexane:EtOAc; 2:1) and then subjected to 
111 mg (70% w/w, 0.0522 mmol) of Pd/C under 1 atm of H2 (reaction time 2 h) to provide an oil 
that was purified by chromatography on SiO2 (hexane:EtOAc; 1:1 with 1% NEt3) to afford 57 
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mg (0.32 mmol, 62%, 2 steps) of 1-115 as an oil: IR (neat) 3327, 2958, 2922, 2864, 1614, 1495, 
1463, 1238, 1033, 810 cm-1; 1H NMR δ 6.87-6.85 (m, 2 H), 6.56-6.53 (m, 1 H), 3.58, 3.51 (AB, 
2 H, J = 10.6 Hz), 3.53, 3.22 (AB, 2 H, J = 9.1 Hz), 2.25 (s, 3 H), 1.30 (s, 3 H); 13C NMR δ 
149.3, 134.1, 128.7, 128.4, 123.8, 110.1, 69.4, 57.3, 47.7, 22.3, 21.0; MS (EI) m/z 177 (M+•, 45), 
146 (100), 131 (69), 130 (38); HRMS (EI) m/z calcd for C11H15NO 177.1153, found 177.1154. 
 
1-116
N
OH
HCH3
 
(3,7-Dimethylindolin-3-yl)methanol (1-116).  According to General Protocol F, 230 mg 
(0.738 mmol) of 1-108, 7.3 mg (0.030 mmol) of Cp2TiCl2, 174 mg (1.10 mmol) of collidine 
hydrochloride, and 60 mg (1.1 mmol) of Mn (reaction time 5 h) provided an oil that was purified 
by chromatography on neutral alumina (hexane:EtOAc; 4:1) and then subjected to 10 mg (10% 
w/w, 4.6 µmol) of Pd/C under 1 atm of H2 to provide a mixture that was purified by 
chromatography on SiO2 (hexane:EtOAc; 4:1 with 1% NEt3) to afford 46 mg (0.25 mmol, 35%, 
2 steps) of 1-116 as an oil: IR (neat) 3317, 2960, 2926, 2867, 1599, 1478, 1030, 749 cm-1; 1H 
NMR δ 6.91 (d, 2 H, J = 7.5 Hz), 6.69 (t, 1 H, J = 7.5 Hz), 3.61, 3.54 (AB, 2 H, J = 10.5 Hz), 
3.60 (d, 1 H, J = 9.3 Hz), 3.29 (d, 1 H, J = 9.3 Hz), 2.12 (s, 3 H), 1.32 (s, 3 H); 13C NMR δ 
150.1, 133.0, 129.3, 120.6, 119.5, 119.2, 69.4, 56.9, 48.0, 22.6, 16.9; MS (EI) m/z 177 (M+•, 14), 
146 (100), 131 (35); HRMS (EI) m/z calcd for C11H15NO 177.1153, found 177.1154. 
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1-117  
(5-Methoxy-3-methylindolin-3-yl)methanol (1-117). According to General Protocol F, 
236 mg (0.720 mmol) of 1-110, 7.1 mg (0.028 mmol) of Cp2TiCl2, 170 mg (1.08 mmol) of 
collidine hydrochloride, and 59 mg (1.1 mmol) of Mn afforded an oil (reaction time 3 h) that was 
subjected to 46 mg (20% w/w, 0.022 mmol) of Pd/C and 1 atm of H2 to provide an oil that was 
purified by chromatography on SiO2 (hexane:EtOAc; 1:1) to afford 28 mg (0.14 mmol, 21%, 2 
steps) of 1-117 as a purple oil: IR (neat) 3339, 2920, 2866, 1596, 1490, 1434, 1280, 1022 cm-1; 
1H NMR δ 6.68-6.57 (m, 3 H), 3.74 (s, 3 H), 3.61, 3.54 (AB, 2 H, J = 10.8 Hz), 3.55, 3.25 (AB, 
2 H, J = 9.3 Hz), 2.64 (bs, 2 H), 1.31 (s, 3 H); 13C NMR δ 154.0, 145.3, 135.8, 113.1, 110.9, 
110.2, 69.3, 57.6, 56.2, 48.2, 22.2; MS (EI) m/z 193 (M+•, 35), 162 (100), 147 (42), 118 (18); 
HRMS (EI) m/z calcd for C11H15NO2 193.1102, found 193.1103. 
 
1-118
N
Cbz
OH
Cl
 
Benzyl 5-chloro-3-(hydroxymethyl)-3-methylindoline-1-carboxylate (1-118).  
According to General Protocol C, 318 mg (0.958 mmol) of 1-112, 7.1 mg (0.029 mmol) of 
Cp2TiCl2, 226 mg (1.43 mmol) of collidine hydrochloride, and 79 mg (1.4 mmol) of Mn 
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(reaction time 4 h) provided a mixture that was purified by chromatography on SiO2 
(hexane:EtOAc; 5:1 to 3:1) to afford 130 mg (0.392 mmol, 41%) of 1-118 as an oil: IR (neat) 
3435, 2959, 1706, 1597, 1485, 1401, 1334, 1075 cm-1; 1H NMR (DMSO-d6, 350 K) δ 7.64 (d, 1 
H, J = 8.4 Hz), 7.46-7.29 (m, 5 H), 7.23 (d, 1 H, J = 2.1 Hz), 7.19 (dd, 1 H, J = 8.7 Hz, J = 2.4 
Hz), 5.24 (s, 2 H), 4.71 (bs, 1 H), 4.06 (d, 1 H, J = 11.1 Hz), 3.64 (d, 1 H, J = 11.1 Hz), 3.45, 
3.42 (AB, 2 H, J = 10.5 Hz), 1.27 (s, 3 H); 13C NMR (DMSO-d6, 350 K) δ 151.9, 140.5, 139.5, 
136.0, 127.9, 127.5, 127.2, 126.9, 126.0, 123.1, 114.7, 67.3, 66.3, 57.2, 44.7, 22.6; MS (EI) m/z 
331 (M+•, 40), 256 (14), 91 (100); HRMS (ESI) m/z calcd for C18H18ClNO3Na (M+Na) 
354.0873, found 354.0851. 
 
1-119
N
OH
MeO
O
H
 
Methyl 3-(hydroxymethyl)-3-methylindoline-5-carboxylate (1-119). According to 
General Protocol F, 206 mg (0.579 mmol) of 1-114, 4.3 mg (0.017 mmol) of Cp2TiCl2, 136 mg 
(0.868 mmol) of collidine hydrochloride, and 47 mg (0.86 mmol) of Mn (reaction time 5 h) 
provided an intermediate that was purified by chromatography on SiO2 (hexane:EtOAc; 5:1). 
The intermediate was subjected to 20 mg (10% w/w, 9.3 µmol) of Pd/C and 1 atm of H2, and the 
reaction mixture was purified by chromatography on SiO2 (hexane:EtOAc; 1:1 with 1% NEt3) to 
afford 72 mg (0.32 mmol, 56%, 2 steps) of 1-119 as an oil: IR (neat) 3368, 2952, 2868, 1687, 
1610, 1502, 1293, 1253, 1110 cm-1; 1H NMR δ 7.78 (dd, 1 H, J = 8.4 Hz, J = 1.8 Hz), 7.68 (d, 1 
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H, J = 1.8 Hz), 6.53 (d, 1 H, J = 8.4 Hz), 4.21 (bs, 1 H), 3.83 (s, 3 H), 3.69 (d, 1 H, J = 9.1 Hz), 
3.64, 3.54 (AB, 2 H, J = 11.1 Hz), 3.34 (d, 1 H, J = 9.3 Hz), 2.02 (bs, 1 H), 1.33 (s, 3 H); 13C 
NMR δ 167.6, 155.8, 133.2, 131.7, 124.9, 119.6, 107.8, 69.1, 57.0, 51.8, 47.1, 22.8;  MS (EI) m/z 
221 (M+•, 23), 190 (81), 158 (100), 130 (68);  HRMS (EI) m/z calcd for C12H15NO3 221.1051, 
found 221.1053. 
 
N
1-121  
1-(2-Methylallyl)-1H-indole (1-121).231 According to a modified literature procedure, a 
solution of 803 mg (6.85 mmol) of indole in 13 mL of DMF and 499 mg (8.90 mmol) of 
powdered KOH was stirred at 60 oC for 10 min, cooled to rt, and treated with 1.0 mL (10 mmol) 
of 3-bromo-2-methylpropene. The reaction mixture was stirred at 60 oC for 18 h, poured onto ice 
and diluted with 15 mL of EtOAc. The combined organic layers were washed with H2O, brine, 
dried (MgSO4), concentrated in vacuo and purified by chromatography on SiO2 (hexane) to 
afford 832 mg (4.85 mmol, 71%) of 1-121 as a light green oil: IR (neat) 3054, 2913, 1657, 1612, 
1462, 1333, 900, 739 cm-1; 1H NMR δ 7.61 (d, 1 H, J = 7.8 Hz), 7.27 (d, 1 H, J = 8.1 Hz), 7.19-
7.05 (m, 2 H), 7.02 (d, 1 H, J = 3.3 Hz), 6.49 (d, 1 H, J = 3.3 Hz), 4.87 (s, 1 H), 4.69 (s, 1 H), 
4.57 (s, 2 H), 1.63 (s, 3 H); 13C NMR δ 141.4, 136.5, 128.8, 128.4, 121.7, 121.1, 119.6, 112.8, 
109.9, 101.5, 52.7, 20.0; MS (EI) m/z 171 (M+•, 88), 156 (70), 130 (100); HRMS (EI) m/z calcd 
for C12H13N 171.1048, found 171.1046. 
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1-122  
3-Bromo-1-((2-methyloxiran-2-yl)methyl)-1H-indole (1-122). To a solution of 746 mg 
(4.35 mmol) of 1-121 in 43 mL of acetonitrile was added 814 mg (4.57 mmol) of NBS. The 
reaction mixture was stirred overnight, quenched with H2O and extracted with 3 x 10 mL of 
Et2O. The combined organic layers were dried (MgSO4) and concentrated in vacuo.  According 
to General Protocol B, the crude oil, 765 mg (6.53 mmol) of NMO and 395 µL of OsO4 (3 
mol%, 0.33 M in toluene) were reacted and the disappearance of starting material was monitored 
by TLC (hexane:EtOAc; 2:1). The resulting golden oil was dissolved in 40 mL of THF and 
cooled to 0 oC. The solution was treated with 1.04 g (26.1 mmol) of NaH (60% dispersion in 
mineral oil) and stirred for 15 min. Upon addition of 1.70 g (5.22 mmol) of p-Ts2O, the 
disappearance of starting material was monitored by TLC (hexane:EtOAc; 2:1). After 35 min, 
the reaction was quenched with H2O and extracted with 3 x 15 mL of Et2O. The combined 
organic layers were dried (MgSO4) and concentrated in vacuo. The residue was purified by 
chromatography on SiO2 (hexane:EtOAc; 6:1) to afford 947 mg (3.55 mmol, 82%, 3 steps) of 1-
122 as an oil: IR (neat) 3117, 3051, 2985, 2928, 1612, 1457, 1322, 1012 cm-1; 1H NMR δ 7.56 
(app dt, 1 H, J = 8.1 Hz, J = 0.6 Hz), 7.36 (d, 1 H, J = 7.8 Hz), 7.30-7.17 (m, 2 H), 7.16 (s, 1 H), 
4.30, 4.09 (AB, 2 H, J = 15.0 Hz), 2.65, 2.55 (AB, 2 H, J = 4.5 Hz), 1.26 (s, 3 H); 13C NMR δ 
136.4, 127.6, 127.5, 123.2, 120.6, 119.6, 110.0, 90.8, 56.4, 52.1, 51.6, 19.0; MS (EI) m/z 265 
(M+•, 50), 208 (67), 186 (24), 129 (39), 69 (100); HRMS (EI) m/z calcd for C12H12NOBr 
265.0102, found 265.0103. 
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1-123
N
OH
Br
 
3-(3-Bromo-1H-indol-1-yl)-2-methylpropan-1-ol (1-123). According to General 
Protocol C, 171 mg (0.642 mmol) of 1-122, 4.7 mg (0.019 mmol) of Cp2TiCl2, 151 mg (0.963 
mmol) of collidine hydrochloride, and 52 mg (0.96 mmol) of Mn (reaction time 22 h) provided a 
mixture that was purified by chromatography on SiO2 (hexane:EtOAc; 6:1) to afford 44 mg (0.16 
mmol, 25%) of 1-123 as an oil: 1H NMR δ 7.55 (d, 1 H, J = 8.1 Hz), 7.36 (d, 1 H, J = 7.8 Hz), 
7.26-7.12 (m, 3 H), 4.22 (dd, 1 H, J = 15.0 Hz, J = 6.9 Hz), 3.95 (dd, 1 H, J = 14.4 Hz, J = 6.9 
Hz), 3.47 (br s, 1 H), 3.43 (d, 1 H, J = 6.0 Hz), 2.30-2.15 (m, 1 H), 1.69 (bs, 1 H), 0.95 (d, 3 H, J 
= 6.9 Hz); MS (EI) m/z 269 (M+•, 13), 188 (14), 146 (46), 118 (100).  
 
N O
1-125  
1-((2-Methyloxiran-2-yl)methyl)-1,2,3,4-tetrahydroquinoline (1-125). To a solution of 
1.48 g (11.1 mmol) of 1,2,3,4-tetrahydroquinoline in 40 mL of acetonitrile was added 7.67 g 
(55.5 mmol) of K2CO3 and 1.6 mL (17 mmol) of 3-bromo-2-methylpropene at room temperature. 
The disappearance of starting material was monitored by TLC (hexane:EtOAc; 4:1). The 
reaction was quenched with H2O and extracted with 3 x 20 mL of Et2O. The combined organic 
layers were dried (MgSO4) and concentrated in vacuo to afford a brown oil that was used without 
purification. According to General Protocol B, the crude reaction mixture, 1.69 g (14.4 mmol) of 
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NMO and 370 µL of OsO4 (1 mol%, 0.33 M in toluene) produced a residue that was filtered 
through a pad of Florisil, purified by chromatography on SiO2 (hexane:EtOAc; 1:1) and 
concentrated in vacuo. The diol intermediate was subsequently dissolved in 89 mL of THF and 
cooled to 0 oC. To this solution was added 564 mg (22.3 mmol) of NaH (95%). The mixture was 
stirred for 15 min and 3.50 g (10.7 mmol) of p-Ts2O was added in portions. The disappearance of 
starting material was monitored by TLC (hexane:EtOAc; 1:1). The reaction mixture was 
quenched with H2O and extracted with 3 x 10 mL of EtOAc. The combined organic layers were 
dried (MgSO4), concentrated in vacuo and purified by chromatography on SiO2 (hexane:EtOAc; 
8:1 with 1% NEt3) to afford 1.38 g (6.78 mmol, 61%, 3 steps) of 1-125 as a colorless oil: IR 
(ATR) 2924, 1660, 1599, 1498, 1455, 1192 cm-1; 1H NMR δ 7.11 (t, 1 H, J = 7.5 H), 7.01 (d, 1 
H, J = 8.1 Hz), 6.65 (t, 2 H, J = 8.1 Hz), 3.53, 3.41 (AB, 2 H, J = 15.9 Hz), 3.48-3.31 (m, 2 H), 
2.82 (app t, 2 H, J = 6.0 Hz), 2.76, 2.66 (AB, 2 H, J = 4.8 Hz), 1.99 (app quint, 2 H, J = 6.0 Hz), 
1.44 (s, 3 H); 13C NMR δ 145.8, 129.2, 127.1, 122.2, 116.1, 111.0, 56.6, 55.9, 51.9, 50.9, 28.3, 
22.2, 19.5;  MS (EI) m/z 203 (M+•, 44), 146 (100), 130 (20); HRMS (EI) m/z calcd for C13H17NO 
203.1310, found 203.1320. 
 
N
OAc
1-126  
(1-Methyl-2,4,5,6-tetrahydro-1H-pyrrolo[3,2,1-ij]quinolin-1-yl)methyl acetate (1-
126). According to General Protocol F, 206 mg (1.01 mmol) of 1-125, 239 mg (1.52 mmol) of 
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collidine hydrochloride, 7.5 mg (0.030 mmol) of Cp2TiCl2, and 111 mg (2.02 mmol) of Mn 
afforded a crude reaction mixture that was subjected to 12 mg (0.10 mmol) of DMAP and 290 
µL (3.04 mmol) of acetic anhydride in 10 mL of THF. The mixture was stirred for 5 h at rt until 
TLC analysis (hexane:EtOAc; 2:1) showed complete consumption of the alcohol. The reaction 
was quenched with satd. NaHCO3 and extracted with 3 x 10 mL of Et2O. The combined organic 
layers were dried (MgSO4), concentrated, and purified by chromatography on SiO2 
(hexane:EtOAc 12:1) to afford 172 mg (0.701 mmol, 69%, 2 steps) of 1-126 as an oil: IR (neat) 
2936, 2806, 1740, 1599, 1489, 1236, 1034 cm-1; 1H NMR δ 6.87 (app t, 2 H, J = 6.8 Hz), 6.63 (t, 
1 H, J = 7.5 Hz), 4.14, 4.06 (AB, 2 H, J = 10.8 Hz), 3.32 (d, 1 H, J = 8.7 Hz), 3.10-3.02 (m, 1 H), 
2.93 (d, 1 H, J = 8.7 Hz), 2.87 (ddd, 1 H, J = 10.5 Hz, J = 7.2 Hz, J = 4.8 Hz), 2.68 (app t, 2 H, J 
= 6.6 Hz), 2.12-2.03 (m, 2 H), 2.08 (s, 3 H), 1.36 (s, 3 H); 13C NMR δ 171.4, 149.5, 132.5, 
127.4, 120.7, 119.9, 118.8, 69.3, 64.7, 46.9, 44.9, 24.0, 23.1, 22.0, 21.1; MS (EI) m/z 245 (M+•, 
40), 172 (100), 170 (28), 144 (47); HRMS (EI) m/z calcd for C15H19NO2 245.1416, found 
245.1416. 
 
N ClCl
O OMe
 
Methyl 2,6-dichloroisonicotinate.95 According to a literature procedure, a flask was 
charged with 9.57 g (61.7 mmol) of citrazinic acid, 7.44 g (67.9 mmol) of Me4NCl, and 17 mL 
(188 mmol) of POCl3. The reaction mixture was heated to 130 oC for 18 h, cooled to 0 oC and 
quenched with 200 mL of freshly distilled MeOH. The solution was neutralized with powdered 
NaHCO3, diluted with 200 mL of H2O and concentrated in vacuo. The residue was extracted 
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with 2 x 150 mL of toluene, dried (MgSO4), concentrated and filtered through a plug of SiO2 
(EtOAc/hexanes; 1:9) to afford 8.01 g (38.9 mmol, 63%) of methyl 2,6-dichloroisonicotinate as a 
pink solid that was used without further purification: mp 80-81 oC (lit. 80-81 oC); 1H NMR δ 
7.82 (s, 2 H), 3.98 (s, 3 H); MS (EI) m/z 209 ([M+4]+•) (5), 207 ([M+2] +•) (35), 205 (M+•, 54), 
174 (100), 146 (53). 
 
N ClCl
O OH
1-138  
2,6-Dichloroisonicotinic acid (1-138).95 According to a literature procedure, a solution 
of 8.91 g (43.2 mmol) of methyl 2,6-dichloroisonicotinate in 20 mL of THF was treated with 
1.24 g (51.9 mmol) of LiOH in 60 mL of H2O. The reaction mixture was stirred for 20 min at rt 
and concentrated in vacuo to remove the THF. The resulting solution was cooled to 0 oC and 
treated with 25 mL of 2 M HCl solution. After 2 h, the solid was filtered and dried to afford 6.05 
g (31.5 mmol, 73%) of 1-138 as a tan solid: mp 208-210 oC (lit. 209-211 oC); 1H NMR δ 7.86 (s, 
2 H); MS (EI) m/z 195 ([M+4] +•) (28), 193 ([M+2] +•) (91), 191 (M+•, 100), 174 (61), 156 (43), 
85 (56). 
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1-139
N ClCl
N
H Cbz
 
Benzyl 2,6-dichloropyridin-4-ylcarbamate (1-139). To a solution of 1.00 g (5.20 
mmol) of 1-138 in 20 mL of THF was added 540 μL (6.35 mmol) of oxalyl chloride at rt. The 
reaction mixture was refluxed for 2 h, cooled to rt and concentrated in vacuo. The resulting oil 
was dissolved in 40 mL of freshly distilled acetone, cooled to 0 oC and treated dropwise with a 
solution of 1.01 g (15.6 mmol) of NaN3 in 20 mL of H2O. The mixture was stirred for 90 min, 
and the temperature was allowed to increase from 0 oC to 10 oC. The mixture was diluted with 15 
mL of distilled Et2O, and the aqueous layer was extracted with 2 x 10 mL of distilled Et2O. The 
combined organic layers were dried (MgSO4) and concentrated in vacuo to ~10% volume. After 
addition of 10 mL of toluene the remaining Et2O and acetone were removed under reduced 
pressure. The residue was dissolved in 15 mL of toluene, stirred with MgSO4 and treated with 
1.1 mL (10 mmol) of benzyl alcohol. The mixture was heated at reflux for 15 h behind a blast 
shield, cooled to rt, diluted with water and extracted with 2 x 10 mL of EtOAc. The combined 
organic layers were dried (MgSO4), concentrated and purified by chromatography on SiO2 
(hexane:EtOAc; 20:1 to 10:1 gradient) to afford 580 mg (1.95 mmol, 33%, 3 steps) of 1-139 as a 
brown oil: IR (ATR) 3302, 3259, 3153, 1699, 1572, 1505, 1250, 1218, 1071 cm-1; 1H NMR δ 
7.37 (bs, 5 H), 7.36 (s, 2 H), 5.21 (s, 2 H); 13C NMR δ 152.4, 151.4, 149.1, 135.1, 129.0, 128.9, 
128.7, 111.4, 68.3; MS (EI) m/z 298 ([M+2] +•) (24), 296 (M+•, 37), 278 (82), 261 (61), 91 (100); 
HRMS (EI) m/z calcd for C13H10Cl2N2O2 296.0119, found 296.0112. 
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N
Cl
Cl N
Cbz  
Benzyl 2,6-dichloropyridin-4-yl(2-methylallyl)carbamate. A solution of 547 mg (1.84 
mmol) of 1-139 in 10 mL of THF at 0 oC was treated with 34 mg (0.092 mmol) of TBAI and 93 
mg (3.7 mmol) of NaH (95%). The reaction mixture was stirred for 5 min, treated with 370 µL 
(3.68 mmol) of 3-bromo-2-methylpropene, warmed to rt and stirred for 16 h. After addition of 
160 mg of NaH and 400 μL of 3-bromo-2-methylpropene, the mixture was stirred until starting 
material was consumed according to TLC (hexane:EtOAc; 4:1). The solution was then cooled to 
0 oC, quenched with water and extracted with 3 x 10 mL of Et2O. The combined organic layers 
were dried (MgSO4), concentrated in vacuo and purified by chromatography on SiO2 
(hexane:EtOAc; 15:1 to 10:1 gradient) to afford 497 mg (1.41 mmol, 77%) of benzyl 2,6-
dichloropyridin-4-yl(2-methylallyl)carbamate as a colorless oil: IR (ATR) 3280, 1716, 1576, 
1367, 1216, 1159 cm-1; 1H NMR δ 7.38-7.36 (m, 5 H), 7.30 (s, 2 H), 5.25 (s, 2 H), 4.94 (s, 1 H), 
4.74 (s, 1 H), 4.26 (s, 2 H), 1.74 (s, 3 H); 13C NMR δ 154.0, 153.4, 151.0, 139.5, 135.4, 128.9, 
128.8, 128.4, 116.2, 111.8, 69.0, 54.4, 20.2; MS (EI) m/z 352 ([M+2] +•) (24), 350 (M+•, 38), 259 
(30), 215 (80), 91 (100); HRMS (EI) m/z calcd for C17H16Cl2N2O2 350.0588, found 350.0571. 
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N
Cl
Cl
N
Cbz
O
1-140  
Benzyl 2,6-dichloropyridin-4-yl((2-methyloxiran-2-yl)methyl)carbamate (1-140). To 
a solution of 429 mg (1.22 mmol) of benzyl 2,6-dichloropyridin-4-yl(2-methylallyl)carbamate in 
10 mL of CH2Cl2 at 0 oC was added 451 mg (1.83 mmol) of m-CPBA (70%). The reaction 
mixture was warmed to rt and after 6 h an additional 1 equiv (300 mg) of m-CPBA was added. 
The mixture was stirred for a total of 11 h, cooled to 0 oC, quenched with aq. Na2S2O3 solution 
and extracted with 3 x 10 mL of CH2Cl2. The combined organic layers were dried (MgSO4), 
concentrated in vacuo and purified by chromatography on SiO2 (hexane:EtOAc; 8:1) to afford 
371 mg (1.01 mmol, 83%) of 1-140 as a colorless oil: IR (ATR) 3089, 1714, 1576, 1535, 1216, 
1149, 1088 cm-1; 1H NMR δ 7.39 (s, 2 H), 7.39-7.37 (m, 5 H), 5.28, 5.21 (AB, 2 H, J = 12.0 Hz), 
4.11, 3.78 (AB, 2 H, J = 15.6 Hz), 2.60, 2.58 (AB, 2 H, J = 4.2 Hz), 1.32 (s, 3 H); 13C NMR δ 
154.1, 153.6, 151.0, 135.1, 129.0, 129.0, 128.7, 117.8, 69.1, 56.1, 53.3, 51.7, 19.5; MS (ESI) m/z 
389 [M+Na]+ (14), 365 (22), 361 (100); HRMS (ESI) m/z calcd for C17H16Cl2O3Na (M+Na) 
389.0436, found 389.0467. 
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N
N
Cbz
OH
Cl
Cl
 
Benzyl 4,6-dichloro-3-(hydroxymethyl)-3-methyl-2,3-dihydro-1H-pyrrolo[3,2-
c]pyridine-1-carboxylate. According to General Protocol F, 269 mg (0.733 mmol) of 1-140, 5.5 
mg (0.022 mmol) of Cp2TiCl2, 173 mg (1.10 mmol) of collidine hydrochloride, and 60 mg (1.1 
mmol) of Mn (reaction time 3 h) afforded an oil that was purified by chromatography on SiO2 
(toluene:acetone; 8:1) to afford 147 mg (0.400 mmol, 55%) of benzyl 4,6-dichloro-3-
(hydroxymethyl)-3-methyl-2,3-dihydro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate as a waxy 
solid: IR (ATR) 3397, 2965, 2877, 1718, 1582, 1449, 1380, 1312 cm-1; 1H NMR δ 7.42-7.37 (m, 
6 H), 5.30-5.20 (m, 2 H), 4.31, 3.74 (AB, 2 H, J = 11.1 Hz), 4.14, 3.58 (AB, 2H, J = 11.1 Hz), 
2.62 (bs, 1 H), 1.41 (s, 3 H); 13C NMR δ 154.8, 152.4, 150.7, 145.0, 135.3, 128.9, 128.9, 128.6, 
127.3, 109.4, 68.5, 66.1, 59.1, 46.3 21.4; MS (EI) m/z 368 ([M+2] +•, 9), 366 (M+•, 15), 201 (10), 
91 (100); HRMS (EI) m/z calcd for C17H16Cl2N2O3 366.0538, found 366.0527. 
 
N
N
H
OH
1-141  
(3-Methyl-2,3-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)methanol (1-141). To a solution 
of 78 mg (0.21 mmol) of benzyl 4,6-dichloro-3-(hydroxymethyl)-3-methyl-2,3-dihydro-1H-
pyrrolo[3,2-c]pyridine-1-carboxylate in 2 mL of MeOH at rt was added 22 mg (0.021 mmol) of 
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Pd/C. The reaction mixture was saturated with 1 atm of H2, stirred for 21 h, quenched with 
Celite®, filtered, concentrated in vacuo and purified on neutral Al2O3 (hexane:EtOAc; 1:1 to 
100% EtOH) to afford a white solid. This solid was washed once each (5 mL) with boiling 
acetone and boiling ethyl acetate. The organic extracts were combined and concentrated in vacuo 
to afford 33 mg (0.20 mmol, 95%) of 1-141 as a colorless oil: IR (ATR) 3248, 3160, 2925, 2866, 
1649, 1608, 1522, 1030 cm-1; 1H NMR (CD3OD) δ 7.94 (d, 1 H, J = 6.3 Hz), 7.90 (s, 1 H) 6.61 
(d, 1 H, J = 6.3 Hz), 3.77, 3.47 (AB, 2 H, J = 10.5 Hz), 3.60, 3.53 (AB, 2 H, J = 10.8 Hz), 1.37 
(s, 3 H); 13C NMR δ 162.2, 144.3, 137.1, 133.1, 103.9, 69.1, 58.1, 47.0, 23.6; MS (ESI) m/z 165 
([M+H]+, 100); HRMS (ESI) m/z calcd for C9H13N2O (M+H) 165.1028, found 165.1038. 
 
OTBS
NH2
 
3-(tert-Butyldimethylsilyloxy)aniline. To a solution of 5.78 g (53.0 mmol) of 3-
aminophenol (1-142) in 200 mL of THF was added 5.77 g (84.8 mmol) of imidazole, followed 
by 10.38 g (68.86 mmol) of TBSCl. The reaction mixture was stirred at rt overnight, quenched 
with 50 mL of satd. NH4Cl, extracted with 3 x 50 mL of Et2O, washed with brine, dried 
(MgSO4), concentrated and purified by chromatography on SiO2 (hexane:EtOAc; 15:1 to 5:1 
gradient) to afford 11.06 g (49.50 mmol, 93%) of 3-(tert-butyldimethylsilyloxy)aniline as a tan 
oil: 1H NMR (600 MHz) δ 6.99 (t, 1 H, J = 8.4 Hz), 6.30 (dd, 1 H, J = 7.8 Hz, J = 1.8 Hz), 6.25 
(dd, 1 H, J = 7.8 Hz, J = 1.8 Hz), 6.20 (app t, 1 H, J = 1.8 Hz), 3.62 (br s, 2 H), 0.97 (s, 9 H), 
0.19 (s, 6 H); 13C NMR (150 MHz) δ 156.9, 147.8, 130.1, 110.7, 108.7, 107.4, 25.9, 18.4, -4.2.  
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OTBS
N
H CO2Et
1-143  
Ethyl 3-(tert-butyldimethylsilyloxy)phenylcarbamate (1-143). To a solution of 6.51 g 
(29.1 mmol) of 3-(tert-butyldimethylsilyloxy)aniline in 150 mL of CH2Cl2 cooled to 0 oC was 
added 3.9 mL of pyridine, followed by 2.9 mL (31 mmol) of ethylchloroformate dropwise over 1 
h. The reaction was allowed to warm to rt, stirred for 1 h, and then quenched with 60 mL of satd. 
NH4Cl. The mixture was diluted with 60 mL of H2O, extracted with 2 x 20 mL of CH2Cl2, dried 
(MgSO4), concentrated, and purified by chromatography on SiO2 (hexane:EtOAc; 10:1) to afford 
8.34 g (28.2 mmol, 97%) of 1-143 as a golden oil: IR (ATR) 3321, 2957, 2930, 2859, 1704, 
1596, 1540, 1220, 1063 cm-1; 1H NMR (600 MHz) δ 7.12 (t, 1 H, J = 7.8 Hz), 7.04 (br s, 1 H), 
6.88 (br d, 1 H, J = 7.8 Hz), 6.68 (br s, 1 H), 6.54 (dd, 1 H, J = 8.1 Hz, J = 2.4 Hz), 4.21 (q, 2 H, 
J = 6.6 Hz), 1.29 (t, 3 H, J = 7.2 Hz), 0.97 (s, 9 H), 0.20 (s, 6 H); 13C NMR (150 MHz) δ 156.5, 
153.7, 139.3, 129.8, 115.2, 111.7, 110.8, 61.3, 25.9, 18.4, 14.7, -4.3; MS (ESI) m/z 318 
([M+Na]+). 
 
TBSO N
CO2Et  
Ethyl 3-(tert-butyldimethylsilyloxy)phenyl(2-methylallyl)carbamate. To a solution of 
6.09 g (20.6 mmol) of 1-143 in 100 mL of distilled THF cooled to 0 oC was added 380 mg (1.03 
mmol) of TBAI, followed by 937 mg (37.1 mmol) of NaH 95% (added piecewise). The reaction 
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mixture was stirred at 0 oC for 20 min when 3.1 mL (31 mmol) of methallyl bromide was added. 
Upon addition of the methallyl bromide, the flask was removed from the ice bath and the mixture 
was stirred for a total of 3 h when TLC (hexane:EtOAc; 4:1) analysis showed the starting 
material was consumed. The mixture was then cooled to 0 oC, quenched with 10 mL of H2O, 
extracted with 3 x 10 mL of Et2O, washed with 10 mL of brine, dried (Na2SO4), concentrated in 
vacuo and purified by chromatography on SiO2 (hexane:EtOAc; 12:1) to afford 4.96 g (14.2 
mmol, 69%) of ethyl 3-(tert-butyldimethylsilyloxy)phenyl(2-methylallyl)carbamate as a tan oil: 
IR (ATR) 2931, 1703, 1597, 1488, 1252, 1193 cm-1; 1H NMR (600 MHz, DMSO-d6) δ 7.20 (t, 1 
H, J = 7.8 Hz), 6.88 (dd, 1 H, J = 7.8 Hz, J = 1.2 Hz), 6.74 (s, 1 H), 6.68 (dd, 1 H, J = 7.8 Hz, J = 
1.8 Hz), 4.79 (s, 1 H), 4.70 (s, 1 H), 4.18 (s, 2 H), 4.07 (q, 2 H, J = 7.2 Hz), 1.66 (s, 3 H), 1.14 (t, 
3 H, J = 6.6 Hz), 0.93 (s, 9 H), 0.17 (s, 6 H); 13C NMR (150 MHz, DMSO-d6) δ 155.0, 154.6, 
142.8, 141.2, 129.3, 119.0, 118.0, 117.4, 111.6, 61.2, 55.0, 25.5, 19.8, 18.0, 14.4, -4.6; MS (ESI) 
m/z 372 ([M+Na]+). 
 
TBSO N
CO2Et
O
1-144  
Ethyl 3-(tert-butyldimethylsilyloxy)phenyl((2-methyloxiran-2-yl)methyl)carbamate 
(1-144). To a solution of 388 mg (1.11 mmol) of ethyl 3-(tert-butyldimethylsilyloxy)phenyl(2-
methylallyl)carbamate in 5 mL of CH2Cl2 cooled to 0 oC was added 235 mg (2.22 mmol) of 
Na2CO3 in 2 mL of water followed by 410 mg (1.67 mmol) of m-CPBA (70% purity). The 
mixture was allowed to warm from 0 oC to rt over 2 h. At this time, an additional 273 mg of m-
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CPBA was added. After 30 min, the reaction was determined to be complete by TLC analysis 
(hexane:EtOAc; 2:1). The mixture was quenched with 15 mL of Na2S2O3 solution, extracted 
with 3 x 10 mL of CHCl3, dried (MgSO4), concentrated in vacuo, and purified by 
chromatography on SiO2 (hexane:EtOAc; 10:1 to 6:1 gradient) to afford 236 mg (0.646 mmol, 
58%) of 1-144 as a light yellow oil: IR (ATR) 2931, 2859, 1703, 1597, 1488, 1260, 954 cm-1; 1H 
NMR (600 MHz) δ 7.19 (t, 1 H, J = 7.8 Hz), 6.84 (d, 1 H, J = 7.8 Hz), 6.74-6.72 (m, 2 H), 4.16 
(q, 2 H, J = 7.2 Hz), 3.99, 3.61 (AB, 2 H, J = 14.4 Hz), 2.54, 2.52 (AB, 2 H, J = 4.8 Hz), 1.38 (s, 
3 H), 1.21 (bs, 3 H), 0.98 (s, 9 H), 0.20 (s, 6 H); 13C NMR (150 MHz) δ 156.2, 156.0, 143.5, 
129.6, 120.0, 119.5, 118.8, 62.1, 55.9, 55.6, 53.0, 25.9, 19.6, 18.4, 14.8, -4.2; MS (EI) m/z 365 
(M+•, 77), 280 (55), 238 (67), 220 (100), 192 (97), 178 (65); HRMS (EI) m/z calcd for 
C19H31NO4Si 365.2022, found 365.2033. 
 
TBSO N
CH3
OH
1-147  
(6-(tert-Butyldimethylsilyloxy)-1,3-dimethylindolin-3-yl)methanol (1-147). A mixture 
of 178 mg (0.486 mmol) of 1-144, 115 mg (0.730 mmol) of coll-HCl, 40 mg (0.73 mmol) of Mn, 
and 3.6 mg (0.015 mmol) of Cp2TiCl2 was purged with argon 3 times, dissolved in 5.0 mL of 
distilled, degassed THF, and heated at reflux. After 4 h, the solution was allowed to cool to room 
temperature and was quenched with 10 mL of satd. NH4Cl, extracted with 3 x 10 mL of EtOAc; 
washed with 10 mL of brine, dried (Na2SO4), concentrated, and purified on neutral alumina 
(hexane:EtOAc; 10:1 to 1:1 gradient) to afford 53 mg (0.14 mmol, 30%) of 1-145. To a solution 
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of 53 mg (0.14 mmol) of 1-145 in 3 mL of dry THF cooled to 0 oC was added 28 mg (0.72 
mmol) of LiAlH4. Upon addition, the mixture was stirred until no gas evolution was observed 
and then heated at reflux. TLC analysis (hexane:EtOAc; 1:1) after 50 min showed that the 
starting material was consumed. The solution was cooled to 0 oC, quenched with MeOH, diluted 
with 5 mL of H2O, saturated with potassium sodium tartrate, and diluted with 5 mL of EtOAc. 
The solution was stirred until biphasic when it was partitioned and extracted with 3 x 5 mL of 
EtOAc. The combined organic extracts were washed with 5 mL of brine, dried (Na2SO4), 
concentrated, and purified by chromatography on SiO2 (hexane:EtOAc; 2:1) to afford 38 mg 
(0.12 mmol, 85%) of 1-147 as a colorless oil: IR (ATR) 3373, 2956, 1612, 1497, 1253, 985 cm-1; 
1H NMR (600 MHz) δ 6.81 (d, 1 H, J = 7.8 Hz), 6.15 (dd, 1 H, J = 7.8 Hz, J = 1.8 Hz), 5.98 (d, 1 
H, J = 1.8 Hz), 3.56, 3.51 (AB, 2 H, J = 10.8 Hz), 3.40, 2.98 (AB, 2 H, J = 9.0 Hz), 2.70 (s, 3 H), 
1.65 (br s, 1 H), 1.28 (s, 3 H), 0.98 (s, 9 H), 0.19 (s, 6 H); 13C NMR (150 MHz) δ 156.8, 154.6, 
127.1, 122.8, 108.8, 100.4, 69.4, 66.0, 45.7, 35.9, 25.9, 22.3, 18.4, -4.2; MS (EI) m/z 307 (M+•, 
40), 276 (100), 204 (20), 73 (24); HRMS (EI) m/z calcd for C17H29NO2Si 307.1968, found 
307.1960. 
 
N
CH3
OH
OH
1-148  
3-(Hydroxymethyl)-1,3-dimethylindolin-4-ol (1-148). A mixture of 178 mg (0.486 
mmol) of 1-144, 115 mg (0.730 mmol) of coll-HCl, 40 mg (0.73 mmol) of Mn, and 3.6 mg 
(0.015 mmol) of Cp2TiCl2 was purged with argon 3 times, dissolved in 5.0 mL of distilled, 
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degassed THF and heated at reflux. After 4 h, the reaction mixture was allowed to cool to room 
temperature and quenched with 10 mL of satd. NH4Cl, extracted with 3 x 10 mL of EtOAc, 
washed with 10 mL of brine, dried (Na2SO4), concentrated, and purified by chromatography on 
neutral alumina (hexane:EtOAc; 10:1 to 1:1 gradient) to afford 59 mg (0.16 mmol, 33%) of 1-
146. To a solution of 59 mg (0.16 mmol) of 1-146 in 3 mL of dry THF cooled to 0 oC was added 
31 mg (0.81 mmol) of LiAlH4. Upon addition and after visible gas evolution had ceased, the 
mixture was heated at reflux. TLC analysis (hexane:EtOAc; 1:1) after 50 min showed that 
starting material was consumed. The mixture was cooled to 0 oC and then quenched dropwise 
with MeOH until no further gas evolution was observed. To this solution was added 2 mL of a 
satd. potassium sodium tartrate followed by 5 mL of EtOAc. The mixture was extracted with 3 x 
5 mL of EtOAc, dried (Na2SO4), concentrated in vacuo and purified by chromatography on SiO2 
(hexane:EtOAc; 2:1) to afford 24 mg (0.12 mmol, 77%, (25% over 2 steps) of 1-148 as a tan 
waxy solid: IR (ATR) 3206, 2959, 1617, 1595, 1477, 1246, 903 cm-1; 1H NMR (600 MHz) δ 
8.37 (bs, 1 H), 7.01 (t, 1 H, J = 7.8 Hz), 6.28 (d, 1 H, J = 8.4 Hz), 6.07 (d, 1 H, J = 7.8 Hz), 3.90, 
3.75 (AB, 2 H, J = 9.6 Hz), 3.09, 2.88 (AB, 2 H, J = 8.4 Hz), 2.85 (bs, 1 H), 2.73 (s, 3 H), 1.42 
(s, 3 H); 13C NMR (150 MHz) δ 154.1, 153.4, 129.9, 119.2, 107.5, 100.1, 70.1, 65.5, 46.3, 36.0, 
21.5; MS (EI) m/z 193 (M+•, 26), 162 (100), 147 (29); HRMS (EI) m/z calcd for C11H15NO2 
193.1103, found 193.1100. 
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N
Cbz
1-154  
Benzyl 2-methylcyclohex-2-enyl(phenyl)carbamate (1-154). To a solution of 224 mg 
(2.00 mmol) of 1-153 in 5 mL of CH2Cl2 cooled to 0 oC was added 840 μL (6.03 mmol) of NEt3 
followed by 310 μL (4.01 mmol) of MsCl. Upon addition, the mixture was allowed to warm 
slowly to 25 oC overnight. The solution was quenched with 10 mL of H2O, extracted with 3 x 5 
mL of CH2Cl2, dried (Na2SO4), concentrated, and used without further purification. To a solution 
of 396 mg (2.40 mmol) of benzyl phenylcarbamate in 10 mL of dry DMF cooled to 0 oC was 
added 120 mg (3.00 mmol) of NaH (60%). The reaction mixture was stirred for 15 min at 0 oC 
and then the crude mesylate intermediate was added in 1 mL of dry DMF. The resulting yellow 
mixture was allowed to warm to 25 oC overnight, quenched with 10 mL of H2O, extracted with 3 
x 10 mL of EtOAc; washed with 10 mL of water and 10 mL of brine, dried (Na2SO4), and 
concentrated. The residue was purified by chromatography on SiO2 (hexane:Et2O; 10:1) to afford 
361 mg (1.12 mmol, 56%, 2 steps) of 1-154 as a light yellow oil: IR (ATR) 3032, 1697, 1597, 
1495, 1453, 1396, 1293, 1120, 1017 cm-1; 1H NMR (300 MHz, 350 K, DMSO-d6) δ 7.39-7.22 
(m, 8 H), 7.17-7.14 (m, 2 H), 5.57 (bs, 1 H), 5.11, 5.06 (AB, 2 H, J = 12.9 Hz), 4.68 (app t, 1 H, 
J = 7.2 Hz), 1.91-1.64 (m, 4 H), 1.76 (s, 3 H), 1.47-1.24 (m, 2 H); 13C NMR (75 MHz, 350K, 
DMSO-d6) δ 154.4, 140.1, 136.4, 133.0, 128.1, 127.7, 127.7, 127.1, 126.7, 126.3, 125.6, 65.9, 
57.2, 27.4, 24.0, 19.9, 19.8; MS (ESI) m/z 322 ([M+H]+). 
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N
Cbz
H3C
O
H
1-157  
(4aS,9aS)-Benzyl 4a-methyl-4-oxo-2,3,4,4a-tetrahydro-1H-carbazole-9(9aH)- 
carboxylate (1-157). To a solution of 952 mg (2.96 mmol) of 1-154 in 12 mL of CH2Cl2 and 691 
mg (6.52 mmol) of Na2CO3 (dissolved in 12 mL of water) at 0 oC was added 1.46 g (5.92 mmol) 
of m-CPBA (70%). Upon addition of the oxidant, the mixture was allowed to warm slowly to 25 
oC. After 2 h, the reaction was quenched with 10 mL of a 1 M Na2S2O3 solution, diluted with 5 
mL of H2O, extracted with 3 x 10 mL of CH2Cl2, washed with 10 mL of brine, dried (MgSO4), 
concentrated, and purified by chromatography on SiO2 (hexane:EtOAc; 10:1 with 1% NEt3 to 
hexane:EtOAc; 5:1 gradient) to afford 841 mg (2.49 mmol, 84%) of 1-155 as a colorless oil. 
A mixture of 841 mg (2.49 mmol) of 1-155, 18.9 mg (0.0759 mmol) of Cp2TiCl2, 589 mg 
(3.73 mmol) of Coll-HCl and 274 mg (4.99 mmol) of Mn was then purged 3 times with Ar, 
diluted with 24 mL of THF and placed in a pre-heated oil bath. After heating at reflux under Ar 
overnight, the solution was cooled to 25 oC, quenched with 10 mL of satd. NH4Cl, extracted with 
3 x 10 mL of EtOAc; washed with 10 mL of brine, dried (Na2SO4), concentrated, and purified by 
chromatography on SiO2 (hexane:EtOAc; 5:1 with 1% NEt3 to hexane:EtOAc; 1:1) to afford 97 
mg (0.29 mmol, 12%) of 1-156 as a light brown oil that was taken on to the Dess-Martin 
oxidation. To a solution of 97 mg (0.29 mmol) of the alcohol intermediate in 5 mL of CH2Cl2 
was added 366 mg (0.862 mmol) of Dess-Martin periodinane reagent. This mixture was stirred 
under N2 at 25 oC overnight and after 13 h reaction time, TLC analysis (hexane:EtOAc; 4:1) 
showed that the starting material had been consumed. The mixture was poured over 10 mL of 
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satd. NaHCO3, partitioned, and extracted with 3 x 5 mL of CH2Cl2. The combined organic layers 
were dried (Na2SO4), concentrated, and purified by chromatography on SiO2 (hexane:EtOAc; 
6:1) to afford 61 mg (0.18 mmol, 63%, 6% over 3 steps) of 1-157 as a colorless oil: IR (ATR) 
2957, 1700, 1597, 1479, 1401, 1287, 1084 cm-1; 1H NMR (300 MHz, 365 K, DMSO-d6) δ 7.71 
(d, 1 H, J = 8.1 Hz), 7.48-7.33 (m, 5 H), 7.28-7.19 (m, 1 H), 7.04-6.96 (m, 2 H), 5.36-5.29 (m, 2 
H), 4.47-4.43 (m, 1 H), 2.44-2.20 (m, 2 H), 2.13-2.00 (m, 1 H), 1.80-1.64 (m, 3 H), 1.33 (s, 3 H); 
13C NMR (75 MHz, 365 K, DMSO-d6) δ 207.8, 151.5, 140.4, 135.8, 133.5, 127.9, 127.8, 127.3, 
127.1, 122.6, 122.5, 114.4, 68.0, 66.3, 55.1, 37.1, 27.2, 24.5, 17.3; HRMS (TOF MS ES+) m/z 
calcd for C21H21NO3 358.1419, found 358.1443. 
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4.3 CHAPTER 2 EXPERIMENTAL6 
 
2-59
N
N
N
O Bn
O
 
4-Benzyl-3,4-dihydro-2H-[1,2,4]triazino[2,3-b]isoquinoline-6,11-dione, (2-59).7 To a 
solution of 230 mg (0.685 mmol) of 2-61 in PhCl (4 mL) was added 206 mg (0.483 mmol) of 
DPPB. Upon addition, the flask was placed in a pre-heated oil bath at 110 oC, and the mixture 
was stirred under a N2 atmosphere overnight, cooled to 25 oC and extracted with 4 x 5 mL of 
10% HCl. The combined acidic aqueous phases were washed once with 10 mL of CH2Cl2 and 
then basicified with 10% NaOH solution until the pH reached ~12. The alkaline solution was 
extracted with 4 x 10 mL of Et2O, dried (Na2SO4), and concentrated in vacuo to afford a 
green/brown residue. The light yellow aqueous was extracted with 2 x 20 mL of CH2Cl2 and the 
combined Et2O and CH2Cl2 extracts were concentrated in vacuo and purified by chromatography 
on SiO2  (CH2Cl2:EtOH; 15:1) to afford 43 mg of a light brown residue. This residue was stored 
at room temperature for 10 d when a purity check revealed a new compound by 1H NMR 
analysis. This material was purified by chromatography on SiO2 (CH2Cl2:EtOH, 30:1 to 15:1) to 
afford 25 mg (0.082 mmol, 12%) of 2-59 as a yellow/brown solid: 1H NMR δ 8.38 (d, 1 H, J = 
                                                 
6 All NMR data were recorded on a 600 MHz Bruker instrument in CDCl3 unless 
otherwise noted. 
7 The results from this reaction are not reproducible. The product obtained has been 
tentatively assigned as 2-59. 
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7.8 Hz), 8.28 (d, 1 H, J = 7.8 Hz), 7.88 (t, 1 H, J = 7.2 Hz), 7.80 (t, 1 H, J = 7.2 Hz), 7.55 (d, 2 
H, J = 7.2 Hz), 7.38 (t, 2 H, J = 7.2 Hz), 7.34 (t, 1 H, J = 7.2 Hz), 4.08 (br s, 2 H), 3.98 (t, 2 H, J 
= 4.8 Hz), 3.13-3.12 (m, 2 H); 13C NMR δ 176.2 157.6, 144.6, 135.8, 135.4, 133.9, 131.6, 130.2, 
129.9, 129.6, 128.9, 128.5, 127.8, 58.9, 43.4, 40.8; MS (ESI) m/z 306 ([M+H]+). 
 
N
O
O
N
Bn
N3
2-61  
2-((2-Azidoethyl)(benzyl)amino)isoquinoline-1,3(2H,4H)-dione (2-61). To a flame-
dried 100 mL flask was added 3.20 g (7.60 mmol) of 2-75, 72 mg (0.37 mmol) of CuI, 94 mg 
(0.76 mmol) of 2-picolinic acid and 7.42 g (22.8 mmol) of Cs2CO3. The mixture was purged 3 
times with N2, diluted with 36 mL of anhydrous dioxane and heated with 2.3 mL (15 mmol) of 
diethyl malonate. The lime green solution was heated at 70 oC under a N2 atmosphere. TLC 
analysis (hexane:EtOAc; 6:1) after 3 h showed that the starting material was consumed. The 
reaction mixture was cooled to 25 oC, quenched with 20 mL of saturated NH4Cl solution, diluted 
with 20 mL of H2O, and filtered through a coarse fritted filter. The collected solid was rinsed 
with EtOAc and the combined phases were partitioned. The aqueous phase was then extracted 
with 3 x 10 mL of EtOAc, and the combined organic phases were concentrated in vacuo. The 
residue was dissolved in 50 mL of toluene with 5 mL of H2O when 433 mg (2.28 mmol) of p-
TSA was added and the mixture was heated at reflux overnight. TLC analysis (hexane:EtOAc; 
4:1) showed the streaky intermediate was converted to one UV active spot (stain with KMnO4). 
The reaction mixture was cooled to 25 oC, quenched with 20 mL of satd. NaHCO3, partitioned, 
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and then the aqueous phase was extracted with 3 x 15 mL of EtOAc. The combined organic 
phases were washed with 12 mL of brine, dried (MgSO4), concentrated in vacuo, and purified by 
chromatography on SiO2 (hexane:EtOAc; 10:1 to 5:1 gradient) to afford 1.87 g (5.57 mmol, 
73%, 2 steps) of 2-61 as a light yellow/green oil: IR (ATR) 3063, 2924, 2098, 1730, 1683, 1605, 
1462, 1345, 1228 cm-1; 1H NMR δ 8.17 (d, 1 H, J = 11.7 Hz), 7.55 (dd, 1 H, J = 7.2 Hz, J = 1.2 
Hz), 7.47 (d, 2 H, J = 7.2 Hz), 7.42 (t, 1 H, J = 7.8 Hz), 7.28-7.26 (m, 2 H), 7.22-7.19 (m, 2 H), 
4.45, 4.39 (AB, 2 H, J = 12.6 Hz), 4.00, 3.83 (AB, 2 H, J = 22.2 Hz), 3.50-3.38 (m, 4 H); 13C 
NMR δ 169.9, 165.2, 137.0, 133.9, 133.8, 129.5, 129.4, 128.5, 127.9, 127.9, 127.2, 125.9, 60.2, 
53.0, 50.4, 37.9; MS (ESI) m/z 336 ([M+H]+). 
 
2-63
H2N N
N3
Bn
 
1-(2-Azidoethyl)-1-benzylhydrazine (2-63). To a solution of 87 mg (0.30 mmol) of 2-72 
in 2.5 mL of THF and 500 µL of H2O at 25 oC was added 96 mg (0.90 mmol) of hydrazine 
dihydrochloride. This mixture was stirred at 25 oC for 3 h, quenched with solid Na2CO3, and 
concentrated in vacuo. The resulting oil was immediately purified by chromatography on SiO2 
(hexane:EtOAc; 1:1 with 1% NEt3) to afford 36 mg (0.19 mmol, 63%) of 2-63 as an unstable, 
colorless oil: IR (ATR) 3345, 2937, 2815, 2099, 1717, 1600, 1495, 1453, 1352, 1279 cm-1; 1H 
NMR δ 7.36-7.33 (m, 4 H), 7.31-7.27 (m, 1 H), 3.74 (s, 2 H), 3.48 (t, 2 H, J = 5.4 Hz), 2.75 (t, 2 
H, J = 6.0 Hz), 2.74 (br s, 2 H); 13C NMR δ 137.3, 129.2, 128.7, 127.7, 67.7, 58.8, 48.8; MS 
(ESI) m/z 192, ([M+H]+). 
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N
H
Ph
N3
2-65  
2-Azido-N-benzylethanamine (2-65). To a solution of 100 µL (0.704 mmol) of N-
benzylethanolamine, 115 µL (0.774 mmol) of DBU, 457 mg (7.04 mmol) of NaN3 in 5 mL of 
CH3CN cooled to 0 oC was added 182 µL (0.845 mmol) of DPPA. Upon addition, the reaction 
mixture was heated at reflux for 7 h, cooled to rt and quenched with 10 mL of water. The 
reaction was then diluted with 5 mL of EtOAc and partitioned. The aqueous phase was extracted 
with 3 x 10 mL of EtOAc. The combined organic layers were washed with water, dried 
(Na2SO4), concentrated under reduced pressure and filtered through a plug of neutral alumina 
using hexane:EtOAc; 4:1 as mobile phase to afford 58 mg (0.41 mmol, 59%) of 2-65 as a light 
golden oil: 1H NMR δ 7.35-7.20 (m, 5 H), 3.81 (s, 2 H), 3.41 (t, 2 H, J = 5.4 Hz), 2.80 (t, 2 H, J 
= 6.0 Hz), 1.56 (br s, 1 H). 
 
NEtO2C
H
N
OH
2-70  
(E)-Ethyl 2-(2-(2-hydroxyethyl)hydrazono)propanoate (2-70). To a solution of 3.6 mL 
(32 mmol) of ethyl pyruvate in 75 mL of THF was added 1 mL of EtOH containing 3.0 mL (45 
mmol) of 2-hydroxyethylhydrazine. This mixture was heated at reflux for 5 h, concentrated in 
vacuo to a thick oil, diluted with 10 mL of water and 10 mL of EtOAc and partitioned. The 
aqueous phase was extracted with 3 x 10 mL of EtOAc, washed with brine, dried (Na2SO4), 
concentrated in vacuo and purified by chromatography on SiO2 (100% EtOAc) to afford 3.32 g 
(19.1 mmol, 59%) of 2-70 as a pale oil: IR (ATR) 3308, 2938, 1697, 1561, 1442, 1369, 1313, 
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1144, 1054 cm-1; 1H NMR δ 6.08 (s, 1 H), 4.27 (q, 2 H, J = 7.2 Hz), 3.85 (t, 2 H, J = 4.8 Hz), 
3.59-3.56 (m, 2 H), 2.98 (s, 1 H), 1.95 (s, 3 H), 1.32 (t, 3 H, J = 7.2 Hz); 13C NMR δ 165.2, 
132.8, 62.5, 61.3, 52.4, 14.5, 10.3; MS (EI) m/z 174 (M+•, 9), 128 (30), 117 (69), 73 (88), 61 
(100); HRMS (EI) m/z calcd for C7H14N2O3 174.1004, found 174.1009. 
 
2-71
NEtO2C
H
N
N3
 
(E)-Ethyl 2-(2-(2-azidoethyl)hydrazono)propanoate (2-71). To a solution of 1.96 g 
(11.3 mmol) of 2-70 and 2.4 mL (17 mmol) of NEt3 in 50 mL of THF was added 1.1 mL (15 
mmol) of MsCl. This was stirred at 25 oC for 15 min, quenched with 20 mL of satd. NaHCO3, 
diluted with 20 mL of water and extracted with 3 x 15 mL of Et2O. The combined organic layers 
were dried (Na2SO4) and concentrated in vacuo to afford a yellow oil that was used without 
further purification. To the crude oil was added 70 mL of DMF followed by 2.19 g (33.8 mmol) 
of NaN3. This mixture was heated to 50 oC behind a blast shield for 16 h when TLC analysis 
(hexane:EtOAc; 1:1) showed that the mesylate intermediate was completely consumed. The 
reaction was cooled to 25 oC, diluted with 50 mL of water and 30 mL of brine and extracted with 
4 x 50 mL of EtOAc. The combined organic phases were washed with 50 mL of water, 50 mL of 
brine, dried (Na2SO4), concentrated in vacuo and purified by chromatography on SiO2 (100% 
hexane to hexane:EtOAc; 2:1 gradient with 1% NEt3) to afford 1.57 g (7.88 mmol, 70%, 2 steps) 
of 2-71 as a yellow oil: IR (ATR) 3310, 2982, 2099, 1699, 1569, 1445, 1369, 1307, 1149 cm-1; 
1H NMR δ 5.84 (s, 1 H), 4.29 (q, 2 H, J = 7.2 Hz), 3.63-3.60 (m, 2 H), 3.55-3.53 (m, 2 H), 1.96 
(s, 3 H), 1.33 (t, 3 H, J = 7.2 Hz); 13C NMR δ 165.1, 134.0, 61.4, 51.5, 49.9, 14.6, 10.5; MS (EI) 
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m/z 184 ([M-CH3]+, 46), 174 (42), 130 (53), 117 (100), 56 (75); HRMS (EI) m/z calcd for 
C6H10N5O2 184.0833 ([M-CH3]), found 184.0835 ([M-CH3]). 
 
2-72
NEtO2C N
N3
Bn
 
(E)-Ethyl 2-(2-(2-azidoethyl)-2-benzylhydrazono)propanoate (2-72). To a solution of 
491 mg (2.46 mmol) of 2-71 in 10 mL of DMF was added 681 mg (4.92 mmol) of K2CO3, 369 
mg (2.46 mmol) of NaI, and 1.8 mL (15 mmol) of benzyl bromide. The mixture was heated at 70 
oC behind a blast shield for 17 h, cooled to 25 oC, quenched with 10 mL of water and extracted 
with 3 x 15 of EtOAc. The combined organic layers were washed with 20 mL of water, 20 mL of 
brine, dried (Na2SO4), concentrated in vacuo and purified by chromatography on SiO2 (100% 
hexane to hexane:EtOAc; 1:1 gradient with 1% NEt3) to afford 510 mg (1.76 mmol, 72%) of 2-
72 as a golden oil: IR (ATR) 2982, 2100, 1710, 1585, 1496, 1453, 1364, 1301, 1150, 1129, 1027 
cm-1; 1H NMR δ 7.38-7.35 (m, 4 H), 7.32-7.29 (m, 1 H), 4.33 (q, 2 H, J = 7.2 Hz), 4.07 (s, 2 H), 
3.34 (t, 2 H, J = 5.4 Hz), 3.23 (t, 2 H, J = 5.4 Hz), 2.22 (s, 3 H), 1.36 (t, 3 H, J = 7.2 Hz); 13C 
NMR δ 165.1, 153.2, 136.8, 128.9, 128.4, 127.9, 62.0, 61.1, 56.2, 49.9, 16.2, 14.5; MS (EI) m/z 
289 (M+•, 27), 234 (62), 188 (54), 91 (71), 65 (100); HRMS (EI) m/z calcd for C14H19N5O2 
289.1542, found 289.1539. 
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2-75
I
O
N
N
Bn
H
N3
 
N'-(2-Azidoethyl)-N'-benzyl-2-iodobenzohydrazide (2-75). To a solution of 4.33 g 
(16.3 mmol) of 2-iodobenzoyl chloride in 20 mL of CH2Cl2 cooled to 0 oC was added a solution  
of 3.27 g (17.1 mmol) of 2-63 in 5 mL of CH2Cl2 via syringe, followed by 3.0 mL (22 mmol) of 
NEt3. After addition, the vessel was removed from the ice bath and the solution was allowed to 
warm to 25 oC overnight. After 12 h, the reaction was quenched with 15 mL of satd. NaHCO3, 
partitioned, and extracted with 3 x 10 mL of CH2Cl2.  The combined organic phases were dried 
(Na2SO4), concentrated in vacuo, and recrystallized using hexane:EtOAc to afford 4.74 g (11.3 
mmol, 69%) of 2-75 as tiny cream colored needles: mp 100-101 oC; IR (ATR) 3232, 2871, 2104, 
1658, 1580, 1513, 1461, 1278 cm-1; 1H NMR δ 7.82 (dd, 2 H, J = 7.9 Hz, J = 0.8 Hz), 7.45 (app 
d, 2 H, J = 7.2 Hz), 7.37 (app t, 2 H, J = 7.2 Hz), 7.33-7.27 (m, 2 H), 7.07, (td, 1 H, J = 7.8 Hz), 
6.93 (dd, 1 H, J = 7.5 Hz, J = 1.2 Hz), 6.74 (s, 1 H), 4.35 (s, 2 H), 3.56 (t, 2 H, J = 6.0 Hz), 3.43 
(t, 2 H, J = 6.0 Hz); 13C NMR δ 169.2, 140.5 140.1, 136.9, 131.6, 129.6, 128.8, 128.3, 128.3, 
128.0, 92.8, 60.5, 54.8, 49.2; MS (ESI) m/z 422 ([M+H]+). 
 
N
O
O
N
Bn
N3
O
2-90  
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2-((2-Azidoethyl)(benzyl)amino)isoquinoline-1,3,4(2H)-trione, (2-90). To a solution of 
251 mg (0.748 mmol) of 2-61 in 6 mL of 1:1;THF:H2O was added 2.46 g (4.49 mmol) of CAN. 
The mixture was stirred at 25 oC, diluted with 10 mL of H2O after 3.5 h, and extracted with 3 x 
10 mL of EtOAc. The combined organic phases were washed with 10 mL of H2O, dried 
(MgSO4), concentrated, and purified by chromatography on SiO2 (hexane:EtOAc; 5:1 to 3:1 
gradient) to afford 70 mg (0.20 mmol, 27%) of 2-90 as a light yellow oil: IR (ATR) 3065, 2925, 
2100, 1693, 1596, 1336, 1283, 1165 cm-1; 1H NMR δ 8.34 (dd, 1 H, J = 8.1 Hz, J = 1.2 Hz), 8.16 
(dd, 1 H, J = 7.8 Hz, J = 1.2 Hz), 7.90 (dt, 1 H, J = 7.5 Hz, J = 1.8 Hz), 7.81 (dt, 1 H, J = 7.2 Hz, 
J = 1.2 Hz), 7.45 (d, 2 H, J = 7.2 Hz), 7.28-7.25 (m, 2 H), 7.21 (t, 1 H, J = 7.8 Hz), 4.49-4.45 (m, 
2 H), 3.50-3.47 (m, 2 H), 3.43-3.41 (m, 2 H); 13C NMR δ 175.3, 162.5, 157.7, 136.4, 136.2, 
134.7, 131.1, 130.3, 129.9, 129.5, 128.7, 128.2, 128.2, 60.3, 53.1, 50.5; MS (ESI) m/z 350 
([M+H]+). 
 
N
O
O
N
Bn
N3
SS
2-92  
2'-((2-Azidoethyl)(benzyl)amino)-1'H-spiro[[1,3]dithiane-2,4'-isoquinoline]-
1',3'(2'H)-dione (2-92). To a flame-dried 100 mL flask was added 1.61 g (3.81 mmol) of 2-75, 
36 mg (0.19 mmol) of CuI, 48 mg (0.39 mmol) of 2-picolinic acid and 3.72 g (11.4 mmol) of 
Cs2CO3. The mixture was purged 3 times with N2, diluted with 19 mL of anhydrous dioxane and 
1.2 mL (7.9 mmol) of diethyl malonate was added. After addition, the vessel was placed in a pre-
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heated oil bath at 70 oC under a N2 atmosphere. TLC analysis (hexane:EtOAc; 6:1) after 3 h 
showed that the starting material was consumed. The reaction was cooled to 25 oC, quenched 
with 10 mL of satd. NH4Cl, extracted with 3 x 10 mL of EtOAc, washed with 20 mL of brine, 
and concentrated in vacuo to be used directly in the next step. The residue was dissolved in 13 
mL of toluene and 3 mL of H2O, and 225 mg (1.18 mmol) of p-TSA was added. The pink 
colored mixture was heated at reflux for 20 h, cooled to 25 oC, and quenched with 20 mL of satd. 
NaHCO3. The biphasic mixture was partitioned and then the aqueous phase was extracted with 3 
x 10 mL of EtOAc. The crude mixture showed to be one spot by TLC (hexane:EtOAc; 5:1). The 
combined organic phases were washed with 10 mL of brine, dried (Na2SO4), concentrated in 
vacuo, and purified by chromatography on SiO2 (hexane:EtOAc; 10:1 to 5:1 gradient) to afford 
889 mg of 2-61 as a light brown oil.   
To a solution of 889 mg (2.65 mmol) of 2-61 in 30 mL of CH2Cl2 at 25 oC was added 760 
μL (5.45 mmol) of NEt3 followed by 1.27 g (3.05 mmol) of S,S'-propane-1,3-diyl bis(4-
methylbenzenesulfonothioate). The green/yellow solution was stirred at 25 oC under N2 for 21 h, 
quenched with 10 mL of satd. NH4Cl, extracted with 2 x 10 mL of CH2Cl2, dried (Na2SO4), 
concentrated, and purified by chromatography on SiO2 (hexane:EtOAc;4:1) to afford 989 mg 
(2.25 mmol, 59%, 3 steps) of 2-92 as a light green oil: IR (ATR) 2921, 2099, 1724, 1684, 1598, 
1455, 1337, 1224 cm-1; 1H NMR δ 8.18 (dd, 1 H, J = 7.9 Hz, J = 1.8 Hz), 8.10 (app d, 1 H, J = 
7.8 Hz), 7.65 (app dt, J = 7.5 Hz, J = 1.8 Hz), 7.52 (d, 2 H, J = 7.8 Hz), 7.53-7.49 (m, 1 H), 7.29 
(app t, 2 H, J = 7.2 Hz), 7.22 (t, 1 H, J = 7.3 Hz), 4.46, 4.41 (AB, 2 H, J = 13.2 Hz), 3.82 (td, 1 
H, J = 13.5 Hz, J = 2.5 Hz), 3.76 (td, 1 H, J = 13.5 Hz, J = 2.5 Hz), 3.50-3.32 (m, 4 H), 2.76 (dt, 
1 H, J = 13.9 Hz, J = 3.7 Hz), 2.68 (dt, 1 H, J = 13.9 Hz, 3.7 Hz), 2.34-2.31 (m, 1 H), 2.07-1.99 
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(m, 2 H); 13C NMR δ 170.0, 163.3, 137.2, 137.0, 134.4, 129.9, 129.7, 129.6, 129.3, 128.5, 127.9, 
125.1, 60.5, 52.5, 50.0, 49.6, 29.2, 29.1; MS (ESI) m/z 440 ([M+H]+). 
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2-93  
4-Benzyl-3,4-dihydrospiro[[1,2,4]triazino[2,3-b]isoquinoline-11,2'-[1,3]dithian]-6(2H)-one 
(2-93). To a flame dried microwave vial was added 51 mg (0.12 mmol) of 2-92 followed by 1.2 
mL of dry PhCl. To this colorless solution was added 150 µL (0.161 mmol) of PBu3 (1.07 M in 
PhCl). Upon addition of the phosphine at 25 oC, the reaction color changed to yellow. The vessel 
was then sealed and heated in the microwave at 180 oC for 20 min. The green solution was 
transferred to a 50 mL flask and the volatiles were removed under reduced pressure. The mixture 
was purified by chromatography on SiO2 (hexane:EtOAc; 6:1 to 5:1 gradient) to afford 14 mg 
(0.035 mmol, 31%) of 2-93 as tan/light green oil as a (tentatively assigned) mixture of 
regioisomers. Further analysis is needed to confirm these putative structures. 1H NMR (600 
MHz, CDCl3) δ 8.15-8.13 (m, 0.93 H), 7.68 (d, 0.61 H, J = 7.8 Hz), 7.65 (d, 0.35 H, J = 7.5 Hz), 
7.63-7.60 (m, 0.96 H), 7.53-7.50 (m, 1.8 H), 7.42 (app t, 1.0 H, J = 7.5 Hz), 7.31-7.26 (m, 2.3 
H), 7.24-7.20 (m, 1.0 H), 4.46, 4.39 (AB of major, J = 12.6 Hz), 4.43, 4.40 (AB of minor, J = 
13.8 Hz), 3.46-3.25 (m, 6.0 H), 2.90-2.87 (m, 0.35 H), 2.74-2.71 (m, 0.37 H), 2.58-2.34 (m, 2.8 
H), 2.23-2.18 (m, 0.65 H); 13C NMR (150 MHz, CDCl3) δ 174.7, 174.5, 164.1, 164.0, 141.6, 
141.4, 137.5, 137.2, 134.5, 134.5, 129.6, 129.4, 129.1, 128.5, 128.5, 128.4, 128.3, 127.9, 127.8, 
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126.8, 126.8, 125.1, 125.1, 62.2, 61.3, 60.6, 60.1, 52.8, 52.6, 50.5, 49.8, 43.3, 42.9, 36.7, 36.4, 
33.7, 33.1;  MS (ESI) m/z 396 ([M+H]+). 
 
N
O
N
Bn
OMeMeO
O N3
2-97  
2-((2-Azidoethyl)(benzyl)amino)-4,4-dimethoxyisoquinoline-1,3(2H,4H)-dione, 2-97. 
To a solution of 343 mg (0.780 mmol) of 2-92 in 8 mL of dry MeOH was added 180 µL (2.35 
mmol) of TFA, and 674 mg (2.35 mmol) of PIFA at 23 oC. The mixture was stirred for 15 min 
when TLC analysis (hexane:EtOAc; 4:1) of a Na2CO3 neutralized aliquot showed the starting 
material was consumed to a slightly more polar spot. After 20 min, the reaction was quenched 
with solid Na2CO3 until the pH was above 7, causing the yellow solution to change to colorless 
as the pH increased. The mixture was extracted with 4 x 10 mL of CH2Cl2, dried (MgSO4), 
concentrated, and purified by chromatography on SiO2 (hexane:EtOAc: 5:1 to 3:1 gradient with 
1% NEt3) to afford 226 mg (0.571 mmol, 73%) of 2-97 as a pale yellow oil: 1H NMR (600 MHz, 
CDCl3) δ 8.16 (d, 1 H, J = 8.1 Hz), 7.68-7.65 (m, 2 H), 7.59-7.56 (m, 1 H), 7.45 (d, 2 H, J = 7.2 
Hz), 7.25 (t, 2 H, J = 7.2 Hz), 7.19 (t, 1 H, J = 7.2 Hz), 4.46, 4.37 (AB, 2 H, J = 12.6 Hz), 3.54-
3.49 (m, 1 H), 3.42-3.37 (m, 3 H), 3.32 (s, 3 H), 3.08 (s, 3 H); 13C NMR (150 MHz, CDCl3) δ 
168.5, 164.0, 136.6, 135.7, 133.9, 130.4, 129.8, 129.3, 128.5, 128.0, 126.6, 126.6, 96.0, 60.3, 
52.9, 52.4, 52.2, 49.8. 
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2-98  
4-Benzyl-11,11-dimethoxy-3,4-dihydro-2H-[1,2,4]triazino[2,3-b]isoquinolin-6(11H)-
one, 2-98. To a flame-dried microwave vial was added 385 mg (0.974 mmol) of 2-97 in 2.5 mL 
of distilled PhCl, followed by 337 mg (1.67 mmol) of PBu3 in 580 µL of PhCl. The green/brown 
mixture was stirred at rt for 10 min then heated at 180 oC for 20 min. TLC analysis 
(CH2Cl2:EtOH; 50:1) showed the starting material was consumed to a single, streaky more polar 
spot. The dark purple solution was concentrated under a stream of N2 then purified by 
chromatography on SiO2  (100% CH2Cl2 to CH2Cl2:EtOH; 100:1 to 25:1) to produce an oily 
semisolid that was triturated with hexanes and then recrystallized from Et2O:hexanes to afford 
210 mg (0.597 mmol, 61%) of 2-98 as tiny cream colored needles: mp 127-128 oC; IR (ATR) 
2938, 2834, 1698, 1646, 1604, 1496, 1457, 1351, 1278, 1237, 1077 cm-1; 1H NMR (600 MHz, 
CDCl3) δ 8.18 (dd, 1 H, J = 7.8 Hz, J = 0.6 Hz), 7.73 (d, 1 H, J = 7.2 Hz), 7.66 (dt, 1 H, J = 7.2 
Hz, J = 1.2 Hz), 7.56-7.53 (m, 3 H), 7.36 (t, 2 H, J = 7.2 Hz), 7.31 (t, 1 H, J = 7.2 Hz), 4.07 (brs, 
2 H), 3.80 (brs, 2 H), 3.39 (brs, 6 H), 3.18 (t, 2 H, J = 6.0 Hz); 13C NMR (150 MHz, CDCl3) δ 
159.8, 148.1, 135.8, 135.6, 133.0, 130.1, 130.0, 129.3, 128.7, 128.2, 127.3, 126.3, 96.4, 58.4, 
45.7, 39.0; MS (ESI) m/z 352 ([M+H]+). 
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4.4 CHAPTER 3 EXPERIMENTAL8 
Ph
NH
OMe
O
Cbz
3-51  
(R)-Methyl 2-(benzyloxycarbonylamino)-2-phenylacetate (3-51).232 To a mixture of 24.0 g 
(119 mmol) of (R)-(-)-2-phenylglycine methyl ester hydrochloride in 1200 mL of EtOAc:H2O 
(1:1) cooled to 0 oC was added 50.1 g (596 mmol) of NaHCO3, followed by a solution of 24 mL 
(142 mmol) of benzyl chloroformate in 20 mL of EtOAc over 20 min. After 2 h, the mixture was 
quenched with 200 mL of H2O, extracted with 3 x 150 mL of EtOAc and washed with 200 mL of 
brine. The combined organic layers were dried (MgSO4), and concentrated in vacuo to a solid. 
The solid was triturated with hexanes, filtered and dried to afford 25.6 g (85.4 mmol, 72%) of 3-
51 as an amorphous solid: mp 64-65 oC; [α]D -116.3 (c 1.78, CH2Cl2); 1H NMR (300 MHz, 
CD3OD) δ 7.40-7.27 (m, 10 H), 5.31 (brs, 1 H), 5.12, 5.07 (AB, 2 H, J = 12.6 Hz), 3.68 (s, 3 H); 
13C NMR (150 MHz, CD3OD) δ 172.9, 158.1 138.1, 137.7, 129.8, 129.5, 129.4, 129.0, 128.8, 
128.6, 67.8, 59.7, 53.0. 
 
 
 
                                                 
8 All NMR data in this section were recorded on Bruker instruments at the indicated 
spectrometer frequency in the solvent listed. 
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3-52  
(1-Ethoxy-1-oxopropan-2-yl)triphenylphosphonium bromide (3-52).233 To a solution of 50.0 
g (191 mmol) of PPh3 in 200 mL of acetone was added 30 mL (231 mmol) of ethyl 2-
bromopropionate. The mixture was heated at reflux for 38 h, causing the formation of a white 
precipitate. The solvent was removed under reduced pressure and to the solid was added 20 mL 
of CH2Cl2 followed by 200 mL of Et2O. The resulting solid was filtered, rinsed with Et2O, 
ground into a fine powder and dried on high vacuum to afford 81.3 g (183 mmol, 96%) of 3-52 
as an amorphous solid: 1H NMR (400 MHz, CDCl3) δ 7.81-7.75 (m, 6 H), 7.66-7.61 (m, 3 H), 
7.56-7.51 (m, 6 H), 6.37 (dq, 1 H, J = 15.8 Hz, J = 7.6 Hz), 3.89-3.74 (m, 2 H), 1.50 (dd, 3 H, J 
= 18.4 Hz, J = 7.2 Hz), 0.80 (t, 3 H, J = 7.2 Hz); 13C NMR (100 MHz, CDCl3) δ 167.5 (d, JC-P = 
1.9 Hz), 134.8 (d, JC-P = 3.0 Hz), 133.9 (d, JC-P = 9.9 Hz), 130.1 (d, JC-P = 12.7 Hz), 117.3 (d, JC-P 
= 85.6 Hz), 62.7, 36.4 (d, JC-P = 49.8 Hz), 13.4, 12.8 (d, JC-P = 2.9 Hz). 
 
Ph
NH
Cbz
CH3
O
OEt
3-53  
(S,E)-Ethyl 4-(benzyloxycarbonylamino)-2-methyl-4-phenylbut-2-enoate (3-53). To a 
suspension of 30.1 g (67.9 mmol) of 3-52 in 170 mL of distilled THF cooled to 0 oC was added 
7.68 g (68.5 mmol) of KOBut in one portion. This caused the suspension to change to a partially 
homogenous yellow solution. The mixture was stirred at 0 oC for 1.5 h, and then used directly in 
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the next step. To a 3-neck flask charged with 10.1 g (33.9 mmol) of 3-51 dissolved in 200 mL of 
dry toluene and cooled to -78 oC was added dropwise via cannula a solution of 9.67 g, (68.0 
mmol) of DIBAl-H in 20 mL of dry toluene over 25 min. After addition, the mixture was stirred 
at -78 oC for 1 h. After 1 h, the light green ylide solution (prepared as described above) was 
added dropwise via cannula over 30 min. After addition of the ylide, the mixture was allowed to 
stir for 45 min at -78 oC then removed from the cooling bath and allowed to warm to ambient 
temperature. The lime green/yellow mixture was then heated at 50 oC for 22 h. After cooling to 
rt, the mixture was quenched with 50 mL of H2O and 200 mL of 1M HCl, stirred for 20 min, 
extracted with 3 x 100 mL of EtOAc, washed with 200 mL of brine, dried (Na2SO4) and 
concentrated in vacuo. The residue was purified by chromatography on SiO2 (hexane:EtOAc; 
10:1 to 5:1 gradient) to afford 10.3 g (29.1 mmol, 86%, 2 steps) of 3-53 as an oil: [α]D -0.6 (c 
0.94, CH2Cl2); IR (ATR) 3331, 3029, 1687, 1521, 1452, 1230,1126, 1023 cm-1; 1H NMR (400 
MHz, CD3OD) δ 7.36-7.24 (m, 10 H), 6.82 (dq, 1 H, J = 9.30 Hz, J = 1.48 Hz), 5.59 (app d, 1 H, 
J = 9.2 Hz), 5.09 (s, 2 H), 4.18 (q, 2 H, J = 7.11 Hz), 1.94 (s, 3 H), 1.27 (t, 3 H, J = 7.13 Hz); 13C 
NMR (100 MHz, CD3OD) δ 169.2, 158.2, 142.1, 141.4, 138.3, 130.2, 129.8, 129.5, 129.0, 128.8, 
128.7, 127.7, 67.7, 62.0, 54.3, 14.5, 13.0; MS (ESI) m/z 354 ([M+H]+); HRMS (ESI) m/z calcd 
for C21H23NO4Na (M+Na) 376.1525, found 376.1501. 
 
Ph
NH
Cbz
CH3
OH
3-54  
(S,E)-Benzyl 4-hydroxy-3-methyl-1-phenylbut-2-enylcarbamate (3-54). To a solution of 10.3 
g (29.1 mmol) of 3-53 in 150 mL of dry CH2Cl2 cooled to -78 oC was added dropwise via 
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cannula a solution of 12.4 g (87.3 mmol) of DIBAl-H in 10 mL of dry CH2Cl2 over 10 min. After 
addition, the reaction mixture was allowed to stir at -78 oC for 1.5 h, removed from the cooling 
bath, warmed to rt, and after 2 h, the mixture was quenched by the dropwise addition of 100 mL 
of a satd. solution of potassium sodium tartrate. After being diluted 100 mL of EtOAc the cloudy 
mixture was stirred until it became biphasic and TLC analysis (hexane:EtOAc; 1:1) showed that 
the starting material was consumed. The mixture was extracted with 2 x 100 mL of EtOAc, 
washed with 50 mL of brine, dried (MgSO4), concentrated in vacuo and purified by 
chromatography on SiO2 (hexane:EtOAc; 2:1) to afford 8.61 g (25.9 mmol, 89%) of 3-54 as a 
tan oil: [α]D +15.2 (c 0.38, CH2Cl2); IR (ATR) 3312, 3064, 3031, 1692, 1523, 1495, 1452, 1240, 
1025 cm-1; 1H NMR (400 MHz, CD3OD) δ 7.35-7.17 (m, 10 H), 5.64 (dq, 1 H, J = 9.2 Hz, J = 
1.3 Hz), 5.57 (br d, 1 H, J = 9.1 Hz), 5.07, 5.03 (AB, 2 H, J = 12.4 Hz), 3.95 (s, 2 H), 1.76 (s, 3 
H); 13C NMR (100 MHz, CD3OD) δ 158.0, 143.9, 138.5, 138.1, 129.4, 129.3, 128.9, 128.7, 
128.0, 127.4, 125.8, 67.8, 67.4, 53.7, 14.2; MS (ESI) m/z 312 ([M+H]+); HRMS (ESI) m/z calcd 
for C19H22NO3 (M+H) 312.1600, found 312.1604. 
 
Ph
NH
Cbz
CH3
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3-55  
(S,E)-Benzyl-4-(tert-butyldiphenylsilyloxy)-3-methyl-1-phenylbut-2-enylcarbamate (3-55). 
To a solution of 8.06 g (25.9 mmol) of 3-54 in 100 mL of dry CH2Cl2 cooled to 0 oC was added 
1.77 g (26.0 mmol) of imidazole, 510 mg (4.14 mmol) of DMAP, and 5.4 mL (21 mmol) of 
TBDPSCl. The mixture was allowed to warm to rt overnight. In the morning, the mixture was 
quenched with 50 mL of satd. NaHCO3, and extracted with 3 x 20 mL of CH2Cl2. The combined 
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organic layers were washed with 50 mL of brine, dried (MgSO4), concentrated in vacuo and 
purified by chromatography on SiO2 (hexane:Et2O; 10:1) to afford 9.27 g (16.9 mmol, 81%) of 
3-55: [α]D +23.1 (c 1.55, CH2Cl2); IR (ATR) 3066, 2928, 2854, 1694, 1493, 1426, 1105, 1023 
cm-1; 1H NMR (400 MHz, CD3OD) δ 7.64-7.60 (m, 4 H), 7.37-7.17 (m, 16 H), 5.72 (d, 1 H, J = 
8.8 Hz), 5.59-5.57 (m, 1 H), 5.07, 5.03 (AB, 2 H, J = 12.8 Hz), 4.07, 4.03 (AB, 2 H, J = 15.2 Hz) 
1.68 (brs, 3 H), 1.01 (s, 9 H); 13C NMR (100 MHz, CD3OD) δ 158.1, 143.9, 138.2, 137.6, 136.5, 
134.6, 134.6, 130.8, 129.5, 129.4, 128.9, 128.7, 128.0, 127.5, 157.7, 69.3, 67.5, 53.6, 27.3, 20.0, 
14.2; MS (ESI) m/z 572 ([M+Na]+); HRMS (ESI) m/z calcd for C35H39NO3NaSi (M+Na) 
572.2597, found 572.2623. 
 
NH
Cbz
CH3
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3-56  
Benzyl-(S)-((1R,2R)-2-((tert-butyldiphenylsilyloxy)methyl)-2-methylcyclopropyl) 
(phenyl)methylcarbamate (3-56). To a freshly prepared solution of 6.28 g (50.9 mmol) of 
Et2Zn in 30 mL of dry CH2Cl2 was added 5.3 mL of freshly distilled DME. The solution was 
cooled to -30 oC (internal temperature) when 8.0 mL (100 mmol) of CH2I2 was added dropwise 
over 20 min. The temperature was maintained at or below -30 oC during the addition. After 
addition, the mixture was stirred for 10 min at -30 oC and a solution of 2.75 g (5.00 mmol) of 3-
55 was added dropwise in 20 mL of CH2Cl2 via addition funnel over 20 min while maintaining 
the temperature. After addition, the reaction mixture was allowed to warm to rt overnight and 
stirred for a total of 25 h, before slowly quenching with 80 mL of satd. NH4Cl. The mixture was 
partitioned and extracted with 4 x 20 mL of CH2Cl2. The combined organic layers were washed 
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with 50 mL of brine, dried (MgSO4) and concentrated in vacuo. The tan oil was purified by 
chromatography on SiO2 (hexane:EtOAc; 10:1) to afford 2.05 g (3.64 mmol, 73%) of 3-56 as an 
oily foam: [α]D -19.5 (c 0.47, CH2Cl2); IR (ATR) 3318, 2952, 2928, 1694, 1497, 1247, 1105, 
1083 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.61-7.59 (m, 4 H), 7.48 (d, 2 H, J = 6.8 Hz), 7.43-
7.24 (m, 14 H), 5.18 (app d, 1 H, J = 7.2 Hz), 5.13, 5.09 (AB, 2 H, J = 12.0 Hz), 4.46 (app t, 1 H, 
J = 8.8 Hz), 3.59, 3.24 (AB, 2 H, J = 10.0 Hz), 1.21, (s, 3 H), 1.02 (s, 9 H), 0.66 (dd, 1 H, J = 8.4 
Hz, J = 4.8 Hz), 0.49 (brs, 1 H); 13C NMR (100 MHz, CDCl3) δ 156.3, 143.0, 136.8, 135.9, 
135.8, 133.8, 133.7, 129.8, 128.7, 128.3, 127.8, 127.4, 126.8, 71.2, 67.0, 55.6, 27.6, 27.0, 23.4, 
19.5, 16.4, 15.1; MS (ESI) m/z 586 ([M+Na]+); HRMS (ESI) m/z calcd for C36H41NO3SiNa 
(M+Na) 586.2753, found 586.2766. 
 
NH
Cbz
CH3
OH
3-57  
Benzyl(S)-((1R,2R)-2-(hydroxymethyl)-2-methylcyclopropyl) (phenyl)methylcarbamate (3-
57). To a solution of 4.18 g (7.41 mmol) of 3-56 in 15 mL of TBAF (15.0 mmol) in THF was 
added 860 µL (14.9 mmol) of AcOH. The mixture was heated at reflux for 4 h, cooled to rt, 
quenched with 40 mL of satd. NaHCO3, and extracted 3 x 15 mL of EtOAc. The combined 
organic layers were washed with 40 mL of brine, dried (Na2SO4), concentrated, and purified by 
chromatography on SiO2 (hexane:EtOAc; 2:1 to 1:2 gradient) to afford 2.10 g (6.44 mmol, 87%) 
of 3-57 as a pale oily foam: HPLC analysis indicated one enantiomer (er >99:1; tR major = 8.76 
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min; tR minor = 11.18 min);9 [α]D -18.7 (c 1.38, CH2Cl2); IR (ATR) 3411, 3316, 2928, 1691, 
1527, 1452, 1253, 1027 cm-1; 1H NMR (400 MHz, CD3OD) δ 7.41-7.27 (m, 9 H), 7.24-7.20 (m, 
1 H), 5.10, 5.05 (AB, 2 H, J = 12.8 Hz), 4.37-4.34 (m, 1 H), 3.34, 3.24 (AB, 2 H, J = 11.2 Hz), 
1.26-1.19 (m, 1 H), 1.17 (s, 3 H), 0.74 (dd, 1, J = 8.6 Hz, J = 4.4 Hz), 0.42-0.39 (m, 1 H); 13C 
NMR (150 MHz, CD3OD) δ 158.6, 144.7, 138.5, 129.4, 129.4, 128.9, 128.7, 128.0, 127.7, 70.9, 
67.4, 56.6, 28.1, 24.4, 16.4, 16.3; MS (ESI) m/z 348 ([M+Na]+); HRMS (ESI) m/z calcd for 
C20H23NO3Na (M+Na) 348.1576, found 348.1551. 
 
H
N
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Benzyl-(S)-((1R,2R)-2-methyl-2-(pyridin-2-ylmethylcarbamoyl)cyclopropyl) (phenyl) 
 methylcarbamate (3-61). To a solution of 467 mg (1.43 mmol) of 3-57 in 5 mL of acetone was 
added 3.8 mL (9.5 mmol, 2.5 M solution) of Jones reagent. After addition, the flask was heated 
at 50 oC for 3 h. TLC analysis (hexane:EtOAc; 1:1) showed starting material remained. To the 
reaction was added an additional 2 mL (5 mmol, 2.5 M) of Jones reagent, and the mixture was 
heated at reflux. After the starting material was consumed (TLC analysis), the mixture was 
cooled to rt, diluted with 10 mL of H2O, and extracted with 3 x 10 mL of EtOAc. The combined 
organic layers were washed with 10 mL of brine, dried (Na2SO4), concentrated under reduced 
                                                 
9 Analytical HPLC data was obtained by analysis of 3-57 through a Chiracel OD column (4.6 
mm ID x 250 mm; 10 µm particle size; Daicel Chemical Industries, LTD.). The eluent was 
composed of 20% isopropanol in 80% hexane, with a flow rate of 1.0 mL/min on a Shimadzu 
instrument. 
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pressure, and used directly in the next coupling step. To a solution of the crude carboxylic in 5 
mL of dry CH2Cl2 was added 871 mg (1.87 mmol) of PyBroP, 27.8 mg (0.227 mmol) of DMAP, 
240 µL (2.32 mmol) of 2-aminomethylpyridine, and 750 µL (4.30 mmol) of DIPEA. The brown 
mixture was stirred at rt overnight, and then concentrated in vacuo. The residue was diluted with 
15 mL of EtOAc, and the organic phase was washed with 20 mL of 5% solution of NaHSO4, 20 
mL of brine, and 20 mL of satd. NaHCO3. The organic phase was dried (Na2SO4), and 
concentrated in vacuo, and purified by chromatography on SiO2 (hexane:EtOAc; 1:1 to 1:7 
gradient with 1% NEt3) to afford 287 mg (0.648 mmol, 45%, 2 steps) of 3-61 as a colorless oil: 
[α]D -37.5 (c 1.57, CH2Cl2); IR (ATR) 3297, 3066, 3005, 1700, 1638, 1514, 1254, 1215, 1027, 
844 cm-1; 1H NMR (400 MHz, CD3OD) δ 8.40 (d, 1 H, J = 4.4 Hz), 7.65 (t, 1 H, J = 7.6 Hz), 
7.40 (d, 2 H, J = 7.2 Hz), 7.32-7.22 (m, 8 H), 7.20-7.17 (m, 1 H), 7.12 (d, 1 H, J = 8.0 Hz), 5.09, 
5.03 (AB, 2 H, J = 12.5 Hz), 4.51 (d, 1 H, J = 10.0 Hz), 4.49, 4.41 (AB, 2 H, J = 16.8 Hz), 2.02-
1.96 (m, 1 H), 1.47 (dd, 1 H, J = 9.0 Hz, J = 4.4 Hz), 1.40 (s, 3 H), 0.81-0.79 (m, 1 H); 13C NMR 
(100 MHz, CD3OD) δ 177.0, 159.3, 158.2, 149.5, 143.9, 138.5, 138.1, 129.5, 129.3, 128.8, 
128.6, 128.3, 127.6, 123.4,122.1, 67.4, 56.1, 45.6, 32.4, 25.4, 20.9, 15.0; MS (ESI) m/z 452 
([M+Na]+); HRMS (ESI) m/z calcd for C26H27N3O3Na (M+Na) 452.1950, found 452.1934. 
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Benzyl-(S)-((1R,2R)-2-methyl-2-((5-methylfuran-2-yl)methylcarbamoyl) cyclopropyl)  
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(phenyl)methylcarbamate (3-62). To a solution of 801 mg (2.46 mmol) of 3-57 in 10 mL of 
acetone cooled to 0 oC was added 6 mL (15.0 mmol, 2.5 M solution) of Jones reagent dropwise. 
After addition, the reaction mixture allowed to warm rt over 1.5 h, and then heated at reflux for 1 
h. TLC analysis (hexane:EtOAc; 4:1) showed the starting material was consumed. The reaction 
was cooled to rt, quenched with 10 mL of H2O, neutralized to pH of 3 with satd. NaHCO3, and 
extracted with 3 x 10 mL of EtOAc. The combined organic layers were washed with 10 mL of 
brine, dried (Na2SO4), concentrated under reduced pressure, and used directly in the next 
coupling step. To a solution of the crude carboxylic acid in 8 mL of dry CH2Cl2 was added 92.6 
mg (0.758 mmol) of DMAP, 510 µL (4.91 mmol) of 5-methylfurfurylamine, and 1 mL (7 mmol) 
of NEt3. To this was added 2.2 mL (3.7 mmol) of T3P (50% w/w solution in ethyl acetate). After 
addition, the reaction mixture was allowed to warm to rt overnight. The reaction mixture was 
quenched with 10 mL of satd. NaHCO3, extracted with 3 x 10 mL of CH2Cl2, washed with 10 
mL of brine, dried (Na2SO4), concentrated in vacuo and purified by chromatography on SiO2 
(hexane:EtOAc; 5:1 to 1:1 gradient) to afford 587 mg (1.36 mmol, 55%, 2 steps) of 3-62 as a 
colorless, foamy oil: [α]D -5.1 (c 1.20, CH2Cl2); IR (ATR) 3295, 2945, 1694, 1635, 1523, 1452, 
1256, 1021 cm-1; 1H NMR (400 MHz, CD3OD) δ 7.35-7.19 (m, 10 H), 5.98 (d, 1 H, J = 2.8 Hz), 
5.87 (dd, 1 H, J = 3.0 Hz, J = 0.8 Hz), 5.09, 5.04 (AB, 2 H, J = 12.4 Hz), 4.44 (br d, 1 H, J = 
10.4 Hz), 4.29-4.22 (m, 2 H), 2.19 (s, 3 H), 1.94-1.88 (m, 1 H), 1.41 (dd, 1 H, J = 9.2 Hz, J = 4.4 
Hz), 1.31 (s, 3 H), 0.75-0.73 (m, 1 H); 13C NMR (100 MHz, CD3OD) δ 176.7, 158.4, 152.4, 
151.5, 143.8, 138.3, 129.5, 129.4, 128.9, 128.7, 128.3, 127.7, 108.5, 107.1, 67.5, 56.0, 37.7, 32.1, 
25.5, 20.8, 15.0, 13.4; MS (ESI) m/z 455 ([M+Na]+); HRMS (ESI) m/z calcd for C26H28N2O4Na 
(M+Na) 455.1947, found 455.1936. 
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Benzyl(S)-((1R,2R)-2-(2-(1H-indol-3-yl)ethylcarbamoyl)-2-methylcyclopropyl) 
(phenyl)methylcarbamate (3-63). To a solution of 563 mg (1.73 mmol) of 3-57 in 5 mL of 
acetone was added 4.6 mL (12 mmol, 2.5 M solution) of Jones reagent. The reaction was heated 
at 50 oC for 2 h. TLC analysis (hexane:EtOAc; 1:1) showed the starting material was consumed. 
The reaction was cooled to rt, diluted with 10 mL of H2O, and extracted with 3 x 10 mL of 
EtOAc. The combined organic layers were washed with 10 mL of brine, dried (Na2SO4), 
concentrated under reduced pressure, and used directly in the next coupling step. To a solution of 
the crude carboxylic acid in 10 mL of dry CH2Cl2 was added 362 mg (2.26 mmol) of tryptamine, 
21.6 mg (0.176 mmol) of DMAP, 893 mg (1.91 mmol) of PyBroP, and 670 µL (3.85 mmol) of 
DIPEA. The brown mixture was stirred at rt overnight, concentrated in vacuo, and the residue 
was diluted with 15 mL of EtOAc. The organic phase was washed with 20 mL of 5% solution of 
NaHSO4, 20 mL of brine, 20 mL of satd. NaHCO3, and dried (Na2SO4). The organic phase was 
concentrated in vacuo, and the residue was purified by chromatography on SiO2 (hexane:EtOAc; 
1:1) to afford 472 mg (0.981 mmol, 57%, 2 steps) of 3-63 as a white foam: [α]D -18.8 (c 0.62, 
CH2Cl2); IR (ATR) 3284, 3062, 2937, 1694, 1637, 1517, 1454, 1256 cm-1; 1H NMR (400 MHz, 
CD3OD) δ 7.54 (d, 1 H, J = 8.0 Hz), 7.50 (app t, 1 H, J = 5.0Hz, N-H), 7.33-7.22 (m, 11 H), 7.07 
(ddd, 1 H, J = 8.1 Hz, J = 7.0 Hz, J = 1.2 Hz), 6.96 (ddd, 1 H, J = 9.5 Hz, J = 4.0 Hz, J = 0.8 
Hz), 6.95 (s, 1 H), 5.09, 5.04 (AB, 2 H, J = 12.4 Hz), 4.41 (d, 1 H, J = 10.4 Hz), 3.45 (app q, 2 
H, J = 6.4 Hz), 2.89 (app t, 2 H, J = 7.4 Hz), 1.93-1.87 (m, 1 H), 1.38 (dd, 1 H, J = 9.2 Hz, J = 
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4.0 Hz), 1.24 (s, 3 H), 0.71 (app t, 1 H, J = 4.4 Hz); 13C NMR (100 MHz, CD3OD) δ 177.0, 
158.5, 143.9, 138.3, 138.1, 129.6, 129.4, 128.9, 128.8, 128.7, 128.3, 127.7, 123.4, 123.3, 119.6, 
119.3, 113.3, 112.2, 67.5, 56.2, 42.1, 31.9, 26.2, 25.6, 20.8, 15.1; MS (ESI) m/z 504 ([M+Na]+); 
HRMS (ESI) m/z calcd for C30H31N3O3Na (M+Na) 504.2263, found 504.2226. 
 
3-68
Ph
NH CH3 H
N
O N
H
O
 
(1R,2R)-N-(2-(1H-Indol-3-yl)ethyl)-2-((S)-acetamido(phenyl)methyl)-1-
methylcyclopropanecarboxamide (3-68). According to general protocol A, 106 mg (0.219 
mmol) of 3-63, and 46.2 mg (0.0434 mmol) of Pd/C (10%) in 2 mL of MeOH was stirred for 1 h 
to provide the amine intermediate. The residue was dissolved in 2 mL of dry CH2Cl2, and treated 
with 27 µL (0.29 mmol) of Ac2O, and 40 µL (0.29 mmol) of NEt3 to afford 76.7 mg (0.197 
mmol, 90%, 2 steps) of 3-68 as a white foam: [α]D -33.4 (c 1.19, CH2Cl2); IR (ATR) 3413, 3290, 
3055, 1625, 1523, 1454, 1430, 1294 cm-1; 1H NMR (400 MHz, CD3OD) δ 10.15 (br s, 1 H, N-
H), 8.70 (d, 1 H, J = 8.4 Hz), 7.56-7.51 (m, 2 H), 7.34-7.20 (m, 6 H), 7.08 (ddd, 1 H, J = 8.5 Hz, 
J = 6.6 Hz, J = 1.2 Hz), 6.97 (ddd, 1 H, J = 8.0 Hz, J = 7.0 Hz, J = 1.2 Hz), 6.96 (br s, 1 H), 
4.76-4.71 (m, 1 H), 4.73 (dt, 1 H, J = 10.8 Hz, J = 6.0 Hz), 3.49-3.44 (m, 2 H), 2.91 (app dt, 2 H, 
J = 7.4 Hz, J = 1.2 Hz), 1.97 (s, 3 H), 1.94-1.89 (m, 1 H), 1.38 (dd, 1 H, J = 9.2 Hz, J = 4.0 Hz), 
1.23 (s, 3 H), 0.69 (dd, 1 H, J = 6.4 Hz, J = 4.4 Hz); 13C NMR (100 MHz, CD3OD) δ 176.9, 
172.3, 143.4, 138.1, 129.6, 128.8, 128.4, 127.8, 123.3, 122.3, 119.6, 119.3, 113.3, 112.2, 54.1, 
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42.1, 31.4, 26.2, 25.6, 22.7, 20.8, 15.0; MS (ESI) m/z 412 ([M+Na]+); HRMS (ESI) m/z calcd for 
C24H27N3O2Na (M+Na) 412.2001, found 412.2035. 
 
3-69
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NH CH3 H
N
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H
O
N
H
Ph
 
(1R,2R)-N-(2-(1H-Indol-3-yl)ethyl)-1-methyl-2-((S)-phenyl(3-phenylureido) 
methyl)cyclopropanecarboxamide (3-69). According to general protocol A, 99.0 mg (0.205 
mmol) of 3-63 and 43.9 mg (0.0439 mmol) of Pd/C (10%) in 2 mL of MeOH was stirred for 1.5 
h to provide the amine intermediate. The residue was dissolved in 2 mL of dry CH2Cl2, and 
treated with 29 µL (0.27 mmol) of PhNCO and 40 µL (0.29 mmol) of NEt3 to afford 85.7 mg 
(0.184 mmol, 89%, 2 steps) of 3-69 as a white, waxy foam: [α]D +14.5 (c 0.98, CH2Cl2); IR 
(ATR) 3316, 3051, 2937, 1616, 1543, 1497, 1439, 732 cm-1; 1H NMR (400 MHz, CD3OD) δ 
7.56-7.52 (m, 2 H), 7.36-7.19 (m, 10 H), 7.08 (ddd, 1 H, J = 8.1 Hz, J = 7.2 Hz, J = 1.2 Hz), 
6.99-6.93 (m, 3 H), 6.73 (br d, 1 H, J = 8.8 Hz), 4.66-4.61 (m, 1 H), 3.49-3.44 (m, 2 H), 2.91 
(app dt, 2 H, J = 7.2 Hz, J = 1.6 Hz), 1.89 (ddd, 1 H, J = 10.4 Hz, J = 9.0 Hz, J = 6.4 Hz), 1.41 
(dd, 1 H, J = 9.2 Hz, J = 4.0 Hz), 1.27 (s, 3 H), 0.79 (dd, 1 H, J = 6.4 Hz, J = 4.0 Hz); 13C NMR 
(100 MHz, CD3OD) δ 177.0, 157.5, 144.3, 140.8, 138.1, 129.8, 129.7, 128.6, 128.3, 127.6, 
123.5, 123.3, 122.3, 120.1, 119.6, 119.3, 113.3, 112.2, 54.4, 42.1, 32.3, 26.2, 25.6, 20.9, 15.0; 
MS (ESI) m/z 489 ([M+Na]+); HRMS (ESI) m/z calcd for C29H30N4O2Na (M+Na) 489.2266, 
found 489.2263. 
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N-((S)-((1R,2R)-2-(2-(1H-Indol-3-yl)ethylcarbamoyl)-2-methylcyclopropyl) 
(phenyl)methyl)nicotinamide (3-70). According to general protocol A, 101 mg (0.210 mmol) 
of 3-63, and 45.4 mg (0.0426 mmol) of Pd/C (10%) in 2 mL of MeOH was stirred for 1.5 h to 
provide the amine intermediate. The residue was dissolved in 2 mL of dry CH2Cl2, and treated 
with 67.0 mg (0.376 mmol) of nicotinoyl chloride hydrochloride, 2.2 mg (0.018 mmol) of 
DMAP, and 90 µL (0.65 mmol) of NEt3 to afford 70.9 mg (0.155 mmol, 75%, 2 steps) of 3-70 as 
a light yellow oil: [α]D -11.5 (c 0.36, CH2Cl2); IR (ATR) 3279, 3049, 1627, 1528, 1431, 1338, 
1029 cm-1; 1H NMR (400 MHz, CD3OD) δ 9.38 (br d, 1 H, J = 8.0 Hz), 9.00 (dd, 1 H, J = 2.0 
Hz, J = 0.8 Hz), 8.64 (dd, 1 H, J = 4.8 Hz, J = 1.6 Hz), 8.26 (ddd, 1 H, J = 8.0 Hz, J = 2.4 Hz, J 
= 1.6 Hz), 7.62 (t, 1 H, J = 5.6 Hz), 7.53 (dt, 1 H, J = 7.6 Hz, J = 1.2 Hz), 7.50 (ddd, 1 H, J = 8.0 
Hz, J = 4.8 Hz, J = 0.8 Hz), 7.43-7.40 (m, 2 H), 7.33-7.23 (m, 4 H), 7.07 (ddd, 1 H, J = 8.1 Hz, J 
= 7.0 Hz, J = 0.8 Hz), 6.96 (ddd, 1 H, J = 8.0 Hz, J = 7.0 Hz, J = 0.8 Hz), 6.97 (s, 1 H), 5.00 (dt, 
1 H, J = 10.4 Hz, J = 5.6 Hz), 3.49-3.44 (m, 2 H), 2.93-2.90 (m, 2 H), 2.11 (ddd, 1 H, J = 10.8 
Hz, J = 9.2 Hz, J = 6.4 Hz), 1.44 (dd, 1 H, J = 9.2 Hz, J = 4.4 Hz), 1.28 (s, 3 H), 0.77 (dd, 1 H, J 
= 6.6 Hz, J = 4.4 Hz); 13C NMR (100 MHz, CD3OD) δ 176.8, 167.0, 152.4, 149.0, 143.2, 138.1, 
137.3, 132.1, 129.7, 128.8, 128.5, 128.0, 125.2, 123.3, 122.3, 119.6, 119.3, 113.3, 112.2, 54.8, 
42.1, 31.1, 26.2, 25.7, 20.9, 15.0; MS (ESI) m/z 453 ([M+H]+); HRMS (ESI) m/z calcd for 
C28H29N4O2 (M+H) 453.2291, found 453.2293. 
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3-71  
N-((S)-((1R,2R)-2-(2-(1H-Indol-3-yl)ethylcarbamoyl)-2-methylcyclopropyl) 
(phenyl)methyl)-5-methylisoxazole-3-carboxamide (3-71). According to general protocol A, 
99.9 mg (0.207 mmol) of 3-63, and 44.8 mg (0.0421 mmol) of Pd/C (10%) in 2 mL of MeOH 
was stirred for 1 h to provide the amine intermediate. The residue was dissolved in 2 mL of dry 
CH2Cl2, and treated with 49.9 mg (0.342 mmol) of 5-methylisoxazole-3-carbonyl chloride, 25 
mg (0.040 mmol) of DMAP, and 90 µL (0.65 mmol) of NEt3 to afford 72.9 mg (0.160 mmol, 
77%, 2 steps) of 3-71 as a light yellow oil: [α]D -24.3 (c 1.11, CH2Cl2); IR (ATR) 3295, 3057, 
2923, 2852, 1637, 1526, 1454, 1225 cm-1; 1H NMR (400 MHz, CD3OD) δ 7.57-7.54 (m, 2 H), 
7.40-7.36 (m, 2 H), 7.34-7.21 (m, 5 H), 7.07 (ddd, 1 H, J = 8.4 Hz, J = 7.2 Hz, J = 1.2 Hz), 6.98 
(s, 1 H), 6.97 (ddd, 1 H, J = 7.9 Hz, J = 7.0 Hz, J = 1.2 Hz), 6.43 (d, 1 H, J = 1.2 Hz), 4.92 (d, 1 
H, J = 10.8 Hz), 3.50-3.45 (m, 2 H), 2.94-2.90 (m, 2 H), 2.41 (d, 3 H, J = 0.8 Hz), 2.08 (ddd, 1 
H, J = 10.8 Hz, J = 9.2 Hz, J = 6.4 Hz), 1.42 (dd, 1 H, J = 9.0 Hz, J = 4.0 Hz), 1.28 (s, 3 H), 0.74 
(dd, 1 H, J = 6.4 Hz, J = 4.4 Hz); 13C NMR (100 MHz, CD3OD) δ 176.8, 172.9, 160.9, 160.0, 
142.8, 138.1, 129.7, 128.8, 128.6, 128.0, 123.3, 122.3, 119.6, 119.3, 113.3, 112.2, 102.0, 54.4, 
42.1, 30.9, 26.2, 25.8, 20.8, 15.0, 12.0; MS (ESI) m/z 479 ([M+Na]+); HRMS (ESI) m/z calcd for 
C27H28N4O3Na (M+Na) 479.2059, found 479.2043. 
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3-72  
(1R,2R)-1-Methyl-2-((S)-phenyl(3-phenylureido)methyl)-N-(pyridin-2-ylmethyl) 
cyclopropanecarboxamide (3-72). General protocol A. To a solution of 68.7 mg (0.160 mmol) 
of 3-61 in 2 mL of MeOH was added 32.1 mg (0.0301 mmol) of Pd/C (10%). This was purged 
with H2 (1 atm) and the mixture was stirred at rt for 1.5 h. TLC analysis (hexane:EtOAc; 1:4) 
showed the starting material was consumed. The mixture was quenched with Celite, filtered, and 
rinsed with MeOH. The filtrate was concentrated in vacuo, and dried on high vacuum to provide 
the amine intermediate. The residue was dissolved in 2 mL of dry CH2Cl2, and treated with 23 
µL (0.21 mmol) of PhNCO, followed by 30 µL (0.22 mmol) of NEt3. The reaction mixture was 
stirred at rt overnight, quenched with 5 mL of satd. NaHCO3, extracted with 3 x 5 mL of CH2Cl2, 
dried (Na2SO4), concentrated in vacuo and purified by chromatography on SiO2 (2%-5% 
MeOH/CH2Cl2) to afford 57 mg (0.14 mmol, 85%, 2 steps) of 3-72 as a waxy oil: [α]D +4.5 (c 
1.25, CH2Cl2); IR (ATR) 3292, 3061, 1635, 1541, 1499, 1437, 1254, 1217, 950 cm-1; 1H NMR 
(300 MHz, CD3OD) δ 8.43 (d, 1 H, J = 4.2 Hz), 7.72 (app dt, 1 H, J = 7.7 Hz, J = 1.8 Hz), 7.41-
7.15 (m, 12 H), 6.95 (d, 1 H, J = 7.5 Hz), 4.68 (d, 1 H, J = 10.2 Hz), 4.52, 4.43 (AB, 2 H, J = 
16.2 Hz), 1.94-1.85 (m, 1 H), 1.49-1.41 (m, 1 H), 1.45 (s, 3 H), 0.89 (dd, 1 H, J = 6.6 Hz, J = 4.2 
Hz); 13C NMR (150 MHz, CD3OD) δ 177.4, 159.5, 157.5, 149.6, 144.4, 140.8, 138.7, 129.8, 
129.7, 128.4, 127.6, 123.6, 123.5, 122.2, 120.1, 54.4, 45.8, 33.0, 25.6, 21.0, 15.1; MS (ESI) m/z 
415 ([M+H]+); HRMS (ESI) m/z calcd for C25H27N4O2 (M+H) 415.2134, found 415.2133. 
 
 170 
 
3-73
Ph
NH CH3 H
N
O
N
N
O
 
N-((S)-((1R,2R)-2-Methyl-2-(pyridin-2-ylmethylcarbamoyl)cyclopropyl) 
(phenyl)methyl)nicotinamide (3-73). To a solution of 108 mg (0.251 mmol) of 3-61 in 2 mL of 
dry CH2Cl2 was added 500 µL (0.500 mmol, 1.0 M solution in CH2Cl2) of BBr3 at rt. The 
mixture was stirred vigorously at rt for 2 h, diluted with 2 mL of Et2O, decanted, and rinsed with 
Et2O to provide a solid that was dried under high vacuum and used directly in the next step. The 
solid was suspended in 2 mL of dry CH2Cl2, and 8.1 mg (0.066 mmol) of DMAP, 111 mg (0.624 
mmol) of nicotinoyl chloride hydrochloride and 440 µL (2.52 mmol) of DIPEA were added at rt. 
The mixture was stirred at rt overnight, before it was slowly quenched with 5 mL of satd. 
NaHCO3. The reaction mixture was extracted with 3 x 5 mL of CH2Cl2, dried (Na2SO4), 
concentrated in vacuo and purified by chromatography on SiO2 (2% MeOH in CH2Cl2 to 5% 
MeOH in CH2Cl2) to afford 47.1 mg (0.117 mmol, 47%, 2 steps) of 3-73 as a light yellow oil: 
[α]D -22.7 (c 1.00, CH2Cl2); IR (ATR) 3297, 3049, 2919, 1625, 1530, 1433, 1418, 1212, 1025 
cm-1; 1H NMR (400 MHz, CD3OD) δ 9.00 (dd, 1 H, J = 2.0 Hz, J = 0.8 Hz), 8.67 (dd, 1 H, J = 
5.2 Hz, J = 1.6 Hz), 8.47 (ddd, 1 H, J = 5.0 Hz, J = 1.6 Hz, J = 0.8 Hz), 8.26 (ddd, 1 H, J = 8.0 
Hz, J = 2.4 Hz, J = 1.6 Hz), 7.81 (td, 1 H, J = 7.6 Hz, J = 2.0 Hz), 7.52 (ddd, 1 H, J = 8.0 Hz, J = 
4.8 Hz, J = 0.8 Hz), 7.48-7.45 (m, 2 H), 7.39-7.23 (m, 5 H), 5.03 (d, 1 H, J = 10.8 Hz), 4.54, 4.46 
(AB, 2 H, J = 16.0 Hz), 2.10 (ddd, 1 H, J = 10.8 Hz, J = 9.0 Hz, J = 6.4 Hz), 1.52-1.48 (m, 1 H), 
1.48 (s, 3 H), 0.87 (dd, 1 H, J = 6.4 Hz, J = 4.4 Hz); 13C NMR (100 MHz, CD3OD) δ 177.3, 
167.0, 159.3, 152.6, 149.2, 149.2, 143.3, 139.4, 137.2, 132.0, 129.8, 128.6, 128.0, 125.1, 123.8, 
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122.5, 54.8, 45.6, 31.8, 25.8, 21.0, 15.0; MS (ESI) m/z 423 ([M+Na]+); HRMS (ESI) m/z calcd 
for C24H24N4O2Na (M+Na) 423.1797, found 423.1797. 
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3-74  
5-Methyl-N-((S)-((1R,2R)-2-methyl-2-(pyridin-2-ylmethylcarbamoyl) 
cyclopropyl)(phenyl)methyl)isoxazole-3-carboxamide (3-74). According to general protocol 
A, a mixture of 92.3 mg (0.215 mmol) of 3-61, and 44.7 mg (0.0420 mmol) of Pd/C (10%) in 2 
mL of MeOH was stirred for 1 h to provide the amine intermediate. The intermediate was 
dissolved in 2 mL of dry CH2Cl2, and treated with 45.5 mg (0.312 mmol) of 5-methylisoxazole-
3-carbonyl chloride, 5.1 mg (0.041 mmol) of DMAP, and 40 µL (0.29 mmol) of NEt3 to afford 
70.6 mg (0.174 mmol, 81%, 2 steps) of 3-74 as a fine white powder: mp 171-172 oC; [α]D -46.6 
(c 1.79, CH2Cl2); IR (ATR) 3006, 1633, 1594, 1435, 1374, 1241 cm-1; 1H NMR (300 MHz, 
CD3OD) δ 8.45 (d, 1H, J = 4.8 Hz), 7.76 (td, 1 H, J = 7.7 Hz, J = 1.2 Hz), 7.45 (d, 2 H, J = 7.2 
Hz), 7.35 (t, 2 H, J = 7.8 Hz), 7.30-7.25 (m, 2 H), 7.20 (d, 1 H, J = 7.8 Hz), 6.44 (s, 1 H), 4.98 
(d, 1 H, J = 10.8 Hz), 4.53, 4.44 (AB, 2 H, J = 16.2 Hz), 2.44 (s, 3 H), 2.16-2.07 (m, 1 H), 1.51-
1.42 (m, 1 H), 1.45 (s, 3 H), 0.83 (dd, 1 H, J = 6.3 Hz, J = 4.5 Hz); 13C NMR (150 MHz, 
CD3OD) δ 177.1, 172.8, 160.8, 160.0, 159.5, 149.6, 142.9, 138.7, 129.7, 128.6, 128.0, 123.6, 
122.2, 102.0, 54.3, 45.7, 31.5, 25.7, 21.0, 150, 12.0; MS (ESI) m/z 405 ([M+H]+); HRMS (ESI) 
m/z calcd for C23H25N4O3 (M+H) 405.1927, found 405.1934. 
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